

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
5 June 2003 (05.06.2003)

PCT

(10) International Publication Number
WO 03/045924 A1

(51) International Patent Classification⁷: C07D 241/20,
241/18, 241/26, 401/12, 403/12, 405/12, 491/04, 409/12,
401/04, 401/14, A61K 31/4965, A61P 25/00

[US/US]; 8117 Black Forest Drive, Portage, MI 49009
(US). **FU, Jian-Min** [CA/US]; 5123 Heathrow Avenue,
Kalamazoo, MI 49009 (US).

(21) International Application Number: PCT/US02/33642

(74) Agent: **ZHANG, Austin, W.**; Global Intellectual Property,
Pharmacia & Upjohn Company, 301 Henrietta Street, Kala-
mazoo, MI 49001 (US).

(22) International Filing Date:
15 November 2002 (15.11.2002)

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US,
UZ, VC, VN, YU, ZA, ZM, ZW.

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

60/332,052	21 November 2001 (21.11.2001)	US
60/358,546	21 February 2002 (21.02.2002)	US
60/338,285	13 June 2002 (13.06.2002)	US
60/410,378	13 September 2002 (13.09.2002)	US

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SK,
TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML, MR, NE, SN, TD, TG).

(71) Applicant (*for all designated States except US*): **PHARMACIA & UPJOHN COMPANY** [US/US]; 301 Henrietta Street, Kalamazoo, MI 49001 (US).

Published:

— with international search report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 03/045924 A1

(54) Title: SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES

(57) Abstract: Substituted aryl 1,4-pyrazine derivatives and their use in treating anxiety disorders, depression and stress related disorders are disclosed.

SUBSTITUTED ARYL 1,4-PYRAZINE DERIVATIVES

FIELD OF THE INVENTION

This invention relates to substituted aryl 1,4-pyrazine derivatives and processes for preparing them, pharmaceutical compositions containing them, and methods of using them to treat a disorder or condition which can be effected or facilitated by antagonizing a CRF receptor, including but not limited to disorders induced or facilitated by CRF, such as anxiety disorders, and depression and stress related disorders. Additionally this invention relates to the use of such compounds as probes for the localization of CRF₁ receptors in cells or tissues.

BACKGROUND OF THE INVENTION

Corticotropin releasing factor (CRF) is a 41 amino acid peptide that is the primary physiological regulator of proopiomelanocortin (POMC) derived peptide secretion from the anterior pituitary gland [J. Rivier et al., *Proc. Natl. Acad. Sci. (USA)* 80:4851 (1983); W. Vale et al., *Science* 213:1394 (1981)]. In addition to its endocrine role at the pituitary gland, immunohistochemical localization of CRF has demonstrated that the hormone has a broad extrahypothalamic distribution in the central nervous system and produces a wide spectrum of autonomic, electrophysiological and behavioral effects consistent with a neurotransmitter or neuromodulator role in the brain [W. Vale et al., *Rec. Prog. Horm. Res.* 39:245 (1983); F. Koob, *Persp. Behav. Med.* 2:39 (1985); E.B. De Souza et al., *J. Neurosci.* 5:3189 (1985)]. There is also evidence that CRF plays a significant role in integrating the response in the immune system to physiological, psychological, and immunological stressors [J.E. Blalock, *Physiological Reviews* 69:1 (1989); J.E. Morley, *Life Sci.* 41:527 (1987)].

There is evidence that CRF has a role in psychiatric disorders and neurological diseases including depression, anxiety-related disorders and feeding disorders. A role for CRF has also been postulated in the etiology and pathophysiology of Alzheimer's disease, Parkinson's disease, Huntington's disease, progressive supranuclear palsy and amyotrophic lateral sclerosis, as they relate to the dysfunction of CRF neurons in the central nervous system [for a review, see: E.B. De Souze, *Hosp. Practice* 23:59 (1988)].

Anxiety disorders are a group of diseases, recognized in the art, that includes phobic disorders, anxiety states, post-traumatic stress disorder and atypical anxiety

disorders [The Merck Manual of Diagnosis and Therapy, 16th edition (1992)].

Emotional stress is often a precipitating factor in anxiety disorders, and such disorders generally respond to medications that lower response to stress.

In affective disorder, or major depression, the concentration of CRF is significantly increased in the cerebral spinal fluid (CSF) of drug-free individuals [C.B. Nemeroff et al., *Science* 226:1342 (1984); C.M. Banki et al., *Am. J. Psychiatry* 144:873 (1987); R.D. France et al., *Biol. Psychiatry* 28:86 (1988); M. Arato et al., *Biol. Psychiatry* 25:355 (1989)]. Furthermore, the density of CRF receptors is significantly decreased in the frontal cortex of suicide victims, consistent with a hypersecretion of CRF [C.B. Nemeroff et al., *Arch. Gen. Psychiatry* 45:577 (1988)]. In addition, there is a blunted adrenocorticotropin (ACTH) response to CRF (i.v. administered) observed in depressed patients [P.W. Gold et al., *Am. J. Psychiatry* 141:619 (1984); F. Holsboer et al., *Psychoneuroendocrinology* 9:147 (1984); P.W. Gold et al., *New Engl. J. Med.* 314:1129 (1986)]. Preclinical studies in rats and non-human primates provide additional support for the hypothesis that hypersecretion of CRF may be involved in the symptoms seen in human depression [R.M. Sapolsky, *Arch. Gen. Psychiatry* 46:1047 (1989)]. There is also preliminary evidence that tricyclic antidepressants can alter CRF levels and thus modulate the numbers of receptors in the brain [Grigoriadis et al., *Neuropsychopharmacology* 2:53 (1989)].

CRF has also been implicated in the etiology of anxiety-related disorders, and is known to produce anxiogenic effects in animals. Interactions between benzodiazepine/non-benzodiazepine anxiolytics and CRF have been demonstrated in a variety of behavioral anxiety models [D.R. Britton et al., *Life Sci.* 31:363 (1982); C.W. Berridge and A.J. Dunn *Regul. Peptides* 16:83 (1986)]. Preliminary studies using the putative CRF receptor antagonist α -helical ovine CRF (9-41) in a variety of behavioral paradigms demonstrates that the antagonist produces "anxiolytic-like" effects that are qualitatively similar to the benzodiazepines [C.W. Berridge and A.J. Dunn *Horm. Behav.* 21:393 (1987), *Brain Research Reviews* 15:71 (1990)].

Neurochemical, endocrine and receptor binding studies have all demonstrated interactions between CRF and benzodiazepine anxiolytics, providing further evidence for the involvement of CRF in these disorders. Chlordiazepoxide attenuates the "anxiogenic" effects of CRF both in the conflict test [K.T. Britton et al., *Psychopharmacology* 86:170 (1985); K.T. Britton et al., *Psychopharmacology*

94:306 (1988)] and in the acoustic startle test [N.R. Swerdlow et al., *Psychopharmacology* 88:147 (1986)] in rats. The benzodiazepine receptor antagonist Ro 15-1788, which was without behavioral activity alone in the operant conflict test, reversed the effects of CRF in a dose-dependent manner while the benzodiazepine inverse agonist FG 7142 enhanced the actions of CRF [K.T. Britton et al., *Psychopharmacology* 94:396 (1988)]. The mechanisms and sites of action through which conventional anxiolytics and antidepressants produce their therapeutic effects remain to be elucidated. Preliminary studies, examining the effects of a CRF₁ receptor antagonist peptide (α -helical CRF₉₋₄₁) in a variety of behavioral paradigms, have demonstrated that the CRF₁ antagonist produces "anxiolytic-like" effects qualitatively similar to the benzodiazepines [for a review, see: G.F. Koob and K.T. Britton, In: *Corticotropin-Releasing Factor: Basic and Clinical Studies of a Neuropeptide*, E.B. De Souza and C.B. Nemeroff eds., CRC Press p.221 (1990)].

The use of CRF₁ antagonists for the treatment of Syndrome X has also been described in U.S. Patent Application No. 09/696,822, filed October 26, 2000, and European Patent Application No. 003094414, filed October 26, 2000, which are also incorporated in their entireties herein by reference. Methods for using CRF₁ antagonists to treat congestive heart failure are described in U.S. Serial No. 09/248,073, filed February 10, 1999, now U.S. patent 6,043,260 (March 28, 2000) which is also incorporated herein in its entirety by reference.


CRF is known to have a broad extrahypothalamic distribution in the CNS, contributing therein to a wide spectrum of autonomic behavioral and physiological effects [see, e.g., Vale et al., 1983; Koob, 985; and E.B. De Souze et al., 1985]. For example, CRF concentrations are significantly increased in the cerebral spinal fluid of patients afflicted with affective disorder or major depression [see, e.g., Nemeroff et al., 1984; Banki et al., 1987; France et al., 1988; Arato et al., 1989]. Moreover, excessive levels of CRF are known to produce anxiogenic effects in animal models [see, e.g., Britton et al., 1982; Berridge and Dunn, 1986 and 1987], and CRF₁ antagonists are known to produce anxiolytic effects; accordingly, therapeutically effective amounts of compounds provided herein are, for example, determined by assessing the anxiolytic effects of varying amounts of the compounds in such animal models.

The following patents or patent applications disclose compounds as antagonists of CRF₁ receptors: WO0160806, WO9735901, WO9829119, WO9736886, WO9736898, and U.S. Patents Nos. 5872136, 5880140, and 5883105. The compounds are useful for treating CNS-related disorders, particularly affective disorders and acute and chronic neurological disorders.

SUMMARY OF THE INVENTION

We have found that compounds of Formula I, as well as stereoisomers thereof, pharmaceutically acceptable salts thereof, and prodrugs thereof, are CRF₁ antagonists and are useful in the treatment of disorders and diseases associated with CRF₁ receptors, including CNS-related disorders and diseases, particularly psychiatric disorders, affective disorders such as anxiety disorders, depression and stress related disorders ,and acute and chronic neurological disorders and diseases. The compounds are also useful in smoking cessation programs.

Thus, in a first aspect, this invention provides a compound of Formula I,



Formula I

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula I:

X is selected from -NR₃R₄, -OR₃, -CR₃R₅R₅, -C(O)R₃, -S(O)_mR₃, -NR₃C(O)R₄, or -NR₃S(O)_mR₄;

m is 0,1 or 2;

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; R₁, R₂, and R₅ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;

R₃ and R₄ are independently selected from R_a, heterocycloalkyl, substituted heterocycloalkyl, substituted heteroaryl, substituted aryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl

heterocycloalkyl, substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, or substituted heteroaryl heterocycloalkyl provided at least one of R₃ or R₄ are heteroaryl, substituted heteroaryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, 5 substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, substituted heteroaryl heterocycloalkyl, heterocycloalkyl or substituted heterocycloalkyl;

R_a each is selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, 10 and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t;

R_t each is selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, 15 benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen; and

Aryl is either phenyl or naphthyl,

provided that the compound is not:

2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-methylpiperidin-4-yl)oxy]pyrazine

20 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-(tetrahydrofuran-3-yl)oxy]pyrazine

2,5-dimethyl-3-(2,4-dichlorophenyl)-6-(tetrahydro-2H-pyran-4-yloxy)pyrazine

25 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-methylpiperidin-3-yl)oxy]pyrazine

2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-ethylpiperidin-3-yl)oxy]pyrazine

2,5-dimethyl-3-(2,4-dichlorophenyl)-6-(1-piperidin-4-yl)oxy]pyrazine

30 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-piperidin-3-yl)oxy]pyrazine

2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-ethylpyrrolidin-3-yl)oxy]pyrazine

35 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-methylpyrrolidin-3-yl)oxy]pyrazine

2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(pyrrolidin-3-yl)oxy]pyrazine

2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(pyridin-4-yl)oxy]pyrazine.

In another aspect, the present invention provides a novel compound of Formula I, or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, which are useful for the treatment of the disorders or diseases that are associated with CRF₁ receptors, or disorders the treatment of which can be effected or facilitated by antagonizing CRF, in a mammal, particularly in a human, such as social anxiety disorder; panic disorder; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; affective disorder; anxiety; and depression.

10 In still another aspect, the present invention provides for the use of a compound of the invention for treatment of a disorder disclosed herein above in a mammal, particularly in a human.

In still another aspect, the present invention provides for a composition comprising a compound of the invention useful for treatment of a disorder disclosed herein above in a mammal, particularly in a human.

15 In still another aspect, the present invention provides for the use of a compound of the invention in a binding assay, wherein one or more of the compounds may be joined to a label, where the label can directly or indirectly provide a detectable signal. Various labels include radioisotopes, fluorescers, chemiluminescers, specific binding molecules, particles, e.g. magnetic particles, and the like.

20 In yet another aspect, the present invention relates to the use of the compounds of the invention (particularly labeled compounds of this invention) as probes for the localization of receptors in cells and tissues and as standards and reagents for use in determining the receptor-binding characteristics of test compounds.

25 Labeled compounds of the invention may be used for *in vitro* studies such as autoradiography of tissue sections or for *in vivo* methods, e.g. PET or SPECT scanning. Particularly, compounds of the invention are useful as standards and reagents in determining the ability of a potential pharmaceutical to bind to the CRF₁ receptor.


DETAILED DESCRIPTION OF THE INVENTION

30 In a first aspect, this invention provides a compound of Formula I, shown and defined above.

Compounds provided herein can have one or more asymmetric centers or planes, and all chiral (enantiomeric and diastereomeric) and racemic forms of the

compound are included in the present invention. Many geometric isomers of olefins, C=N double bonds, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. Compounds of the invention are isolated in either the racemic form, or in the optically pure form, for example, by resolution of the racemic form by conventional methods such as crystallization in the presence of a resolving agent, or chromatography, using, for example, a chiral HPLC column, or synthesized by an asymmetric synthesis route enabling the preparation of enantiomerically enriched material. The present invention encompasses all possible tautomers of the compounds represented by Formula I.

Preferred compound of the invention include those of Formula II



Formula II

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula II,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
m is 0,1 or 2;

R₁ and R₂ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -


C(S)OR_a, or -OC(O)OR_a;

R₃ and R₄ are independently selected from R_a, heterocycloalkyl, substituted heterocycloalkyl, substituted heteroaryl, substituted aryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, or substituted heteroaryl heterocycloalkyl provided at least one of R₃ or R₄ are heteroaryl, substituted heteroaryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, substituted heteroaryl heterocycloalkyl, heterocycloalkyl or substituted heterocycloalkyl;

R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

Other preferred compounds of the invention include those of Formula III



Formula III

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula III,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; m is 0, 1 or 2;

R₁ and R₂ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a, -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;


R₃ is selected from heteroaryl, substituted heteroaryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, substituted heteroaryl heterocycloalkyl, heterocycloalkyl or substituted heterocycloalkyl;

R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl,

heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

Still other preferred compounds of the invention include those of Formula IV



Formula IV

10

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula IV,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; m is 0, 1 or 2;


15 R₁ and R₂ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;

R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;

20 R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

Still other preferred compounds of the invention include those of Formula V



Formula V

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula V,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
10 m is 0,1 or 2;


R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -

15 C(S)OR_a, or -OC(O)OR_a;

R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

20 R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

25 Still other preferred compounds of the invention include those of Formula VI



Formula VI

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula VI,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

5 m is 0,1 or 2;


R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;

10 R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t;

15 R_m is C₁-C₆ alkyl substituted with from 1-2 of halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, oxo (=O), thione (=S), heterocycloalkyl, or substituted heterocycloalkyl; and

20 R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.


Still other preferred compounds of the invention include those of Formula VII



or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula VII,

- Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- W is O, NR_p, or S(O)_m;
- m is 0, 1 or 2;
- R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;
- R₁ and R₂ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;
- R_p each is independently selected from -R_a, -S(O)_mR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -C(O)OR_a, or -C(S)OR_a;
- R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and
- R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.


Still other preferred compounds of the invention include those of Formula VIII



or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula VIII,

- Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- 5 W is O, NR_p, or S(O)_m;
- m is 0, 1 or 2;
- R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -10 C(S)OR_a, or -OC(O)OR_a;
- R_p is independently selected from -R_a, -S(O)_mR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -C(O)OR_a, or -C(S)OR_a;
- R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, -NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and
- R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -20 S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

Still other preferred compounds of the invention include those of Formula IX



Formula IX

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula IX,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

5 m is 0, 1 or 2;

Y= O or S

R_m is C₁-C₆ alkyl substituted with from 1-2 of halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, oxo (=O), thione (=S), heterocycloalkyl, or substituted heterocycloalkyl;

10 R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

15 R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

20 Still other preferred compounds of the invention include:

compounds of Formula I where X is NR₃R₄;

compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is aryl cycloalkyl or heteroaryl cycloalkyl;

25 compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is aryl cycloalkyl or heteroaryl cycloalkyl and the point of attachment is the cycloalkyl ring;

compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is aryl cycloalkyl or heteroaryl cycloalkyl and the point of attachment is the cycloalkyl ring and one of R₃ or R₄ is hydrogen;

- 5 compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is heterocycloalkyl and one of R₃ or R₄ is hydrogen;

compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is substituted aryl cycloalkyl or substituted heteroaryl cycloalkyl and the point of attachment is the cycloalkyl ring and one of R₃ or R₄ is hydrogen;

- 10 compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is substituted aryl cycloalkyl or substituted heteroaryl cycloalkyl where the substituent is either alkyl or alkoxy and is on the cycloalkyl ring and the point of attachment is the cycloalkyl ring and one of R₃ or R₄ is hydrogen;

- 15 compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is substituted heterocycloalkyl where the substituent is either alkyl or alkoxy and one of R₃ or R₄ is hydrogen;

compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is substituted heterocycloalkyl where the substituent is either alkyl or alkoxy and the absolute stereochemistry of these ring substituents are either (R,R), (R,S), (S,R), or (S,S) and one of R₃ or R₄ is hydrogen;

- 20 compounds of Formula I where X is NR₃R₄ and one of R₃ or R₄ is substituted aryl cycloalkyl or substituted heteroaryl cycloalkyl where the substituent is either alkyl or alkoxy and is on the cycloalkyl ring and the absolute stereochemistry of these ring substituents are either (R,R), (R,S), (S,R), or (S,S) and the point of attachment is the cycloalkyl ring and one of R₃ or R₄ is hydrogen;

- 25 compounds of Formula I where X is NR₃R₄ and R₃ is 2-substituted-1-indanyl and R₄ is hydrogen;

compounds of Formula I where X is NR₃R₄ and R₃ is 2-alkoxy-1-indanyl and R₄ is hydrogen;

- 30 compounds of Formula I where X is NR₃R₄ and R₃ is 2(S)-alkoxy-1(R)-indanyl and R₄ is hydrogen;


compounds of Formula I where X is NR₃R₄ and R₃ is 4-substituted-3-pyrrolidinyl and R₄ is hydrogen;

compounds of Formula I where X is NR₃R₄ and R₃ is 4-alkoxy-3-pyrrolidinyl and R₄ is hydrogen; and


compounds of Formula I where X is NR₃R₄ and R₃ is 4(S)-alkoxy-3(R)-pyrrolidinyl-1-carboxylate and R₄ is hydrogen.

5 Following are examples of particular compounds of the invention, with each compound being identified by both a chemical name and a structural formula immediately below the chemical name:


10 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




15 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine



5 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




N-[(1R,2S)-2-(cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine.




10


5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(prop-2-nyloxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.




15 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-methoxyethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.




N-[(1R,2S)-2-(allyloxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine.



5 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-propoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.




10


2-[((1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)oxy]ethanol.




(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl dimethylcarbamate.




(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate.




5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.




10 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



(1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate.




N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine.



- 5 3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine.



5-(2,4-dimethoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.




10


5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.




5-[2-chloro-4-(dimethylamino)phenyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.




5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.




5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.



10 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine




N-(2,3-dihydro-1H-inden-1-yl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



5 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




N-[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazin-2-yl]isoquinolin-1-amine




10

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(3-ethyl-6-methylpyridin-2-yl)pyrazin-2-amine




5-(2,4-dichlorophenyl)-N-(4,6-dimethylpyridin-2-yl)-3,6-diethylpyrazin-2-amine




15


5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine



5 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[{(cis)-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl}]pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[{(trans)-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl}]pyrazin-2-amine




10

5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-


15 amine




2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1,2,3,4-tetrahydronaphthalen-1-yloxy)pyrazine



5 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




10

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine


15




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R) and (1S,2S)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine



- 5 5-(2,4-dichlorophenyl)-N-[(1R,2R) and (1S,2S)-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-diethylpyrazin-2-amine




cis-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol




10


(cis)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-N-[(cis)-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-diethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine




5
5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine



10 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




15


5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine




5-(2-chloro-4-methylphenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine




5 N-(3,4-dihydro-2H-chromen-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




10 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine



5 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




10

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine




15


5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(cis)-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine



5 N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine




N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine




10

N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine




N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine


15




(+/-)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-[*cis*-2-ethyl-2,3-dihydro-1*H*-inden-1-yl]pyrazin-2-amine.



5 (+/-)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-[*trans*-2-ethyl-2,3-dihydro-1*H*-inden-1-yl]pyrazin-2-amine.




benzyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




10


5-(2,4-dichlorophenyl)-N-[(*cis*)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxy-1-propionylpyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine



5 methyl (cis)-3- {[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxy-1-(methylsulfonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




10


ethyl (cis)-3- {[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




(*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N,N-dimethylpyrrolidine-1-carboxamide




(*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N,N-dimethylpyrrolidine-1-carbothioamide




isopropyl (*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrrolidine-1-carboxylate




10 (*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N-methylpyrrolidine-1-carbothioamide




5-(2,4-dichlorophenyl)-N-[(*cis*)-4-ethoxy-1-(morpholin-4-ylcarbonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




2-fluoroethyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate



5 benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




5-(2,4-dichlorophenyl)-N-[(3R,4S)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




10


methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




5 **5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine**




methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




10 **Preparation of methyl(3R,4S)-3-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate**



methyl (3R,4S)-3-({5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazin-2-yl}amino)-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate




5


benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




10 benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




5-(2-chloro-4-methoxyphenyl)-N-[(3R,4S)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate



5 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine




methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




10


trans-(+/-)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine



cis-(+/-)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine.




cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[4-methoxytetrahydrofuran-3-yl]pyrazin-2-amine.




5


cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethylpyrazin-2-amine.




10 cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-N-[4-propoxytetrahydrofuran-3-yl]-3,6-diethylpyrazin-2-amine.




5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine




5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-4-propoxymethyl]pyrazin-2-amine




- 5 (+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[**cis**-4-(3-fluoropropoxy)tetrahydrofuran-3-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-propyl-1H-imidazol-2-yl)pyrazin-2-amine




- 10 3,6-dicyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-methylpyrazin-2-amine




3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methylpyrazin-2-amine



5 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine




5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine




10


6-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine




15 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine




3-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine



5 5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine




5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine




10


5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methylpyrazin-2-amine




5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methylpyrazin-2-amine



5 (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-ethyl-2,3-dihydro-1H-indene-1,2-diamine




N-((1R,2R)-1-{[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)acetamide




10

(1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-(2-methoxyethyl)-2,3-dihydro-1H-indene-1,2-diamine




15

5-(2,4-dichlorophenyl)-N-[(1S,2R)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine




5-(2,4-dichlorophenyl)-N-[(1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine



- 5 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




methyl 3-(2,4-dichlorophenyl)-6-{{(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl}amino}-5-methoxypyrazine-2-carboxylate



10


methyl 6-{{(1R,2S)-2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl}amino}-3-(2,4-dichlorophenyl)-5-methoxypyrazine-2-carboxylate




- 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy-15 3-vinylpyrazin-2-amine




methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-propoxypyrrolidine-1-carboxylate




- 5 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate




- 10 methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate




methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-propoxypyrrolidine-1-carboxylate




- 15 methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionyloxy)pyrrolidine-1-carboxylate




methyle (3S,4R)-3-(acetyloxy)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}pyrrolidine-1-carboxylate



- 5 methyl (3S,4R)-3-(acetyloxy)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}pyrrolidine-1-carboxylate




methyle (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionyloxy)pyrrolidine-1-carboxylate




10

- methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionylamino)pyrrolidine-1-carboxylate




15


- methyl (3S,4R)-3-(acetylamino)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}pyrrolidine-1-carboxylate




methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(ethylamino)pyrrolidine-1-carboxylate



- 5 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propylamino)pyrrolidine-1-carboxylate




O-methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carbothioate




10

O-methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carbothioate




15


O-methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carbothioate




ethyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate



- 5 ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




pyridin-2-ylmethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




10


- pyridin-3-ylmethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




- 15 pyridin-4-ylmethyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




2-piperidin-1-ylethyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




- 5 2-morpholin-4-ylethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




2-morpholin-4-ylethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionyloxy)pyrrolidine-1-carboxylate




- 10 2-(dimethylamino)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate




- 15 2-pyrrolidin-1-ylethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate




2-(1H-imidazol-1-yl)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




- 5 2-(methylamino)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




2-aminoethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




- 10 2-hydroxyethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




- 15 2-methoxyethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate



2-(2-oxopyrrolidin-1-yl)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




- 5 2-(2-oxopyridin-1(2H)-yl)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




(3S,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidin-2-one




- 10 10 (3S,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-1-methylpyrrolidin-2-one



- 15 (3S,4S)-1-benzyl-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidin-2-one




(3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-3-(2-fluoroethoxy)pyrrolidin-2-one



5 (3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-3-(2-fluoroethoxy)-1-methylpyrrolidin-2-one




(3R,4R)-1-benzyl-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-3-(2-fluoroethoxy)pyrrolidin-2-one




10


5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethyl-1H-imidazol-2-yl)pyrazin-2-amine




15 ethyl (2S,3S)-3-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-2,3-dihydrofuro[2,3-b]pyridine-2-carboxylate




(2S,3S)-N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]-2-(ethoxymethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine



5 (2R,3S)-N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]-2-ethyl-2,3-dihydrofuro[2,3-b]pyridin-3-amine



(2R,3S)-N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]-2-propyl-2,3-dihydrofuro[2,3-b]pyridin-3-amine




10

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine




5

5-(2,4-dichlorophenyl)-N-[(2R)-2-(ethoxymethyl)pyrrolidin-1-yl]-3,6-diethylpyrazin-2-amine



10

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(propoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine




15

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(2R)-2-[(2-fluoroethoxy)methyl]pyrrolidin-1-yl]pyrazin-2-amine




20


5-(2-chloro-4-methoxyphenyl)-N-[(2R)-2-(ethoxymethyl)pyrrolidin-1-yl]-3,6-diethylpyrazin-2-amine




5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)pyrazin-2-amine




5 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)pyrazin-2-amine



10 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-bis(methoxymethyl)pyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-bis(methoxymethyl)pyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




15

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




20


5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




5 (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl hydroxyacetate




10 (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl hydroxyacetate




15 (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl methoxycacetate



20 (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl methoxycacetate




25 N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-amine




N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine

5




(1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl glycinate

10




(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl glycinate

15




5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-{(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl}pyrazin-2-amine


20




5-(2,4-dichlorophenyl)-3,6-diethyl-N-{(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl}pyrazin-2-amine




5 (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N-methylglycinate




10 (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N-methylglycinate




15 5-(2-chloro-4-methoxyphenyl)-N-{(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl}-3,6-diethylpyrazin-2-amine



20 5-(2,4-dichlorophenyl)-N-{(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl}-3,6-diethylpyrazin-2-amine



(1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate



5


(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate

10




5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine

15



(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl methylcarbamate


20




5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




5
5-(3,5-dichloropyridin-2-yl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




10
6
5-(3-chloro-5-methoxypyridin-2-yl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




7
7
(1R,2S)-1-{[5-(4-chloro-2-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate



15
8
(1R,2S)-1-{[5-(3,5-dichloropyridin-2-yl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate



20
9
(1R,2S)-1-{[5-(3-chloro-5-methoxypyridin-2-yl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate




5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




5

(3R,4R)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-yl acetate




10

(3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-yl acetate




15

(3R,4R)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-yl propionate




20

(3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-yl propionate




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-propoxymethyl]pyrazin-2-amine

5




5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydrofuran-3-yl]pyrazin-2-amine

10




(3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)dihydrofuran-2(3H)-one

15




(3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxydihydrofuran-2(3H)-one

20




(3R,4S)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-5-oxotetrahydrofuran-3-yl acetate




(3R,4S)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-5-oxotetrahydrofuran-3-yl propionate

5




(3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-propoxydihydrofuran-2(3H)-one

10




(3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)dihydrofuran-2(3H)-one


15




20 (1R,2S)-N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-N'-ethyl-2,3-dihydro-1H-indene-1,2-diamine




N-((1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)acetamide



5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethoxypyrazin-2-amine




5
3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxypyrazin-2-amine




10
3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-ethylpyrazine-2-carboxamide




3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxamide




15
3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-(methylthio)pyrazine-2-carboxamide




20
5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-(methylthio)pyrazin-2-amine



5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methoxypyrazin-2-amine




5 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methoxypyrazin-2-amine



10 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-(methylthio)pyrazin-2-amine



5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methylthio)pyrazin-2-amine




15

6-(2,4-dichlorophenyl)-3-{{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-ethylpyrazine-2-carboxamide



20


6-(2,4-dichlorophenyl)-3-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxamide




5 6-(2,4-dichlorophenyl)-3-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-(methylthio)pyrazine-2-carboxamide



10 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-N'-methylpyrazine-2,3-diamine




15 6-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-N',N''-dimethylpyrazine-2,3,5-triamine



15


20 3-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-5-ethyl-N'-methylpyrazine-2,6-diamine



20

Compounds of the invention can be prepared using the reactions depicted in the following charts or variations thereof known to those skilled in the art. As illustrated in Chart A, the aminopyrazine A-II can be prepared from the suitably

functionalized chloropyrazine **A-I** (see Chart C) by reaction with the appropriate heterocyclic or carbocyclic amine in the presence of a transition metal catalyst (e.g. palladium(II) acetate or tris(dibenzylideneacetone)dipalladium(0)), base (e.g. sodium or potassium tert-butoxide) in solvents such as but not limited to toluene, DMF, or dioxane. (for example see Buchwald, S.L. et al *J. Org. Chem.* **2000**, *65*, 1158.). A variety of heterocyclic and carbocyclic amines are commercially available or can be synthesized by those skilled in the art. Halogenation of **A-II** can be accomplished by a number of methods well-known to those skilled in the art utilizing reagents such as N-chlorosuccinimide, N-bromosuccinimide, N-iodosuccinimide, bromine, iodine, pyridinium tribromide in solvents such as dichloromethane, acetic acid, DMF, etc, to give the halopyrazine **A-III**. Formation of the claimed compounds **I** is accomplished by a transition metal catalyzed coupling reaction **A-III** and an appropriate metallocaryl reagent such as aryl boronic acids (see for example Miyaura, N.; et al *Chem. Rev.* **1995**, *95*, 2457), aryl stannanes (see for example Mitchell, T.N. *Synthesis* **1992**, *15*, 803), or aryl Grignards (see for example Miller, J.A. *Tetrahedron Lett.* **1998**, *39*, 7275). Alternatively, **A-I** can be coupled with a suitable metallocaryl reagent as described above to provide the arylpyrazine **A-IV**. Oxidation of the sterically less hindered nitrogen can be effected by using a variety of known oxidizing agents (eg, MCPBA, hydrogen peroxide), and the resulting N-oxide can be treated with phosphorous oxybromide to provide the bromopyrazine **A-V**. Reaction of the halogen with an amine as described above provides **I**.

Chart A

Another way of preparing the compounds of this invention is illustrated in Chart B. Dialkyl-dichloropyrazines **B-I** (see Chart C) can serve as the starting point for sequential displacement of one chlorine with the appropriate secondary amine (as described in Chart A) followed by biaryl formation with a suitable metallocaryloyl reagent (as described in Chart A) to afford **I**. In some instances, this sequence can also be conducted in the opposite order, i.e. biaryl formation followed by nucleophilic displacement by a secondary amine.





Chart C illustrates the preparation of mono- and dichloropyrazine **A-I** and **B-I** respectively when R1 and R2 are alkyl and the same. The reaction sequence shown below follows that described in *Chemical and Pharmaceutical Bulletin of Japan*,

5 1979, 27, 2027.


Chart C



As illustrated in Chart D, treatment of **A-V** (depicted in Chart A) with an alkoxide or sodium or potassium salt of a thiol should afford compounds such as **D-1**.
 10 Alternatively, if direct alkoxide addition fails, palladium catalysis (see Buchwald, S.L. et al *J. Am. Chem. Soc.* 2001, 123, 10770) or copper catalysis (see Fagan, P.J. et al *J. Am. Chem. Soc.* 2000, 122, 5043) of an alkoxide will provide the desired pyrazinyl aryl ether. Another literature method for forming aryl sulfur bonds is demonstrated by the work of Herradura et al. (see, Herradura, P.S. et al *Org. Lett.* 2000, 2, 2019).

15


Chart D



As illustrated in Chart E, treatment of **A-V** (depicted in Chart A) with a nucleophile such as an alkyl Grignard or alkyl lithium reagent would afford compounds such as **E-I**. Alternatively, treatment with an alkyl boronic acid (see Fu,


G.C. et al *J. Am. Chem. Soc.* **2000**, *122*, 4020.) under transition metal catalysis should also provide compounds like **E-I**.

Chart E



As illustrated in Chart F, reaction of an amine with a pyrazinyl chloride following the protocol of Buchwald et al (*J. Org. Chem.* 2000, 1158.) provides the desired aniline (**F-I**). Halogenation with NBS (or other suitable reagents as described above) and standard palladium mediated coupling provides the biaryl product (**F-III**). Alkylation with a base such as NaH and an alkyl halide affords the desired alkyl ethers (**F-IV**).

Chart F




15

The preparation of unsymmetrically substituted pyrazines ($R_1 \neq R_2$) is shown in Chart G. The synthesis commences with the coupling of a suitably protected amino acid, such as **G-I**, to an N-protected amino acid, such as **G-II**, using methods known to those skilled in the art. The N-protecting group is removed from **G-III** to afford **G-IV**. Cyclization of **G-IV** to **G-V** and the conversion of **G-V** into the regiosomeric


chloro-pyrazines **G-VI** and **G-VII** proceed through standard methods (see *Chemical and Pharmaceutical Bulletin of Japan*, 1979, 27, 2027).

Chart G



Yet another method for preparing the compounds of the present invention is detailed in Chart H. Following literature precedence (*J. Heterocyclic Chem.* 1986, 23, 10 1465), compounds **H-I** and **H-II** may be reacted in a suitable solvent (e.g. DME) in the presence of a base, such as NaH, to form **H-III**. Formation of the triflate compound **H-IV** from the ketone **H-III** is achieved by standard methods such as reaction of **H-III** with 2-[N,N-bis(trifluoromethylsulfonyl)amino]-5-chloropyridine and triethylamine in methylene chloride. The coupling partner **H-V** may be prepared from **A-V** (from Chart A) using the methods described in Buckwald, S.L. et al *Tetrahedron Lett.* 1997, 38, 6367. Palladium-catalyzed coupling (see, for example, *Tetrahedron Lett.* 1997, 38, 6363) of **H-IV** and **H-V** gives **H-VI**, which may be reduced by standard methods, such as catalytic hydrogenation, to give **H-VII**.


Chart H



As illustrated in Chart I, the epoxide I-1 is prepared by treatment of the commercially available olefin (benzyl 2,5-dihydro-1H-pyrrole-1-carboxylate) with MCPBA. The resultant epoxide can be opened in an asymmetric fashion with azide following the protocol of Jacobsen et al (*J. Org. Chem.* 1997, 62, 4197) or in a racemic fashion by treatment with ammonium hydroxide. Conversion of the trans amino alcohol to the cis follows the protocol of Jacobsen et al (*J. Org. Chem.* 1997, 62, 4197). Reaction of the pyrrolidine amine with a pyrazinyl chloride following the protocol of Buchwald et al (*J. Org. Chem.* 2000, 1158.) provides the desired aniline. Halogenation with NBS and standard palladium mediated coupling provides the biaryl product. Alkylation with NaH and an alkyl halide or acid chloride affords the desired alkyl ethers or esters. Removal of the CBZ group and treatment of the amine with

chloroformates provides carbamates. Alternatively treatment with an acid chloride results in the production of amides. Other functionalization of the amine can be carried out by those skilled in the art.


Chart I



5

As illustrated in Chart J, the commercially available epoxide J-1 is opened in a
 10 racemic fashion by treatment with ammonium hydroxide or in an asymmetric fashion
 with azide following the protocol of Jacobsen et al (*J. Org. Chem.* 1997, 62, 4197).
 Conversion of the trans amino alcohol to the cis follows the protocol of Jacobsen et al
 15 (*J. Org. Chem.* 1997, 62, 4197). Reaction of the tetrahydrofuran amine J-3 with a
 pyrazinyl chloride following the protocol of Buchwald et al (*J. Org. Chem.* 2000,
 1158.) provides the desired aniline J-4. Halogenation with NBS affords J-5 followed
 by standard palladium mediated coupling provides the biaryl product J-6. Alkylation
 with NaH and an alkyl halide or acid chloride affords the desired alkyl ethers or esters
 J-7.

Chart J



In a second aspect, the present invention provides a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective amount of a compound of the invention useful for the treatment of a disorder described herein above in a mammal, particularly in a human.

In another aspect, the present invention provides a method of antagonizing a CRF₁ receptor in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of the invention.

In another aspect, the present invention provides a method of treating a disorder manifesting hypersecretion of CRF in a mammal, comprising administering to the animal a therapeutically effective amount of a compound of the invention.

In another aspect, the present invention provides a method for the treatment of a disorder, the treatment of which can be effected or facilitated by antagonizing CRF₁ receptor, in a mammal, comprising administering to the mammal a therapeutically effective of a compound of the invention.

In another aspect, the present invention provides a method of treating anxiety or depression in a mammal, particularly in a human, comprising administering to the mammal or human a therapeutically effective amount of a compound of the invention.

In another aspect, the present invention provides a method for screening for 5 ligands for CRF₁ receptors, which method comprises: a) carrying out a competitive binding assay with CRF₁ receptors, a compound of the invention which is labelled with a detectable label, and a candidate ligand; and b) determining the ability of said candidate ligand to displace said labelled compound.

In another aspect, the present invention provides a method for detecting CRF 10 receptors in tissue comprising: a) contacting a compound of the invention which is labelled with a detectable label, with a tissue, under conditions that permit binding of the compound to the tissue; and b) detecting the labelled compound bound to the tissue.

In another aspect, the present invention provides a method of inhibiting the 15 binding of CRF to a CRF₁ receptor, comprising contacting a compound of the invention with a solution comprising cells expressing the CRF₁ receptor, wherein the compound is present in the solution at a concentration sufficient to inhibit the binding of CRF to the CRF₁ receptor.

In another aspect, the present invention provides an article of manufacture 20 comprising: a) a packaging material; b) a compound of the invention; and c) a label or package insert contained within said packaging material indicating that said compound is effective for treating a pre-selected disorder described herein above.

Compounds of the invention are useful for treating various disorders in a mammal, particularly in a human, such as social anxiety disorder; panic disorder; 25 obsessive-compulsive disorder; anxiety with co-morbid depressive illness; affective disorder; anxiety; depression; irritable bowel syndrome; post-traumatic stress disorder; supranuclear palsy; immune suppression; gastrointestinal disease; anorexia nervosa or other feeding disorder; drug or alcohol withdrawal symptoms; substance abuse disorder (e.g., nicotine, cocaine, ethanol, opiates, or other drugs); inflammatory 30 disorder; fertility problems; disorders the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF; a disorder selected from inflammatory disorders such as

rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic, phobias, obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single 5 episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer, human immunodeficiency virus (HIV) infections; neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease; gastrointestinal diseases such as ulcers, irritable bowel 10 syndrome, Crohn's disease, spastic colon, diarrhea, and post operative ileus and colonic hypersensitivity associated by psychopathological disturbances or stress; eating disorders such as anorexia and bulimia nervosa; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone (ADH); obesity; infertility; head traumas; spinal cord trauma; 15 ischemic neuronal damage (e.g., cerebral ischemia such as cerebral hippocampal ischemia); excitotoxic neuronal damage; epilepsy; cardiovascular and heart related disorders including hypertension, tachycardia and congestive heart failure; stroke; immune dysfunctions including stress induced immune dysfunctions (e.g., stress induced fevers, porcine stress syndrome, bovine shipping fever, equine paroxysmal 20 fibrillation, and dysfunctions induced by confinement in chickens, sheering stress in sheep or human-animal interaction related stress in dogs); muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions (e.g., dependences on alcohol, cocaine, heroin, benzodiazepines, or other drugs); 25 osteoporosis; psychosocial dwarfism and hypoglycemia.

Thus, in another aspect, the present invention provides a method of treating a disorder described herein above in a mammal, particularly in a human, comprising administering to the mammal or human a therapeutically effective amount of a compound of the invention.

30 Particular disorders that can be treated by the method of the invention preferably include the following: affective disorder; anxiety; depression; irritable bowel syndrome; post-traumatic stress disorder; supranuclear palsy; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; Alzheimer's disease;

gastrointestinal disease; skin disorders (e.g., acne, psoriasis); anorexia nervosa; social anxiety disorder; bulimia nervosa or other feeding disorder; drug (e.g., dependencies on cocaine, heroin, benzodiazepines, nicotine or other drugs) or alcohol withdrawal symptoms; substance abuse disorder (e.g., nicotine, cocaine, ethanol, opiates, or other drugs); inflammatory disorder; disorders; the treatment of which can be effected or facilitated by antagonizing CRF, including but not limited to disorders induced or facilitated by CRF; or a disorder selected from inflammatory disorders such as rheumatoid arthritis and osteoarthritis, pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder; sleep disorders induced by stress; pain perception such as fibromyalgia; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; dysthymia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; neurodegenerative diseases such as, Parkinson's disease and Huntington's disease; gastrointestinal diseases such as ulcers, Crohn's disease, spastic colon, diarrhea, and post operative ilius and colonic hypersensitivity associated by psychopathological disturbances or stress; stress-induced psychotic episodes; syndrome of inappropriate antidiarrhetic hormone (ADH); cardiovascular and hear related disorders including hypertension, tachycardia and congestive heart failure; stroke; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis.

Particular disorders that can be treated by the method of the invention more preferably include the following: generalized anxiety disorder; social anxiety disorder; anxiety; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; panic disorder; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; bipolar disorders; post-traumatic stress disorder; substance abuse disorder (e.g., nicotine, cocaine, ethanol, opiates, or other drugs); inflammatory disorders such as rheumatoid arthritis and osteoarthritis; gastrointestinal diseases such as irritable bowel syndrome, ulcers, Crohn's disease, spastic colon, diarrhea, and post operative ilius and colonic hypersensitivity associated by psychopathological disturbances or stress; inflammatory disorder; and skin disorders such as acne and psoriasis.

Particular disorders that can be treated by the method of the invention even more preferably include the following: generalized anxiety disorder; social anxiety disorder; anxiety; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; panic disorder; mood disorders such as depression, including major depression, single episode depression, recurrent depression, child abuse induced depression, and postpartum depression; bipolar disorders; and post-traumatic stress disorder.

A compound of this invention can be administered to treat these abnormalities in a mammal or human by means that produce contact of the active agent with the agent's site of action in the body of the mammal or human. The compounds can be administered by any conventional means available for use in conjunction with pharmaceuticals either as individual therapeutic agent or in combination of therapeutic agents. It can be administered alone, but will generally be administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard pharmaceutical practice.

The dosage administered will vary depending on the use and known factors such as pharmacodynamic character of the particular agent, and its mode and route of administration; the recipient's age, weight, and health; nature and extent of symptoms; kind of concurrent treatment; frequency of treatment; and desired effect.

For use in the treatment of said diseases or conditions, a compound of this invention can be orally administered at a dosage of the active ingredient of 0.002 to 200 mg/kg of body weight. Ordinarily, a dose of 0.01 to 10 mg/kg in divided doses one to four times a day, or in sustained release formulation will be effective in obtaining the desired pharmacological effect.

Dosage forms (compositions) suitable for administration contain from about 1 mg to about 100 mg of active ingredient per unit. In these pharmaceutical compositions, the active ingredient will ordinarily be present in an amount of about 0.5 to 95% by weight based on the total weight of the composition.

The active ingredient can be administered orally in solid dosage forms, such as capsules, tablets and powders; or in liquid forms such as elixirs, syrups, and/or suspensions. The compounds of this invention can also be administered parenterally in

sterile liquid dose formulations. Gelatin capsules can be used to contain the active ingredient and a suitable carrier such as but not limited to lactose, starch, magnesium stearate, steric acid, or cellulose derivatives. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of time. Compressed tablets can be sugar coated or film-coated to mask any unpleasant taste, or used to protect the active ingredients from the atmosphere, or to allow selective disintegration of the tablet in the gastrointestinal tract. Liquid dose forms for oral administration can contain coloring or flavoring agents to increase patient acceptance.

5 In general, water, pharmaceutically acceptable oils, saline, aqueous dextrose (glucose), and related sugar solutions and glycols, such as propylene glycol or polyethylene glycol, are suitable carriers for parenteral solutions. Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents, such as

10 sodium bisulfite, sodium sulfite, or ascorbic acid, either alone or in combination, are suitable stabilizing agents. Also used are citric acid and its salts, and EDTA. In addition, parenteral solutions can contain preservatives such as benzalkonium chloride, methyl- or propyl-paraben, and chlorobutanol. Suitable pharmaceutical carriers are described in "Remington's Pharmaceutical Sciences", A. Osol, a standard

15 reference in the field.

20

Useful pharmaceutical dosage forms or administration of the compounds of this invention can be illustrated as follows: (1) Capsules. A large number of units capsules are prepared by filling standard two-piece hard gelatin capsules each with 100 mg of powdered active ingredient, 150 mg lactose, 50 mg cellulose, and 6 mg magnesium stearate. (2) Soft Gelatin Capsules. A mixture of active ingredient in a digestible oil such as soybean, cottonseed oil, or olive oil is prepared and injected by means of a positive displacement was pumped into gelatin to form soft gelatin capsules containing 100 mg of the active ingredient. The capsules were washed and dried. (3) Tablets. A large number of tablets are prepared by conventional procedures so that the dosage unit was 100 mg active ingredient, 0.2 mg of colloidal silicon dioxide, 5 mg of magnesium stearate, 275 mg of microcrystalline cellulose, 11 mg of starch, and 98.8 mg lactose. Appropriate coatings may be applied to increase palatability or delayed adsorption.

25

30

The compounds of this invention may also be used as reagents or standards in the biochemical study of neurological function, dysfunction, and disease.

DEFINITIONS AND CONVENTIONS

The term "substituted aryl" means an aryl group optionally substituted with 1-5 substituents independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, and -OC(O)OR_a;

The term "aryl cycloalkyl" means a bicyclic ring system containing 8 to 14 carbon atoms wherein one ring is aryl and the other ring is fused to the aryl ring and may be fully or partially saturated in the portion of the ring fused to the aryl ring, provided that either ring may act as a point of attachment;

The term "substituted aryl cycloalkyl" means an aryl cycloalkyl group having 1-5 substituents independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, and -OC(O)OR_a;

The term "heteroaryl cycloalkyl" means a bicyclic ring system containing 8 to 14 atoms, wherein one ring is heteroaryl and the other ring is fused to the heteroaryl ring and may be fully or partially saturated in the portion of the ring fused to the heteroaryl ring, provided that either ring may act as a point of attachment;

The term "substituted heteroaryl cycloalkyl" means a heteroaryl cycloalkyl group having 1-5 substituents independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, and -OC(O)OR_a;

The term "aryl heterocycloalkyl" means a bicyclic ring system containing 8 to 14 atoms, wherein one ring is aryl and the other ring is heterocycloalkyl, provided that either ring may act as a point of attachment;

The term "substituted aryl heterocycloalkyl" means an aryl heterocycloalkyl group having 1-5 substituents independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, and -OC(O)OR_a;

The term "heteroaryl heterocycloalkyl" means a bicyclic ring system containing 8 to 14 atoms, wherein one ring is heteroaryl and the other ring is heterocycloalkyl, provided that either ring may act as a point of attachment;

The term "substituted heteroaryl heterocycloalkyl" means an heteroaryl heterocycloalkyl group having 1-5 substituents independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, and -OC(O)OR_a;

The term "heteroaryl" means a radical attached via a ring carbon or nitrogen atom of a monocyclic aromatic ring containing five or six ring atoms consisting of carbon and 1, 2, 3, or 4 heteroatoms each selected from the group consisting of non-peroxide O, S, N, with appropriate bonding to satisfy valence requirements as well as a radical (attachment at either carbon or nitrogen) of a fused bicyclic heteroaromatic of about eight to ten ring atoms, and includes radicals such as thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, and benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, and furopyridinyl;

The term "substituted heteroaryl" means a heteroaryl group having 1-5 substituents independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, and -OC(O)OR_a

The term "heterocycloalkyl", unless otherwise specified, means a 4 to 8 membered monocyclic ring or bicyclic ring, wherein at least one carbon atom is replaced with a heteromember selected from oxygen, nitrogen, -NH-, or -S(O)_m- wherein m is zero, 1, or 2, optionally containing from one to three double bonds, provided that the molecule is not aromatic; and provided that ring attachment can occur at either a carbon or nitrogen atom; Heterocycloalkyl includes tetrahydrofuran, tetrahydropyran, morpholinyl, pyrrolidinyl, piperidinyl, piperazinyl, [2.2.1]-azabicyclic rings, [2.2.2]-azabicyclic rings, [3.3.1]-azabicyclic rings, quinuclidinyl,

azetidinyl, azetidinonyl, oxindolyl, dihydroimidazolyl, and pyrrolidinonyl

The term "substituted heterocycloalkyl" is a heterocycloalkyl group having 1-5 substituents independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, and -OC(O)OR_a;

Halogen is a group selected from -F, -Cl, -Br, and -I;

The term "alkyl" means both straight and branched chain moieties having from 1-10 carbon atoms optionally containing one or more double or triple bonds;

The term "cycloalkyl" means a monocyclic or bicyclic alkyl moiety, having from 3-10 carbon atoms optionally containing 1 to 2 double bonds provided that the moiety is not aromatic;

The term "haloalkyl" means an alkyl moiety having from 1-10 carbon atoms and having 1 to (2v+1) independently selected halogen substituent(s) where v is the number of carbon atoms in the moiety;

The term "pharmaceutically acceptable salt" refers to a salt prepared from pharmaceutically acceptable non-toxic acids, including inorganic acids and organic acids. Suitable non-toxic acids include inorganic and organic acids of basic residues such as amines, for example, acetic, benzenesulfonic, benzoic, amphorsulfonic, citric, ethenesulfonic, fumaric, gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, barbaric acid, p-toluenesulfonic and the like; and alkali or organic salts of acidic residues such as carboxylic acids, for example, alkali and alkaline earth metal salts derived from the following bases: sodium hydride, sodium hydroxide, potassium hydroxide, calcium hydroxide, aluminum hydroxide, lithium hydroxide, magnesium hydroxide, zinc hydroxide, ammonia, trimethylammonia, triethylammonia, ethylenediamine, lysine, arginine, ornithine, choline, N,N'-dibenzylethylenediamine, chloroprocaine, diethanolamine, procaine, n-benzylphenethylamine, diethylamine, piperazine, tris(hydroxymethyl)-aminomethane, tetramethylammonium hydroxide, and the like. Pharmaceutically acceptable salts of the compounds of the invention can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or

acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, PA, 1985, p. 1418, the disclosure of which is hereby incorporated by reference.

The term "prodrug" as used herein means any covalently bonded carrier which releases the active parent drug of Formula I in vivo when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of Formula I are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the invention. The term "prodrug" means compounds that are rapidly transformed in vivo to yield the parent compound of formula I, for example by hydrolysis in blood.

Functional groups which may be rapidly transformed, by metabolic cleavage, in vivo form a class of groups reactive with the carboxyl group of the compounds of this invention. They include, but are not limited to such groups as alkanoyl (such as acetyl, propionyl, butyryl, and the like), unsubstituted and substituted aroyl (such as benzoyl and substituted benzoyl), alkoxy carbonyl (such as ethoxycarbonyl), trialkylsilyl (such as trimethyl- and triethylsilyl), monoesters formed with dicarboxylic acids (such as succinyl), and the like. Because of the ease with which the metabolically cleavable groups of the compounds useful according to this invention are cleaved in vivo, the compounds bearing such groups act as pro-drugs. The compounds bearing the metabolically cleavable groups have the advantage that they may exhibit improved bioavailability as a result of enhanced solubility and/or rate of absorption conferred upon the parent compound by virtue of the presence of the metabolically cleavable group. A thorough discussion of prodrugs is provided in the following: Design of Prodrugs, H. Bundgaard, ed., Elsevier, 1985; Methods in Enzymology, K. Widder et al, Ed., Academic Press, 42, p.309-396, 25 1985; A Textbook of Drug Design and Development, Krosgaard-Larsen and H. Bundgaard, ed., Chapter 5; "Design and Applications of Prodrugs" p.113-191, 1991; Advanced Drug Delivery Reviews, H. Bundgaard, 8, p.1-38, 1992; Journal of Pharmaceutical Sciences, 77, p. 285, 30 1988; Chem. Pharm. Bull., N. Nakaya et al, 32, p. 692, 1984; Pro-drugs as Novel Delivery

Systems, T. Higuchi and V. Stella, Vol. 14 of the A.C.S. Symposium Series, and Bioreversible Carriers in Drug Design, Edward B. Roche, ea., American Pharmaceutical Association and Pergamon Press, 1987, which are incorporated herein by reference. "Prodrugs" are considered to be any covalently bonded carriers which release the active parent drug of Formula I *in vivo* when such prodrug is administered to a mammalian subject. Prodrugs of the compounds of Formula I are prepared by modifying functional groups present in the compounds in such a way that the modifications are cleaved, either in routine manipulation or *in vivo*, to the parent compounds.

10 Prodrugs include compounds wherein hydroxy, amine, or sulfhydryl groups are bonded to any group that, when administered to a mammalian subject, cleaves to form a free hydroxyl, amino, or sulfhydryl group, respectively. Examples of Prodrugs include, but are not limited to, acetate, formate and benzoate derivatives of alcohol and amine functional groups in the compounds of Formula I, and the like.

15 The term "therapeutically effective amount" of a compound of this invention means an amount effective to antagonize abnormal level of CRF or treat the symptoms of affective disorder, anxiety, depression, or other disorders described herein above, in a host.

20 The term "compound of the invention" means a compound of Formula I, a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof.

PREPARATIONS AND EXAMPLES

25 The invention is illustrated further by the following examples and preparations, which are not to be construed as limiting the invention in scope or spirit to the specific procedures described in them.

EXAMPLE A.

CRF₁ Receptor Binding Assay for the Evaluation of Biological Activity

30 The following is a description of the isolation of rat brain membranes for use in the standard binding assay as well as a description of the binding assay itself. It is based on a modified protocol described by De Souza (De Souza, 1987).

To prepare brain membranes for binding assays, rat frontal cortex is homogenized in 10 mL of ice cold tissue buffer (50 mM HEPES buffer pH 7.0, containing 10 mM MgCl₂, 2 mM EGTA, 1 µg/ml aprotinin, 1 µg/ml leupeptin and 1 µg/ml pepstatin). The homogenate is centrifuged at 48,000 x g for 10 min. and the 5 resulting pellet rehomogenized in 10 mL of tissue buffer. Following an additional centrifugation at 48,000 x g for 10 min., the pellet is resuspended to a protein concentration of 300 µg/mL.

Binding assays are performed in 96 well plates at a final volume of 300 µL. The assays are initiated by the addition of 150 µL membrane suspension to 150 µL of 10 assay buffer containing ¹²⁵I-ovine-CRF (final concentration 150 pM) and various concentrations of inhibitors. The assay buffer is the same as described above for membrane preparation with the addition of 0.1% ovalbumin and 0.15 mM bacitracin. Radioligand binding is terminated after 2 hours at room temperature by filtration through Packard GF/C unifilter plates (presoaked with 0.3% polyethyleneimine) using 15 a Packard cell harvester. Filters are washed three times with ice cold phosphate buffered saline pH 7.0 containing 0.01% Triton X-100. Filters are assessed for radioactivity in a Packard TopCount. Nonspecific binding is determined in the presence of excess (10 µM) α-helical CRF.

Alternatively, tissues and cells that naturally express CRF receptors, such as 20 IMR-32 human neuroblastoma cells (ATCC; Hogg et al., 1996), can be employed in binding assays analogous to those described above.

IC₅₀ values are calculated using standard methods known in the art, such as with the non-linear curve fitting program RS/1 (BBN Software Products Corp., Cambridge, MA). A compound is considered to be active if it has an IC₅₀ value of less 25 than about 10 micromolar (µM) for the inhibition of CRF₁ receptors. The binding affinity of the compounds of Formula I expressed as IC₅₀ values generally ranges from about 0.5 nanomolar to about 10 micromolar. Preferred compounds of Formula I exhibit IC₅₀ of 1 micromolar or less, more preferred compounds of Formula I exhibit IC₅₀ of less than 100 nanomolar or less, still more preferred compounds of Formula I 30 exhibit IC₅₀ of less than 10 nanomolar or less.

EXAMPLE B.

Inhibition of CRF-Stimulated Adenylate Cyclase Activity


Inhibition of CRF-stimulated adenylate cyclase activity can be performed as previously described [G. Battaglia *et al.*, *Synapse* 1:572 (1987)]. Briefly, assays are carried out at 37 °C for 10 min in 200 mL of buffer containing 100 mM Tris-HCl (pH 5 7.4 at 37 °C), 10 mM MgCl₂, 0.4 mM EGTA, 0.1% BSA, 1 mM isobutylmethylxanthine (IBMX), 250 units/mL phosphocreatine kinase, 5 mM creatine phosphate, 100 mM guanosine 5'-triphosphate, 100 nM o-CRF, antagonist peptides (various concentrations) and 0.8 mg original wet weight tissue (approximately 40-60 mg protein). Reactions are initiated by the addition of 1 mM 10 ATP/[³²P]ATP (approximately 2-4 mCi/tube) and terminated by the addition of 100 mL of 50 mM Tris-HCl, 45 mM ATP and 2% sodium dodecyl sulfate. In order to monitor the recovery of cAMP, 1 mL of [³H]cAMP (approximately 40,000 dpm) is added to each tube prior to separation. The separation of [³²P]cAMP from [³²P]ATP is performed by sequential elution over Dowex and alumina columns.

15 Alternatively, adenylate cyclase activity can be assessed in a 96-well format utilizing the Adenylyl Cyclase Activation FlashPlate Assay from NEN Life Sciences according to the protocols provided. Briefly, a fixed amount of radiolabeled cAMP is added to 96-well plates that are precoated with anti-cyclic AMP antibody. Cells or tissues are added and stimulated in the presence or absence of inhibitors. Unlabeled 20 cAMP produced by the cells will displace the radiolabeled cAMP from the antibody. The bound radiolabeled cAMP produces a light signal that can be detected using a microplate scintillation counter such as the Packard TopCount. Increasing amounts of unlabeled cAMP results in a decrease of detectable signal over a set incubation time (2-24 hours).

25

Preparation 1

(1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



30

A solution of 3-chloro-2,5-diethylpyrazine (171 mg, 1.0 mmol), (1R,2S) – (+)-cis-1-amino-2-indanol (298 mg, 2.0 mmol), tris(dibenzylideneacetone)dipalladium (0) (28 mg, 0.03 mmol), and 2-(di-tertbutylphosphino)biphenyl (18 mg, 0.06 mmol) in toluene (2.0 mL) was purged with nitrogen and treated with sodium tertbutoxide (135 mg, 1.4 mmol). The resulting brown suspension was heated to 100 °C for 2 hours. At 5 this time, the reaction was quenched with a saturated water solution of NaHCO₃ and extracted twice with ethyl acetate (20 mL). The combined organics were washed with brine (15 mL), dried over MgSO₄, filtered, and concentrated to give a black solid. This material was purified by biotage MPLC (40 g column, 25% ethyl 10 acetate/heptane) to afford 184 mg (65%) of the title compound as a light purple solid. IR (diffuse reflectance) 3435, 3241, 2962, 2935, 2912, 2873, 1581, 1547, 1500, 1453, 1184, 1163, 1047, 744, 733 cm⁻¹; OAMS supporting ions at: ESI+ 384.0; MS (CI) m/z 284 (MH⁺); HRMS (FAB) calcd for C₁₇H₂₁N₃O +H₁ 284.1763, found 284.1754. [α]²⁵_D = 12 (c 0.55, methylene chloride); Anal. Calcd for C₁₇H₂₁N₃O: C, 72.06; H, 7.47; N, 14.83. Found: C, 72.15; H, 7.53; N, 14.42.

Preparation 2

(1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol




20 A solution of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (1.94 g, 6.8 mmol) in dichloromethane (35 mL) was purged with nitrogen and cooled to 0 °C. This light purple/grey homogenous solution was treated with a single portion of N-bromosuccinimide (1.34 g, 7.5 mmol) instantly becoming a lighter color. The 25 reaction was warmed to room temperature for 15 minutes, transferred to a separatory funnel, diluted with 100 mL additional dichloromethane, washed twice with water (75 mL), and once with brine (75 mL). The organics were dried over MgSO₄, filtered, and concentrated to give a golden oil. This material was purified by biotage MPLC (90 g column, 15% ethyl acetate/heptane) to afford 2.24 g (90%) of the title compound as a 30 pale yellow solid. IR (diffuse reflectance) 3416, 3355, 2969, 2941, 1555, 1538, 1482, 1385, 1378, 1295, 1285, 1200, 1181, 1043, 733 cm⁻¹; OAMS supporting ions at:

ESI+ 361.9; MS (EI) *m/z* 361 (M^+); $[\alpha]^{25}_D = -35$ (*c* 0.53, methylene chloride); Anal. Calcd for $C_{17}H_{20}BrN_3O$: C, 56.36; H, 5.56; N, 11.60. Found: C, 56.46; H, 5.59; N, 11.50.

Preparation 3


5 (1*R*,2*S*)-1-{{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1*H*-inden-2-ol



10 A solution of (1*R*,2*S*)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1*H*-inden-2-ol (1.48 g, 4.12 mmol) and 2,4-dichlorophenyl boronic acid (858 mg, 4.5 mmol) in benzene (41 mL) and 2M sodium carbonate (7 mL) was purged with nitrogen and treated with a single portion of
15 bistrifphenylphosphinepalladium(II)chloride (287 mg, 0.41 mmol). The resulting golden 2-phase solution was heated to 80 °C gradually darkening in color. After 16 hours, the reaction was cooled to room temperature, transferred to a separatory funnel, and washed with water (50 mL). The aqueous layer was extracted twice with ethyl acetate (75 mL) and the combined organics were washed once with brine (75 mL), dried over $MgSO_4$, filtered, and concentrated to give 2.36 g of a brown syrup. This
20 material was purified by biotage MPLC (90 g column, 20% ethyl acetate/heptane) to afford 1.25 g (71%) of the title compound as a tan solid. OAMS supporting ions at:
ESI+ 428.0; HRMS (FAB) calcd for $C_{23}H_{23}CL_2N_3O +H_1$ 428.1296, found 428.1292.

Example 1


The preparation of 5-(2,4-dichlorophenyl)-N-[(1*R*,2*S*)-2-ethoxy-2,3-dihydro-1*H*-inden-1-yl]-3,6-diethylpyrazin-2-amine
25



A solution of sodium hydride (60% oil dispersion, 26 mg, 0.65 mmol) was suspended in DMF (1.5 mL), purged with nitrogen, and treated with a single portion of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol (214 mg, 0.5 mmol) with copious gas evolution. The resulting green/golden
 5 solution was stirred for 5 minutes at room temperature and treated with iodoethane (88 μ L, 1.1 mmol). After 3 hours, the reaction was poured into 20 mL 1:1 water/brine and extracted twice with ethyl acetate (20 mL). The combined organics were washed once with brine, dried over MgSO₄, filtered, and concentrated to give 389 mg of a golden oil. This material was purified by LC (18 g silica gel, 7% ethyl
 10 acetate/heptane) to afford 157 mg (69%) of the title compound as a pale yellow syrup.
 IR (liq.) 3446, 2972, 2935, 2896, 2874, 1565, 1552, 1498, 1470, 1391, 1206, 1184,
 1101, 1091, 1080 cm⁻¹; OAMS supporting ions at: ESI+ 456.1; MS (EI) *m/z* 455
 (M^+); $[\alpha]^{25}_D = -94$ (*c* 0.38, methylene chloride); Anal. Calcd for C₂₅H₂₇Cl₂N₃O: C, 65.79; H, 5.96; N, 9.21. Found: C, 66.06; H, 6.10; N, 9.17.

15 Example 2

The preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




20

Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting iodomethane provided the title compound as colorless syrup. OAMS supporting ions at: ESI+ 442.0; MS (EI) *m/z* 441 (M^+); HRMS (FAB) calcd for C₂₄H₂₅Cl₂N₃O +H₁ 442.1453, found 442.1456.

25 Example 3


The preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting 2-
5 iodopropane (20 equivalents iodide and sodium hydride with portion-wise addition) provided the title compound as a light yellow syrup. IR (liq.) 2971, 2935, 1564, 1552,
1497, 1471, 1392, 1379, 1368, 1206, 1177, 1140, 1123, 1101, 1061 cm⁻¹; OAMS supporting ions at: ESI+ 470.2; MS (EI) m/z 469 (M⁺); HRMS (FAB) calcd for C₂₆H₂₉Cl₂N₃O +H₁ 470.1766, found 470.1773. [α]²⁵_D = -93 (c 0.33, methylene chloride); Anal. Calcd for C₂₆H₂₉Cl₂N₃O: C, 66.38; H, 6.21; N, 8.93. Found: C, 66.53; H, 6.19; N, 8.89.

Preparation 4

Preparation of (1S,2R)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol




15

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1S,2R) – (-)-cis-1-amino-2-indanol and making non-critical variations provided the title compound as a light purple solid. MS (ESI+) for C₁₇H₂₁N₃O m/z 284.0 (M+H)⁺.

20 Preparation 5

Preparation of (1S,2R)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1S,2R)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a pale yellow solid. MS (ESI+) for C₁₇H₂₀BrN₃O m/z 361.9 (M+H)⁺.

Preparation 6

Preparation of (1S,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol.



10

Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting (1S,2R)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a tan solid. IR (diffuse reflectance) 3439, 2964, 1568, 1551, 1500, 1469, 1391, 1373, 1204, 1183, 1102, 1048, 819, 748, 741 cm⁻¹; OAMS supporting ions at: ESI+ 427.9; MS (EI) m/z 427 (M⁺); HRMS (FAB) calcd for C₂₃H₂₃Cl₂N₃O +H₁ 428.1296, found 428.1286. Anal. Calcd for C₂₃H₂₃Cl₂N₃O: C, 64.49; H, 5.41; N, 9.81. Found: C, 64.43; H, 5.54; N, 9.42.

20 **Example 4**


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1S,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and iodomethane and making non-critical variations provided the title compound as a colorless syrup. IR (liq.) 3447, 2972, 2934, 2907, 2877, 1589, 1565, 1552, 1498, 1471, 1391, 1375, 1196, 1177, 1093 cm⁻¹; OAMS supporting ions at: ESI+ 442.0; MS (EI) *m/z* 441 (M⁺); [α]²⁵_D = 55 (*c* 0.51, methanol); Anal. Calcd for C₂₄H₂₅Cl₂N₃O: C, 65.16; H, 5.70; N, 9.50. Found: C, 65.20; H, 5.63; N, 9.43.

10 Preparation 7


Preparation of (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate.



A solution of (1S,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol (321 mg, 0.75 mmol), 4-nitrobenzoic acid (552 mg, 3.3 mmol), and triphenylphosphine (964 mg, 3.7 mmol) in benzene (19 mL) was purged with nitrogen and cooled to 0°C. The resulting yellow suspension was treated with diethylazodicarboxylate (0.58 mL, 3.7 mmol) becoming lighter in color with gradual warming to RT. After 18 hours, the volatiles were removed under reduced pressure with the resulting crude residue being absorbed on 6 g silica gel and purified by Biotage MPLC (40 g column, 15% ethyl acetate/heptane) to afford the title compound as a light yellow solid. IR (diffuse reflectance) 1725, 1568, 1550, 1527, 1498, 1467, 1392, 1372, 1349, 1320, 1273, 1119, 1103, 836, 719 cm⁻¹; OAMS supporting ions at: ESI+ 576.8; MS (CI) *m/z* 577 (MH⁺); HRMS (FAB) calcd for C₃₀H₂₆Cl₂N₄O₄ +H₁ 25 577.1409, found 577.1417.

Preparation 8


Preparation of (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol.



- 5 A solution of (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate (369 mg, 0.64 mmol) in methanol (3 mL) and tetrahydrofuran (6 mL) was treated with a 1M solution of lithium hydroxide (5 mL, 5 mmol). After 16 hrs, the volatiles were removed under reduced pressure and the aqueous residue was diluted with 1M sodium hydroxide (10 mL) and extracted twice with ethyl acetate (20 mL). The combined organics were washed once with brine (20 mL), dried over MgSO₄, filtered, and concentrated to give 302 mg of a yellow syrup. This material was purified by Biotage MPLC (40 g column, 20% ethyl acetate/heptane) to afford 250 mg (91%) of the title compound as a white solid. IR (diffuse reflectance) 3325, 2976, 2936, 2900, 2876, 1571, 1550, 1503, 1471, 1449, 1435, 1399, 861, 819, 753 cm⁻¹; OAMS supporting ions at: ESI+ 427.9; MS (EI) m/z 427 (M⁺); [α]²⁵_D = -108 (c 0.58, methylene chloride); Anal. Calcd for C₂₃H₂₃Cl₂N₃O: C, 64.49; H, 5.41; N, 9.81; Cl, 16.55. Found: C, 64.27; H, 5.46; N, 9.58.

Example 5 and 6

- 20 Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine and 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-N-methylpyrazin-2-amine.




- 25 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting

(1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol. and iodomethane and making non-critical variations provided the title compounds. Analytical data for 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine; IR (diffuse reflectance) 2965, 5 1569, 1551, 1500, 1468, 1397, 1393, 1372, 1203, 1189, 1106, 988, 838, 819, 748 cm⁻¹; OAMS supporting ions at: ESI+ 442.1; MS (EI) *m/z* 441 (M⁺); Anal. Calcd for C₂₄H₂₅Cl₂N₃O: C, 65.16; H, 5.70; N, 9.50; Cl, 16.03. Found: C, 65.14; H, 5.90; N, 9.32. Analytical data for 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-N-methylpyrazin-2-amine; OAMS supporting ions at: 10 ESI+ 455.8; HRMS (FAB) calcd for C₂₅H₂₇Cl₂N₃O +H₁ 456.1609, found 456.1601.

Preparation 9

Preparation of (1R,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate.



15 Following the procedure for the preparation of (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate but substituting (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a yellow solid. IR (diffuse reflectance) 1725, 1568, 1550, 1527, 1498, 1467, 1392, 1372, 1349, 1320, 20 1273, 1119, 1103, 1014, 719 cm⁻¹; OAMS supporting ions at: ESI+ 577.1; MS (CI) *m/z* 577 (MH⁺); HRMS (FAB) calcd for C₃₀H₂₆Cl₂N₄O₄ +H₁ 577.1409, found 577.1393; [α]²⁵_D = -118 (*c* 0.62, methylene chloride).

Preparation 10

Preparation of (1R,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-

25 2,3-dihydro-1H-inden-2-ol.




Following the procedure for the preparation of (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting (1R,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl

- 5 4-nitrobenzoate and making non-critical variations provided the title compound as an off-white solid. IR (diffuse reflectance) 3326, 2976, 1572, 1550, 1503, 1472, 1449, 1435, 1399, 1358, 1198, 1074, 862, 819, 753 cm⁻¹; OAMS supporting ions at: ESI+ 428.1; MS (EI) *m/z* 427 (M⁺); HRMS (FAB) calcd for C₂₃H₂₃Cl₂N₃O +H₁ 428.1296, found 428.1295. [α]²⁵_D = 112 (*c* 0.58, methylene chloride).
- 10 Anal. Calcd for C₂₃H₂₃Cl₂N₃O: C, 64.49; H, 5.41; N, 9.81. Found: C, 64.60; H, 5.34; N, 9.75.

Example 7 and 8

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine and 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-N-methylpyrazin-2-amine.




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting

- (1R,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and iodomethane and making non-critical variations provided the title compounds. Analytical data for 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine: IR (diffuse reflectance) 3382, 2963, 2933, 1568, 1550, 1500, 1469, 1396, 1371, 1203, 1189, 1105, 988, 838, 748 cm⁻¹; OAMS supporting ions at: ESI+ 441.1; MS (EI) *m/z* 441 (M⁺); HRMS (FAB) calcd for C₂₄H₂₅Cl₂N₃O +H₁ 442.1453, found 442.1455. [α]²⁵_D = -76 (*c* 0.64,

methylene chloride). Analytical data for 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-N-methylpyrazin-2-amine: OAMS supporting ions at: ESI+ 456.1.

Example 9

- 5 Preparation of N-[(1R,2S)-2-(cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine.




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting

- 10 (bromomethyl)cyclopropane and making non-critical variations provided the title compound as a yellow amorphous solid. IR (liq.) 3442, 2971, 2935, 2874, 1565, 1552, 1498, 1471, 1393, 1206, 1184, 1101, 1077, 1021, 740 cm⁻¹; OAMS supporting ions at: ESI+ 481.8; MS (EI) *m/z* 481 (M^+); HRMS (FAB) calcd for C₂₇H₂₉Cl₂N₃O + H₁ 482.1766, found 482.1775. [α]²⁵_D = -65 (c 0.73, methylene chloride); Anal.
- 15 Calcd for C₂₇H₂₉Cl₂N₃O: C, 67.22; H, 6.06; N, 8.71. Found: C, 67.15; H, 6.08; N, 8.66.

Example 10

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(prop-2-ynyoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



20


Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting propargylbromide and making non-critical variations provided the title compound as a white solid. IR (diffuse reflectance) 3451, 3293, 2964, 2932, 1563, 1493, 1469, 1390, 1204, 1184, 1087, 1076, 820, 742, 646 cm⁻¹; OAMS supporting ions at: ESI+ 465.8;

MS (EI) *m/z* 465 (M^+); HRMS (FAB) calcd for $C_{26}H_{25}Cl_2N_3O + H_2$ 466.1453, found 466.1455. $[\alpha]^{25}_D = -56$ (*c* 0.83, methylene chloride).

Anal. Calcd for $C_{26}H_{25}Cl_2N_3O$: C, 66.96; H, 5.40; N, 9.01. Found: C, 66.96; H, 5.49; N, 8.93.

5 Example 11


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1*R*,2*S*)-2-(2-methoxyethoxy)-2,3-dihydro-1*H*-inden-1-yl]pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1*R*,2*S*)-2-ethoxy-2,3-dihydro-1*H*-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting 2-bromoethylmethylether and making non-critical variations provided the title compound as a light yellow syrup. IR (liq.) 3418, 2971, 2934, 2875, 1565, 1552, 1498, 1471, 1392, 1376, 1201, 1183, 1132, 1100, 748 cm^{-1} ; OAMS supporting ions at: ESI+ 485.8; MS (CI) *m/z* 486 (MH^+); $[\alpha]^{25}_D = -102$ (*c* 0.57, methylene chloride); Anal. Calcd for $C_{26}H_{29}Cl_2N_3O_2$: C, 64.20; H, 6.01; N, 8.64. Found: C, 63.92; H, 6.14; N, 8.53.

Example 12

Preparation of N-[(1*R*,2*S*)-2-(allyloxy)-2,3-dihydro-1*H*-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine.




20

Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1*R*,2*S*)-2-ethoxy-2,3-dihydro-1*H*-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting allybromide and making non-critical variations provided the title compound as a light yellow semi-solid. IR (liq.) 3446, 2972, 2935, 2874, 1565, 1552, 1497, 1471, 1392, 1206, 1181, 1101, 1087, 1078, 744 cm^{-1} ; OAMS supporting ions at: ESI+ 467.9;

MS (EI) m/z 467 (M^+); $[\alpha]^{25}_D = -73$ (c 0.79, methylene chloride); Anal. Calcd for $C_{26}H_{27}Cl_2N_3O$: C, 66.67; H, 5.81; N, 8.97. Found: C, 66.49; H, 5.87; N, 8.91.

Example 13


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting 1-bromo-2-fluoroethane and making non-critical variations provided the title compound as a light yellow amorphous solid. IR (diffuse reflectance) 2972, 2934, 1564, 1551, 1498, 1468, 1392, 1377, 1206, 1182, 1123, 1102, 1046, 826, 750 cm^{-1} ; OAMS supporting ions at: ESI+ 473.9; MS (EI) m/z 473 (M^+); $[\alpha]^{25}_D = -87$ (c 0.77, methylene chloride); Anal. Calcd for $C_{25}H_{26}Cl_2FN_3O$: C, 63.30; H, 5.52; N, 8.86. Found: C, 63.10; H, 5.60; N, 8.79.

Example 14

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-propoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting 1-iodopropane and making non-critical variations provided the title compound as a light yellow syrup. IR (liq.) 3446, 2967, 2935, 2875, 1564, 1552, 1497, 1470, 1392, 1206, 1184, 1101, 1091, 1082, 748 cm^{-1} ; OAMS supporting ions at: ESI+ 469.9; MS (EI) m/z 469 (M^+); $[\alpha]^{25}_D = -98$ (c 0.91, methylene chloride); Anal. Calcd for $C_{26}H_{29}Cl_2N_3O$: C, 66.38; H, 6.21; N, 8.93. Found: C, 66.53; H, 6.15; N, 9.05.

Example 15


Preparation of 2-[((1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)oxy]ethanol.



- 5 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting 2-(bromoethoxy)-tertbutyldimethylsilane and making non-critical variations provided N-[(1R,2S)-2-(2-{[tert-butyl(dimethyl)silyl]oxy}ethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine. The crude product was treated with
- 10 5% hydrochloric acid in ethanol for 18 hrs followed by removal of the volatiles under reduced pressure. The resulting residue was basified with 1N sodium hydroxide and extracted twice with ethyl acetate. The combined organics were washed once with brine, dried over MgSO₄, filtered, and concentrated to give a tan syrup. This material was purified by Biotage MPLC (40 g column, 25% ethyl acetate/heptane) to afford 67
- 15 mg of the title compound as a white solid. IR (diffuse reflectance) 2969, 2933, 1567, 1551, 1498, 1468, 1392, 1373, 1206, 1182, 1101, 1079, 1061, 1046, 749 cm⁻¹; OAMS supporting ions at: ESI+ 472.2; MS (EI) *m/z* 471 (M⁺); HRMS (FAB) calcd for C₂₅H₂₇Cl₂N₃O₂ + H₁ 472.1558, found 472.1560. [α]²⁵_D = -73 (*c* 0.50, methylene chloride); Anal. Calcd for C₂₅H₂₇Cl₂N₃O₂: C, 63.56; H, 5.76; N, 8.89. Found: C,
- 20 63.23; H, 5.91; N, 8.75.

Example 16


Preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl dimethylcarbamate.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting dimethylcarbamylchloride and making non-critical variations provided the title compound as a white solid. IR (diffuse reflectance) 3374, 2965, 1694, 1568, 1551, 1503, 1469, 1397, 1354, 1218, 1205, 1182, 765, 759, 751 cm⁻¹; OAMS supporting ions at: ESI+ 499.1; MS (EI) *m/z* 498 (M⁺); HRMS (FAB) calcd for C₂₆H₂₈Cl₂N₄O₂ +H₁ 499.1667, found 499.1684. [α]²⁵_D = 63 (c 0.71, methylene chloride); Anal. Calcd for C₂₆H₂₈Cl₂N₄O₂: C, 62.53; H, 5.65; N, 11.22. Found: C, 62.37; H, 5.74; N, 11.09.

10 Example 17


Preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate.



A solution of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol (214 mg, 0.5 mmol) and pyridine (44 μL, 0.55 mmol) in dichloromethane (5 mL) was purged with nitrogen and cooled to 0°C. The light yellow homogenous solution was treated with acetyl chloride (34 μL, 0.48 mmol) with no visible change. The reaction mixture was gradually warmed to RT. After 16 hrs, the volatiles were removed under reduced pressure and the resulting residue was absorbed on 4 g silica gel and purified by Biotage MPLC (40 g column, 15% ethyl acetate/heptane) to afford the title compound as an off-white solid. IR (diffuse reflectance) 2971, 2934, 1743, 1568, 1550, 1498, 1467, 1393, 1372, 1238, 1207, 1177, 1101, 1036, 751 cm⁻¹; OAMS supporting ions at: ESI+ 470.1; MS (EI) *m/z* 469 (M⁺); HRMS (FAB) calcd for C₂₅H₂₅Cl₂N₃O₂ +H₁ 470.1402, found 470.1404. [α]²⁵_D = 73 (c 0.60, methylene chloride); Anal. Calcd for C₂₅H₂₅Cl₂N₃O₂: C, 63.83; H, 5.36; N, 8.93. Found: C, 63.45; H, 5.40; N, 8.79.

Preparation 11


Preparation of (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 2-chloro-4-methoxyphenylboronic acid and making non-critical variations provided the title compound as an off-white amorphous solid. IR (diffuse reflectance) 2969, 2934, 1604, 1568, 1550, 1482, 1448, 1439, 1392, 1287, 1228, 1203, 1180, 1045, 740 cm⁻¹; OAMS supporting ions at: ESI+ 423.9; MS (CI) m/z 424 (MH⁺); HRMS (FAB) calcd for C₂₄H₂₆ClN₃O₂ +H₁ 424.1792, found 424.1789. Anal. Calcd for C₂₄H₂₆ClN₃O₂: C, 68.00; H, 6.18; N, 9.91. Found: C, 67.86; H, 6.29; N, 9.79.

10 Example 18


Preparation of 5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a pale yellow semi-solid. IR (liq.) 2971, 2935, 2875, 1606, 1565, 1480, 1440, 1391, 1287, 1230, 1206, 1183, 1091, 1079, 1044 cm⁻¹; OAMS supporting ions at: ESI+ 452.1; MS (EI) m/z 451 (M⁺); MS (FAB) calcd for C₂₆H₃₀ClN₃O₂ +H₁ 452.2104, found 452.2100. [α]²⁵_D = -91 (c 0.39, methylene chloride); Anal. Calcd for C₂₆H₃₀ClN₃O₂: C, 69.09; H, 6.69; N, 9.30. Found: C, 69.04; H, 6.74; N, 9.30.

Example 19


Preparation of 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and 1-bromo-2-fluoroethane and making non-critical variations provided the title compound as a pale yellow semi-solid. IR (diffuse reflectance) 2970, 1604, 1564, 1481, 1439, 1391, 1286, 1228, 1204, 1182, 1123, 1109, 1044, 876, 750 cm⁻¹; OAMS supporting ions at: ESI+ 470.1; MS (EI) m/z 469 (M⁺); HRMS (FAB) calcd for C₂₆H₂₉ClFN₃O₂ +H₁ 470.2010, found 470.2013. [α]²⁵_D = -82 (c 0.39, methylene chloride); Anal. Calcd for C₂₆H₂₉ClFN₃O₂: C, 66.45; H, 6.22; N, 8.94. Found: C, 66.41; H, 6.37; N, 8.84.

Example 20


Preparation of (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate.



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate but substituting (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a light yellow semi-solid. IR (diffuse reflectance) 2969, 2933, 1742, 1604, 1568, 1551, 1482, 1439, 1393, 1372, 1286, 1232, 1204, 1176, 1037 cm⁻¹; OAMS supporting ions at: ESI+ 465.2; MS (EI) m/z 465 (M⁺); [α]²⁵_D = 79 (c 0.80, methylene chloride); Anal. Calcd for C₂₆H₂₈ClN₃O₃: C, 67.02; H, 6.06; N, 9.02. Found: C, 66.99; H, 6.18; N, 8.92.

25 Preparation 12


Preparation of (1R,2S)-1-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol.



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 2-methyl-4-methoxyphenylboronic acid and making non-critical variations provided the title compound as a peach colored foam. IR (diffuse reflectance) 3439, 2968, 2933, 2875, 1608, 1564, 1482, 1391, 1294, 1279, 1242, 1204, 1175, 1050, 742 cm⁻¹; OAMS supporting ions at: ESI+ 404.0 & ESI- 402.1; MS (EI) *m/z* 403 (M⁺); HRMS (FAB) calcd for C₂₅H₂₉N₃O₂ +H₁ 404.2338, found 404.2324. Anal. Calcd for C₂₅H₂₉N₃O₂: C, 74.41; H, 7.24; N, 10.41. Found: C, 74.05; H, 7.44; N, 10.28.

Example 21


Preparation of N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a light yellow semi-solid. IR (liq.) 2971, 2934, 1609, 1562, 1480, 1391, 1294, 1243, 1206, 1184, 1171, 1161, 1119, 1091, 1054 cm⁻¹; OAMS supporting ions at: ESI+ 432.1; MS (EI) *m/z* 431 (M⁺); HRMS (FAB) calcd for C₂₇H₃₃N₃O₂ +H₁ 432.2651, found 432.2650. Anal. Calcd for C₂₇H₃₃N₃O₂: C, 75.14; H, 7.71; N, 9.74. Found: C, 74.86; H, 7.72; N, 9.67.

Example 22


Preparation of 3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting
 5 (1R,2S)-1-{{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and 1-bromo-2-fluoroethane and making non-critical variations provided the title compound as a pale yellow semi-solid. IR (liq.) 2969, 2935, 1609, 1563, 1482, 1391, 1294, 1243, 1206, 1182, 1172, 1159, 1124, 1110, 1047
 10 cm⁻¹; OAMS supporting ions at: ESI+ 450.0; MS (CI) *m/z* 450 (MH⁺); HRMS (FAB) calcd for C₂₇H₃₂FN₃O₂ +H₁ 450.2556, found 450.2544. Anal. Calcd for C₂₇H₃₂FN₃O₂: C, 72.14; H, 7.17; N, 9.35. Found: C, 72.24; H, 7.20; N, 9.33.

Preparation 13


Preparation of (1R,2S)-1-{{[5-(2,4-dimethoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol.



Following the procedure for the preparation of (1R,2S)-1-{{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 2,4-dimethoxyphenylboronic acid and making non-critical variations provided the title
 20 compound as an off-white foam. IR (diffuse reflectance) 2966, 2934, 1610, 1567, 1483, 1391, 1303, 1280, 1253, 1208, 1159, 1128, 1046, 1034, 741 cm⁻¹; OAMS supporting ions at: ESI+ 420.1; MS (EI) *m/z* 419 (M⁺); HRMS (FAB) calcd for C₂₅H₂₉N₃O₃ +H₁ 420.2287, found 420.2278.

Example 23


Preparation of 5-(2,4-dimethoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dimethoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a white solid, m.p. 120-121 °C (uncorrected). IR (diffuse reflectance) 2965, 2935, 1615, 1566, 1480, 1390, 1305, 1256, 1215, 1209, 1183, 1165, 1040, 825, 747 cm⁻¹; OAMS supporting ions at: ESI+ 448.1; MS (EI) *m/z* 447 (M⁺); HRMS (FAB) calcd for C₂₇H₃₃N₃O₃ +H₁ 448.2600, found 448.2600. Anal. Calcd for C₂₇H₃₃N₃O₃: C, 72.46; H, 7.43; N, 9.39. Found: C, 72.46; H, 7.59; N, 9.39.

Example 24


Preparation of 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dimethoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and 1-bromo-2-fluoroethane and making non-critical variations provided the title compound as a white solid. IR (diffuse reflectance) 2964, 2935, 1614, 1567, 1480, 1392, 1305, 1256, 1215, 1209, 1165, 1158, 1040, 825, 747 cm⁻¹; OAMS supporting ions at: ESI+ 466.2; MS (EI) *m/z* 465 (M⁺); Anal. Calcd for C₂₇H₃₂FN₃O₃: C, 69.66; H, 6.93; N, 9.03. Found: C, 69.61; H, 7.02; N, 8.98.

25 Preparation 14

Preparation of (1R,2S)-1-{[5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol.




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-

- 5 3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 2-chloro-4-dimethylaminophenylboronic acid and making non-critical variations provided the title compound as a pale yellow amorphous solid. IR (diffuse reflectance) 2969, 2932, 1607, 1567, 1550, 1486, 1443, 1391, 1353, 1225, 1207, 1177, 1043, 961, 740 cm⁻¹; OAMS ESI+ 437.2; MS (EI) *m/z* 436 (M⁺); HRMS (FAB) calcd for C₂₅H₂₉ClN₄O +H₁ 437.2108, found 437.2089. [α]²⁵_D = -7 (*c* 0.70, methylene chloride); Anal. Calcd for C₂₅H₂₉ClN₄O: C, 68.72; H, 6.69; N, 12.82. Found: C, 68.48; H, 6.84; N, 12.66.

Example 25

Preparation of 5-[2-chloro-4-(dimethylamino)phenyl]-N-[(1R,2S)-2-ethoxy-2,3-

- 15 **dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.**




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting

- (1R,2S)-1-{[5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a pale yellow amorphous solid. IR (diffuse reflectance) 2971, 2932, 2890, 2875, 1608, 1563, 1482, 1442, 1389, 1366, 1352, 1207, 1175, 1090, 961 cm⁻¹; OAMS supporting ions at: ESI+ 465.2; MS (EI) *m/z* 464 (M⁺); HRMS (FAB) calcd for C₂₇H₃₃ClN₄O +H₁ 465.2421, found 465.2406. Anal. Calcd for C₂₇H₃₃ClN₄O: C, 69.74; H, 7.15; N, 12.05. Found: C, 69.68; H, 7.16; N, 11.99.

Example 26


Preparation of 5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.



- 5 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-({5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazin-2-yl}amino)-2,3-dihydro-1H-inden-2-ol and 1-bromo-2-fluoroethane and making non-critical variations provided the title compound as a light yellow amorphous solid. IR (diffuse reflectance) 2969, 2932, 2907, 2877, 1608, 1563, 1545, 1483, 1447, 1392, 1353, 1207, 1177, 1123, 1042 cm⁻¹; OAMS supporting ions at: ESI+ 483.2; MS (EI) *m/z* 482 (M⁺); HRMS (FAB) calcd for C₂₇H₃₂ClFN₄O +H₁ 483.2327, found 483.2324. [α]²⁵_D = -79 (c 0.52, methylene chloride); Anal. Calcd for C₂₇H₃₂ClFN₄O: C, 67.14; H, 6.68; N, 11.60. Found: C, 67.19; H, 6.90; N, 11.63.

15 Preparation 15

Preparation of (1R,2S)-1-({5-[6-(dimethylamino)-4-methylpyridin-3-yl]-3,6-diethylpyrazin-2-yl}amino)-2,3-dihydro-1H-inden-2-ol.




- Following the procedure for the preparation of (1R,2S)-1-({5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl}amino)-2,3-dihydro-1H-inden-2-ol but substituting 6-(dimethylamino)-4-methylpyridin-3-ylboronic acid and making non-critical variations provided the title compound as a light yellow amorphous solid. IR (diffuse reflectance) 3448, 2962, 2954, 2933, 1611, 1567, 1520, 1482, 1392, 1376, 1174, 1160, 1046, 741, 737 cm⁻¹; OAMS supporting ions at: ESI+ 418.3; MS (EI) *m/z* 417 (M⁺); HRMS (FAB) calcd for C₂₅H₃₁N₅O +H₁ 418.2607, found 418.2611. Anal.

Calcd for C₂₅H₃₁N₅O: C, 71.91; H, 7.48; N, 16.77. Found: C, 71.59; H, 7.57; N, 16.40.

Example 27


Preparation of 5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{5-[6-(dimethylamino)-4-methylpyridin-3-yl]-3,6-diethylpyrazin-2-yl}amino)-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a light golden amorphous solid. IR (diffuse reflectance) 3446, 2969, 2931, 2893, 2874, 1604, 1562, 1517, 1487, 1392, 1372, 1208, 1174, 1123, 1089 cm⁻¹; OAMS supporting ions at: ESI+ 446.3; MS (EI) m/z 445 (M⁺); HRMS (FAB) calcd for C₂₇H₃₅N₅O +H₁ 446.2920, found 446.2915. [α]²⁵_D = -89 (c 0.47, methylene chloride); Anal. Calcd for C₂₇H₃₅N₅O: C, 72.78; H, 7.92; N, 15.72. Found: C, 72.58; H, 7.94; N, 15.59.

Preparation 16


Preparation of N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{(3,6-diethylpyrazin-2-yl)amino}-2,3-dihydro-1H-inden-2-ol but substituting 1-Aminoindane and 3-chloro-2,5-dimethylpyrazine, and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.88, 2.35, 2.41, 2.77, 2.94, 3.03, 4.55, 5.78, 7.3, 7.64; MS (ESI+) for C₁₅H₁₇N₃ m/z 240.30 (M+H)⁺.

25 Preparation 17

Preparation of 5-bromo-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine



- Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.86, 2.26, 2.53, 2.70, 2.93, 3.03, 4.50, 5.72, 7.28; ^{13}C NMR (CDCl_3) δ 19.23, 23.21, 30.25, 34.56, 56.45, 124.05, 124.81, 124.97, 126.78, 128.03, 136.98, 143.71, 144.09, 148.36, 151.15; MS (ESI+) for $\text{C}_{15}\text{H}_{16}\text{N}_3\text{Br}_1$ m/z 319.20 ($\text{M}+\text{H}$) $^+$.

Example 28


- Preparation of 5-(2,4-dichlorophenyl)-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine



- Following the procedure for the preparation of (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.94, 2.29, 2.39, 2.80, 2.96, 3.08, 4.64, 5.83, 7.33, 7.51; MS (ESI+) for $\text{C}_{21}\text{H}_{19}\text{Cl}_2\text{N}_3$ m/z 385.30 ($\text{M}+\text{H}$) $^+$.

Example 29

- Preparation of N-(2,3-dihydro-1H-inden-1-yl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethylpyrazin-2-amine




- Following the procedure for the preparation of (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine and 2-methyl-4-methoxy

phenyl boronic acid, and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.92, 2.17, 2.26, 2.39, 2.80, 2.98, 3.07, 3.85, 4.54, 5.82, 6.84, 7.15, 7.30, 7.41; MS (ESI+) for $\text{C}_{23}\text{H}_{25}\text{N}_3\text{O}_1$ m/z 360.4 ($\text{M}+\text{H}$) $^+$.

Preparation 18

- 5 Preparation of 3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 1,2,3,4-tetrahydronaphthalen-1-amine and 3-chloro-2,5-dimethylpyrazine, and making non-critical variations

- 10 provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.91, 2.11, 2.31, 2.40, 2.87, 4.50, 5.16, 7.21, 7.35, 7.62; MS (ESI+) for $\text{C}_{16}\text{H}_{19}\text{N}_3$ m/z 254.4 ($\text{M}+\text{H}$) $^+$.

Preparation 19

Preparation of 5-bromo-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




15

Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.92, 2.08, 2.29, 2.53, 2.86, 4.48, 5.40, 7.21, 7.33; ^{13}C NMR (CDCl_3) δ 19.63, 20.32, 23.67, 29.81, 30.00, 49.20, 124.85, 126.66, 127.69, 129.23, 129.63, 137.17, 138.12, 138.25, 148.78, 151.23; MS (ESI+) for $\text{C}_{16}\text{H}_{18}\text{N}_3\text{Br}_1$ m/z 333.3 ($\text{M}+\text{H}$) $^+$.

Example 30

Preparation of 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-


- 25 1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting Preparation of 5-bromo-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as
 5 a oil: ^1H NMR (CDCl_3) δ 1.95, 2.15, 2.28, 2.35, 2.90, 4.62, 5.52, 7.23, 7.34, 7.41, 7.51; MS (ESI+) for $\text{C}_{22}\text{H}_{21}\text{Cl}_3\text{N}_3$ m/z 399.1 ($\text{M}+\text{H}$)⁺.

Example 31

Preparation of 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




10

Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and 2-methyl-4-methoxy phenyl boronic acid, and making non-
 15 critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.81, 2.01, 2.06, 2.13, 2.22, 2.77, 3.71, 4.38, 5.39, 6.70, 7.09, 7.31; ^{13}C NMR (CDCl_3) δ 20.07, 20.47, 20.54, 22.09, 29.96, 30.28, 48.94, 55.68, 111.58, 116.05, 126.64, 127.57, 129.43, 129.60, 131.24, 132.37, 135.83, 138.31, 138.56, 138.74, 140.69, 147.04, 150.92, 159.51; HRMS (ESI+) for $\text{C}_{24}\text{H}_{27}\text{N}_3\text{O}_1$ m/z cald 374.2232 ($\text{M}+\text{H}$)⁺
 20 found 374.2226

Preparation 20

Preparation of 3-(2,4-dichlorophenyl)-2,5-dimethylpyrazine




To a solution of 3-chloro-2,5-dimethylpyrazine (2g, 14mmol) in DME (35 ml)
 25 and 2N sodium bicarbonate (14 ml) was added 2,4-dichloroboronic acid (15.4mmol, 2.94g) and tetrakis(triphenylphosphine)palladium (810mg). The reaction mixture was heated at 85°C for 12hr. The reaction mixture was cooled, diluted with Et_2O , washed with NaHCO_3 (sat'd) and dried (MgSO_4). Flash chromatography (Silica gel, Heptane:

EtOAc 20: 1) gave the title compound (91% yield). ^1H NMR (CDCl_3) δ 2.40, 2.60, 7.29, 7.40, 8.43; ^{13}C NMR (CDCl_3) δ 21.52, 21.72, 127.97, 129.99, 131.80, 134.18, 135.69, 136.77, 143.58, 149.73, 150.66, 150.82; MS (ESI+) for $\text{C}_{12}\text{H}_{10}\text{Cl}_2\text{N}_2$ m/z 254.2 ($\text{M}+\text{H}$) $^+$.

5 Preparation 21


Preparation of 2-bromo-5-(2,4-dichlorophenyl)-3,6-dimethylpyrazine



POBr₃ (573mg) was added to the solution of 3-(2,4-dichlorophenyl)-2,5-dimethylpyrazine 1-oxide (270mg) and proton sponge (197mg) in CH_2Cl_2 at 0°C. The reaction mixture was warmed to r. t. for 10 h. The reaction mixture was washed with 1N HCl, NaHCO₃ and brine, dried (MgSO_4), filtered and concentrated. Flash chromatography (silica gel Heptane: EtOAC 100:1) gave the title compound (110mg, 35%) and 3-(2,4-dichlorophenyl)-2,5-dimethylpyrazine (100mg, 38%). ^1H NMR (CDCl_3) δ 2.40, 2.71, 7.28, 7.40, 7.54; MS (ESI+) for $\text{C}_{12}\text{H}_9\text{Cl}_2\text{N}_2\text{Br}_1$ m/z 333.0 ($\text{M}+\text{H}$) $^+$.

Example 32


Preparation of N-[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazin-2-yl]isoquinolin-1-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 2-bromo-5-(2,4-dichlorophenyl)-3,6-dimethylpyrazine and isoquinolin-1-amine, and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 2.36, 2.93, 6.75, 7.38, 7.53, 7.57, 8.96; HRMS (ESI+) calcd for $\text{C}_{21}\text{H}_{16}\text{Cl}_2\text{N}_4$ ($\text{M}+\text{H}$) $^+$ 395.0830, found 395.0821.

Preparation 22


Preparation of 3-(2,4-dichlorophenyl)-2,5-dimethylpyrazine 1-oxide



To a solution of 3-(2,4-dichlorophenyl)-2,5-dimethylpyrazine at 0°C in dioxane was added mCPBA (750 mg). The reaction mixture was heated at 45°C for 3 h. The reaction was diluted with CH₂Cl₂, washed with NaHCO₃, dried (MgSO₄), filtered, and concentrated. It was used without purification: ¹H NMR (CDCl₃) δ 2.30, 2.54, 7.33, 7.42, 7.54, 8.13; ¹³C NMR (CDCl₃) δ 14.04, 21.85, 128.10, 130.12, 131.64, 132.14, 134.07, 135.23, 136.44, 141.66, 153.87, 154.24.

Preparation 23


Preparation of 3-(2,4-dichlorophenyl)-2,5-diethylpyrazine



Following the procedure for the preparation of 3-(2,4-dichlorophenyl)-2,5-dimethylpyrazine but 3-chloro-2,5-diethylpyrazine and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.19, 1.35, 2.65, 2.88, 7.29, 7.39, 7.54, 8.47; ¹³C NMR (CDCl₃) δ 13.52, 14.48, 28.03, 28.97, 128.01, 130.22, 132.07, 134.61, 135.77, 137.02, 143.22, 150.44, 154.57, 155.84; MS (ESI+) for C₁₄H₁₄Cl₂N₂ m/z 282.2 (M+H)⁺.

Preparation 24


Preparation of 3-(2,4-dichlorophenyl)-2,5-diethylpyrazine 1-oxide



Following the procedure of 3-(2,4-dichlorophenyl)-2,5-dimethylpyrazine 1-oxide but substituting Preparation of 3-(2,4-dichlorophenyl)-2,5-diethylpyrazine and making non-critical variations, the title compound was obtained (quantitative). It was used without preparation. ¹H NMR (CDCl₃) δ 1.12, 1.34, 2.55, 2.81, 2.89, 7.28, 7.40, 7.55, 8.11.

Preparation 25

Preparation of 2-bromo-5-(2,4-dichlorophenyl)-3,6-diethylpyrazine




Following the procedure of 2-bromo-5-(2,4-dichlorophenyl)-3,6-diethylpyrazine but substituting 3-(2,4-dichlorophenyl)-2,5-diethylpyrazine 1-oxide

and making non-critical variations provided the title compound as an oil: ^1H NMR (CDCl_3) δ 1.19, 7.5, 1.33, 2.63, 3.02, 7.28, 7.39, 7.54; MS (ESI+) for $\text{C}_{14}\text{H}_{13}\text{Br}_1\text{Cl}_2\text{N}_2$ m/z 361.1 ($\text{M}+\text{H}$) $^+$.

Example 33

- 5 Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(3-ethyl-6-methylpyridin-2-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 2-bromo-5-(2,4-

- 10 dichlorophenyl)-3,6-diethylpyrazine and 3-ethyl-6-methylpyridin-2-amine, and making non-critical variations provided the title compound as a oil: ^1H NMR ($\text{DMSO}-d_6$) δ 0.95, 1.15, 2.33, 2.31, 2.51, 2.70, 6.95, 7.51, 7.75, 8.57; HRMS (ESI+) calcd for $\text{C}_{22}\text{H}_{24}\text{Cl}_2\text{N}_4$ ($\text{M}+\text{H}$) $^+$ 415.1456, found 415.1442.

Example 34

- 15 Preparation of 5-(2,4-dichlorophenyl)-N-(4,6-dimethylpyridin-2-yl)-3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 2-bromo-5-(2,4-

- 20 dichlorophenyl)-3,6-diethylpyrazine and 4,6-dimethylpyridin-2-amine, and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.31, 1.38, 2.37, 2.46, 2.62, 2.90, 6.68, 7.31, 7.37, 7.52, 8.28; HRMS (ESI+) Calcd for $\text{C}_{21}\text{H}_{22}\text{Cl}_2\text{N}_4$ ($\text{M}+\text{H}$) $^+$ 401.1299, found 401.1317.

Preparation 26

- 25 Preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine




To a solution of 6,7-dihydro-1-benzofuran-4(5H)-one (2.0g) in methanol (50 ml) was added 3 Å sieves (15 g), ammonium acetate (11.3 g) and sodium cyanoborohydride (1.22 g). After 48 h of stirring, the reaction mixture was filtered through celite, concentrated, dissolved in 1 N HCl (100 ml) and washed with ethyl ether (3 x 100 ml). The Aqueous layer was basified to pH 10 (NaOH), extracted methylene chloride (3 x 100 ml), dried MgSO₄, filtered and concentrated to yield (760 mg, 38%) of the title compound as an oil:

¹H NMR (400 MHz, CDCl₃) δ 7.27, 6.39, 3.87, 2.61, 2.00, 1.81, 1.48; ¹³C NMR (100 MHz, CDCl₃) δ 151.47, 141.11, 122.31, 109.29, 45.93, 34.81, 23.38, 20.63.

10 Preparation 27

Preparation of 3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 4,5,6,7-tetrahydro-1-

15 benzofuran-4-amine and making non-critical variations provided the title compound as a oil:

¹H NMR (400 MHz, CDCl₃) δ 7.66, 7.29, 6.32, 5.25, 4.40, 2.69, 2.57, 2.07, 1.92, 1.36; (MS/CI) calcd for C₁₆H₂₁N₃O+H 272.1, found 272.1.

Preparation 28

20 Preparation of 5-bromo-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-

25 diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.29,

6.03, 5.18, 4.49, 2.81, 2.65, 2.55, 2.03, 1.89, 1.23; (FAB) calcd for $C_{16}H_{20}BrN_3O+H$ 351.0, found 351.0.

Example 35

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-{{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: 1H NMR (400 MHz, $CDCl_3$) δ

10 7.50, 7.34, 5.30, 4.53, 2.68, 2.62, 2.51, 2.09, 1.94 1.26, 1.20; HRMS (EI) calcd for $C_{22}H_{23}Cl_2N_3O$ 415.1218, found 415.1217.

Preparation 29

Preparation of 5-methyl-6,7-dihydro-1-benzofuran-4(5H)-one




15

Following the procedure for the preparation of 5-methyl-6,7-dihydro-1-benzothiophen-4(5H)-one but substituting 6,7-dihydro-1-benzofuran-4(5H)-one and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 1.24, 1.95, 2.25, 2.55, 2.93, 6.68, 7.33; MS (EI) m/z (rel. intensity) 150 (M+, 54), 20 150 (54), 121 (10), 109 (8), 108 (99), 86 (26), 84 (39), 80 (56), 52 (19), 51 (26), 50 (7). HRMS (FAB) calcd for $C_9H_{10}O_2+H$ 151.0759, found 151.0760. Anal. Calcd for $C_9H_{10}O_2$: C, 71.98; H, 6.71. Found: C, 71.55; H, 6.74; N, 0.19.

Preparation 30

Preparation of 5-methyl-4,5,6,7-tetrahydro-1-benzofuran-4-amine




25

Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 5-methyl-6,7-dihydro-1-benzofuran-4(5H)-one and making

non-critical variations provided the title compound as a oil: MS (EI) m/z (rel. intensity) 151 (M+, 64), 151 (64), 134 (86), 110 (83), 109 (99), 108 (55), 88 (56), 86 (87), 84 (92), 80 (76), 51 (67). HRMS (FAB) calcd for C₉H₁₃NO+H 152.1075, found 152.1066.

5 Example 36


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 2-bromo-5-(2,4-dichlorophenyl)-3,6-diethylpyrazine and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.13, 1.19, 1.26, 1.78, 2.04, 2.50, 2.65, 4.50, 5.02, 6., 7.31, 7.50; HRMS (ESI+) calcd for C₂₃H₂₅Cl₂N₃O₁ (M+H)⁺ 480.1453, found 430.1436.

15 Preparation 31


Preparation of 5-ethyl-6,7-dihydro-1-benzofuran-4(5H)-one



Following the procedure for the preparation of 5-methyl-6,7-dihydro-1-benzothiophen-4(5H)-one but substituting 6,7-dihydro-1-benzofuran-4(5H)-one and ethyl iodide and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.00, 1.54, 1.95, 2.29, 2.91, 6.67, 7.3; MS (EI) m/z (rel. intensity) 164 (M+, 36), 164 (36), 136 (90), 135 (24), 108 (76), 88 (13), 86 (69), 84 (99), 80 (58), 52 (21), 51 (57). HRMS (FAB) calcd for C₁₀H₁₂O₂+H 165.0916, found 165.0919. Anal. Calcd for C₁₀H₁₂O₂: C, 73.15; H, 7.37. Found: C, 72.81; H, 7.60.

25 Preparation 32

Preparation of (4E) and (4Z)-5-ethyl-6,7-dihydro-1-benzofuran-4(5H)-one oxime




Following the procedure for the preparation of (4E)-2,3-dihydro-4H-chromen-4-one oxime but substituting 5-ethyl-6,7-dihydro-1-benzofuran-4(5H)-one and making non-

critical variations provided the title compound as a oil: MS (EI) m/z (rel. intensity) 179 (M+, 21), 162 (50), 151 (43), 135 (99), 134 (99), 107 (86), 106 (83), 84 (34), 79 (35), 52 (47), 51 (48). HRMS (FAB) calcd for C₁₀H₁₃NO₂+H 180.1024, found 180.1015.

5 Preparation 33


Preparation of cis 5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-amine



Following the procedure for the preparation of cis-5-propyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine but substituting (4E) and (4Z)-5-ethyl-6,7-dihydro-1-benzofuran-4(5H)-one oxime and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.02, 1.30-1.73, 2.50-2.67, 3.84, 6.38, 7.27; HRMS (FAB) calcd for C₁₀H₁₅NO+H 166.1232, found 166.1231. Anal. Calcd for C₁₀H₁₅NO: C, 72.69; H, 9.15; N, 8.48. Found: C, 72.33; H, 9.14; N, 8.08.

Preparation 34

15 Preparation of trans 5- ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-amine



Following the procedure for the preparation of cis-5-propyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine but substituting (4E) and (4Z)-5-ethyl-6,7-dihydro-1-benzofuran-4(5H)-one oxime and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.02, 1.30-1.73, 2.50-2.67, 4.46, 6.10, 7.24; HRMS (FAB) calcd for C₁₀H₁₅NO+H 166.1232, found 166.1231. Anal. Calcd for C₁₀H₁₅NO: C, 72.69; H, 9.15; N, 8.48. Found: C, 72.33; H, 9.14; N, 8.08

Example 37

25 Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(cis)-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl]pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting cis 5-ethyl-4,5,6,7-tetrahydro-1-

benzofuran-4-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 0.89, 1.11, 1.16, 1.53-1.65, 1.86, 2.42-2.49, 2.53, 2.65-2.74, 3.66, 3.77, 4.21, 5.48, 6.27, 7.01, 7.10-7.31, 7.40; MS (EI) m/z (rel. intensity) 443 (M+, 29), 443 (29), 296 (22), 295 (23), 207 (39), 149 (99), 148 (57), 119 (39), 107 (23), 91 (45), 55 (22). HRMS (FAB) calcd for $\text{C}_{24}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 444.1609, found 444.1610.

Example 38

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(cis)-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl]pyrazin-2-amine




10

Following the procedure for the preparation of (1*R*,2*S*)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1*H*-inden-2-ol but substituting trans-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.05, 1.17, 1.29, 1.80, 1.90, 2.04, 2.49, 2.63, 3.49, 3.83, 4.50, 5.11, 6.32, 7.30-7.38, 7.50; HRMS (FAB) calcd for $\text{C}_{24}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 444.1609, found 444.1600.

Preparation 35


Preparation of 3,4-dihydro-2*H*-thiochromen-4-ylamine



Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 2,3-dihydro-4*H*-thiochromen-4-one and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.30, 7.07, 4.07, 3.28, 2.96, 2.16, 1.61; (MS/CI) calcd for $\text{C}_9\text{H}_{11}\text{NS}+\text{H}$ 166.3, found 166.3.

Preparation 36

Preparation of N-(3,4-dihydro-2*H*-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,4-dihydro-2H-thiochromen-4-ylamine and making non-critical variations provided the title compound as a oil:

¹H NMR (400 MHz, CDCl₃) δ 7.71, 7.30, 7.15, 7.05, 5.44, 4.51, 3.17, 2.98, 2.68,

- 5 2.64, 2.56, 2.14, 1.31; HRMS (FAB) calcd for C₁₇H₂₁N₃S+H 300.1534, found 300.1532.

Preparation 37

Preparation of 5-bromo-N-(3,4-dihydro-2H-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine




10

Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting N-(3,4-dihydro-2H-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.28, 7.19, 7.04, 5.38, 4.50, 3.53, 2.99, 2.84, 2.64, 2.55, 2.13, 1.31, 1.24; ¹³C NMR (100 MHz, CDCl₃) δ 152.50, 149.99, 141.71, 134.14, 134.03, 131.10, 128.59, 127.30, 125.65, 124.88, 48.74, 29.40, 27.58, 25.83, 23.05, 12.52, 11.26; HRMS (EI) calcd for C₁₇H₂₀BrN₃S 377.0562, found 377.0565.

Example 39

- 20 Preparation of 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-

- 25 N-(3,4-dihydro-2H-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.51, 7.36, 7.32, 7.29, 7.20, 7.07, 5.49, 4.64, 3.23, 3.02, 2.72, 2.64, 2.53, 2.20, 1.27,

1.22; ^{13}C NMR (100 MHz, CDCl_3) δ 151.42, 150.26, 140.63, 137.74, 137.67, 135.29, 134.57, 134.22, 132.88, 131.23, 129.81, 129.11, 128.53, 127.52, 127.28, 124.87, 48.48, 27.58, 26.34, 23.18, 23.11, 13.30, 11.64; HRMS (FAB) calcd for $\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{N}_3\text{S}+\text{H}$ 444.1068, found 444.1055.

5 Preparation 38

Preparation of 3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 1,2,3,4-tetrahydronaphthalen-1-amine and making non-critical variations provided the title compound as a oil:

^1H NMR (400 MHz, CDCl_3) δ 7.81, 7.38, 7.19, 5.49, 4.56, 2.87, 2.69, 2.57, 2.12, 1.98, 1.91, 1.32; ^{13}C NMR (100 MHz, CDCl_3) δ 153.69, 151.42, 140.81, 138.70, 138.29, 129.85, 129.56, 129.18, 127.49, 126.58, 48.71, 30.07, 29.94, 28.56, 26.07, 20.42, 13.96, 11.16; HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{23}\text{N}_3+\text{H}$ 282.1970, found 282.1975.

15 Preparation 39


Preparation of 5-bromo-3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.34, 7.21, 5.40, 4.54, 2.55, 2.09, 1.95, 1.28; ^{13}C NMR (100 MHz, CDCl_3) δ 152.49, 150.66, 141.49, 138.29, 138.21, 129.63, 129.27, 127.64, 126.65, 124.90, 60.81, 49.31, 29.89, 28.87, 29.39, 21.46, 20.32, 14.61, 11.26. (MS/CI) calcd for $\text{C}_{18}\text{H}_{22}\text{BrN}_3+\text{H}$ 360.3, found 360.3.

Example 40


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-5,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.40, 7.32, 7.20, 7.08, 5.41, 4.57, 2.80, 2.53, 2.41, 2.06, 1.96, 1.90, 1.18; ^{13}C NMR (100 MHz, CDCl_3) δ 151.50, 150.93, 140.37, 138.53, 138.37, 137.87, 137.123, 135.36, 134.43, 132.95, 129.78, 129.62, 129.44, 127.57, 127.51, 125.63, 60.82, 49.01, 29.96, 27.62, 26.93, 14.61, 13.32, 11.67; HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{22}\text{BrN}_3\text{+H}$ 360.1076, found 360.1065.

Example 41


Preparation of 2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1,2,3,4-tetrahydronaphthalen-1-yloxy)pyrazine



A solution of 1,2,3,4-tetrahydronaphthalen-1-ol (248mg) in DMSO (3 ml) was added to NaH (100mg) suspended in DMSO (4 ml). The reaction mixture was stirred at r.t. for 1 hour and heated at 75°C for 1 hour. 2-bromo-5-(2,4-dichlorophenyl)-3,6-diethylpyrazine in DMSO (3 ml) was added. After 24 h, the rxn mixture was diluted with 30ml of H_2O , extracted with CH_2Cl_2 , washed with NaHCO_3 , brine, dried (MgSO_4), filtered and concentrated. Flash chromatography (1:50 EtOAC: Heptane) gave the title compound: ^1H NMR (CDCl_3) δ 1.23, 1.95, 2.13, 2.20, 2.58, 2.83, 2.96, 6.46, 7.36; HRMS (ESI+) calcd for $\text{C}_{24}\text{H}_{24}\text{Cl}_2\text{N}_2\text{O}_1$ (M+H^+) 427.1344, found 427.1359.

Preparation 40


Preparation of 7-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine



Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 7-methoxy-3,4-dihydronaphthalen-1(2H)-one and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 6.99, 6.75, 3.95, 3.82, 2.74, 2.05, 1.96, 1.71, 1.67, 1.56; ¹³C NMR (100 MHz, CDCl₃) δ 158.28, 142.62, 130.30, 129.19, 113.44, 112.88, 55.73, 50.12, 34.17, 29.12, 20.26.

Preparation 41

Preparation of 3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




10

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 7-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.67, 7.08, 6.92, 6.81, 5.42, 4.54, 3.75, 2.84-2.77, 2.68, 2.56, 2.10, 1.88, 1.36-1.27; (MS/CI) calcd for C₁₉H₂₅N₃O+H 312.4, found 312.1.

Preparation 42

Preparation of 5-bromo-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



20

Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.08, 6.88, 6.81, 5.36, 4.52, 3.76, 2.79, 2.56, 2.08, 1.91, 1.31; (FAB) calcd for C₁₉H₂₄BrN₃O+H 390.0, found 390.0.

Example 42

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



- 5 Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.51, 7.34, 7.10, 6.99, 6.83, 5.47, 4.68, 3.78, 2.85, 2.65, 2.53, 2.15, 10. 2.01, 1.27, 1.21; ^{13}C NMR (100 MHz, CDCl_3) δ 173.14, 157.25, 150.37, 149.81, 139.28, 138.42, 136.72, 136.05, 134.21, 133.33, 131.82, 129.41, 129.26, 128.65, 126.39, 112.41, 54.61, 48.17, 28.92, 28.00, 26.49, 25.27, 19.52, 12.19, 10.54; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 456.1609, found 456.1601.

Example 43

- 15 Preparation of 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




- Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and 2-chloro-4-methoxyphenylboronic acid, and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.29, 7.11, 7.04, 6.99, 6.91, 6.84, 5.47, 4.64, 3.86, 3.78, 2.83, 2.68, 2.55, 2.15, 1.91, 1.74, 1.27, 1.21; ^{13}C NMR (100 MHz, CDCl_3) δ 160.08, 158.37, 151.72, 150.71, 140.19, 139.72, 138.22, 136.12, 135.06, 132.59, 131.63, 130.50, 130.39, 115.13, 114.20, 113.41, 55.99, 55.74, 49.29,

30.08, 29.16, 27.66, 26.50, 20.66, 13.35, 11.82; HRMS (FAB) calcd for C₂₆H₃₀ClN₃O₂+H 452.2104, found 452.2097.

Preparation 43

Preparation of 5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine




5

Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 5-methoxy-3,4-dihydronaphthalen-1(2H)-one and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.19, 7.05, 6.75, 4.00, 3.84, 2.76, 2.61, 1.97, 1.70; ¹³C NMR (100 MHz, CDCl₃) δ 157.44, 142.83, 126.67, 126.02, 120.53, 108.09, 55.72, 49.75, 33.21, 23.57, 19.11; HRMS (FAB) calcd for C₁₁H₁₅NO+H 178.1232, found 178.1233.

Preparation 44

Preparation of 3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




15

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.66, 7.19, 7.00, 6.78, 5.47, 4.54, 3.87, 2.83, 2.68, 2.54, 2.06, 2.02, 1.97, 1.31; ¹³C NMR (100 MHz, CDCl₃) δ 157.50, 153.66, 161.36, 140.81, 139.90, 129.80, 127.37, 126.82, 121.33, 108.49, 55.75, 48.72, 29.44, 28.55, 26.08, 23.59, 19.62, 13.93, 11.14; HRMS (FAB) calcd for C₁₉H₂₅N₃O+H 312.2076, found 312.2066.

Preparation 45


25 Preparation of 5-bromo-3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.18, 6.97, 6.79, 5.37, 4.53, 2.87-2.76, 2.70-2.64, 2.54, 2.01-1.86, 1.35-1.24; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{24}\text{BrN}_3\text{O}+\text{H}$ 390.1181, found 390.1186.

Example 44


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.51, 7.33, 7.23, 7.07, 6.81, 5.50, 4.68, 3.89, 2.87-2.80, 2.72-2.61, 2.12-2.01, 1.91, 1.30-1.19; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 456.1609, found 456.1627.

Preparation 46

Preparation of 6-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine




Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 6-methoxy-3,4-dihydronaphthalen-1(2H)-one and making non-

critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.34, 6.78, 6.63, 3.97, 3.79, 2.74, 1.77, 1.89; ^{13}C NMR (100 MHz, CDCl_3) δ 158.47, 138.45, 133.91, 129.64, 113.71, 112.67, 55.61, 49.23, 34.25, 30.31, 24.6, 23.23, 19.87.

5 Preparation 47


Preparation of 3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 6-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine and making non-critical variations provided the title compound as a oil: HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}+\text{H}$ 312.2076, found 312.2075; Anal. Calcd for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}$: C, 73.28; H, 8.09; N, 13.49. Found: C, 73.38; H, 8.11; N, 13.32.

15 Preparation 48


Preparation of 5-bromo-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.26, 6.78, 6.69, 5.33, 4.49, 3.82, 2.89-2.78, 2.55, 2.05-1.84, 1.33-1.26; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{24}\text{BrN}_3\text{O}+\text{H}$ 390.1181, found 390.1180.

25 Example 45


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.51, 7.31, 6.81, 6.71, 5.44, 4.63, 3.83, 2.93-2.76, 2.66-2.51, 2.10, 1.91, 1.32-1.14; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 456.1609, found 456.1624; Anal. Calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}$: C, 65.79; H, 5.96; N, 9.21. Found: C, 65.58; H, 5.96; N, 8.99.

Preparation 49


15 Preparation of racemic mixture of (trans)-1-amino-1,2,3,4-tetrahydronaphthalen-2-ol



To a mixture of 1,2-dihydronaphthalene (5.12g) and trifluoroacetone (1.34g) in acetonitrile (60 ml) and aqueous potassium carbonate (1.5M in 0.4mM EDTA, 60 ml) was added H_2O_2 (30%, 18.2 ml) at 0°C. Upon stirring at 0°C for 4 hours, the rxn 20 mixture was extracted with Et_2O , washed with aqueous $\text{Na}_2\text{S}_2\text{O}_3$ (1M) and brine, dried (MgSO_4), filtered and concentrated. The epoxide was used without purification. A mixture of 1a,2,3,7b-tetrahydronaphtho[1,2-b]oxirene and ammonium hydroxide was stirred at 40°C for 3 days. The excess solvent was removed in vacuo. Flash chromatography (Silica gel, 1:20 MeOH: CH_2Cl_2 , 0.5% NH_4OH) gave the title 25 compound. HRMS (FAB) calcd for $\text{C}_{10}\text{H}_{13}\text{NO}+\text{H}$ 164.1075, found 164.1075.

Preparation 50

Preparation of (trans)-1-[(3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (trans)-1-amino-1,2,3,4-tetrahydronaphthalen-2-ol and making non-critical variations provided the title

5 compound as a oil: ^1H NMR (CDCl_3) δ 1.27-1.34, 2.01, 2.24, 2.64, 2.84, 2.93, 4.03, 4.76, 5.06, 5.17, 7.19-7.21, 7.25-7.27, 7.34-7.37, 7.66;

Preparation 51

Preparation of racemic mixture of *trans*-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol



10

Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (trans)-1-[(3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.30 (m, 6 H), 1.95 (m, 1 H), 2.25 (m, 1 H), 2.64 (dd, $J = 7.5, 15.1$ Hz, 2 H), 2.84 (dd, $J = 7.6, 15.2$ Hz, 2 H), 2.94 (m, 2 H), 4.03 (m, 1 H), 4.74 (d, $J = 6.7$ Hz, 1 H), 5.08 (s, 1 H), 5.16 (dd, $J = 6.7, 7.2$ Hz, 1 H), 7.2 (m, 1 H), 7.28 (m, 2 H), 7.35 (m, 1 H); MS (EI) m/z (rel. intensity) 375 (M+, 9), 359 (68), 357 (67), 230 (45), 146 (35), 129 (69), 128 (56), 118 (55), 117 (99), 115 (68), 91 (45). HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{22}\text{BrN}_3\text{O}+\text{H}$

15 376.1025, found 376.1029. Anal. Calcd for $\text{C}_{18}\text{H}_{22}\text{BrN}_3\text{O}$: C, 57.45; H, 5.89; N, 11.17; Br, 21.23. Found: C, 57.61; H, 5.88; N, 10.70.

Preparation 52

Preparation of racemic mixtures of *trans*-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol




25

Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting *trans*-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.10, 1.23, 1.85, 2.20, 2.44, 2.62, 2.87, 3.97, 4.83, 5.14, 5.97, 7.12–7.27, 7.43; HRMS (FAB) calcd for $\text{C}_{24}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 442.1453, found 442.1448.

Example 46


Preparation of racemic mixture of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R) and (1S,2S)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2R) and (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol and methyl iodide, and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.28, 2.04, 2.12, 2.53, 2.60, 2.78, 3.05, 3.59, 3.98, 4.55, 5.39, 7.19–7.43, 7.51; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 456.1609, found 456.1598. Anal. Calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}$: C, 65.79; H, 5.96; N, 9.21; Cl, 15.54. Found: C, 65.80; H, 6.08; N, 9.09

Example 47

Preparation of racemic mixture of 5-(2,4-dichlorophenyl)-N-[(1R,2R) and (1S,2S)-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2R) and (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol and making non-critical variations provided the title

compound as a oil: ^1H NMR (CDCl_3) δ 0.81, 1.10-1.23, 1.91, 1.99, 2.43, 2.51, 2.67, 2.96, 3.70, 3.95, 4.46, 5.25, 7.10-7.28, 7.42; HRMS (FAB) calcd for $\text{C}_{28}\text{H}_{33}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 498.2079, found 498.2079

Preparation 53


- 5 Preparation of racemic mixture *trans*-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-yl 4-nitrobenzoate



Following the procedure for the preparation of benzyl (cis)-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-[(4-nitrobenzoyl)oxy]pyrrolidine-1-carboxylate but substituting *trans*-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-yl 4-nitrobenzoate and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.15-1.23, 2.23, 2.40, 2.54, 2.68, 3.01, 3.10, 4.62, 5.77, 5.94, 7.23-7.30, 7.40, 7.95, 8.22.

Preparation 54


- 15 Preparation of racemic mixture of *cis*-(5-bromo-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol



Following the procedure for the preparation of benzyl (cis)-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate but substituting *trans*-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-yl 4-nitrobenzoate and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.24-1.32, 2.07, 2.62, 2.84, 2.87, 3.02, 4.29, 4.39, 4.63, 5.36, 7.18-7.29; ^{13}C NMR (CDCl_3) δ 11.22, 12.56, 25.94, 26.94, 27.39, 29.33, 32.29, 55.13, 70.92, 125.84, 127.09, 128.44, 129.41, 130.12, 135.89, 137.71, 142.35, 151.62, 151.91.


Example 48

Preparation of racemic mixture of *cis*-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting *cis*-(5-bromo-3,6-diethylpyrazin-2-yl)amino]-1,2,3,4-tetrahydronaphthalen-2-ol, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.18-1.31, 2.09, 2.54, 2.64, 2.95, 2.99, 4.33, 4.69, 5.43, 7.22-7.35, 7.51; HRMS (FAB) calcd for $\text{C}_{24}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 442.1453, found 442.1454.

- Example 49**
- 10 Preparation of racemic mixture of (cis)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting *cis*-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-1,2,3,4-tetrahydronaphthalen-2-ol and methyl iodide, and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.12, 1.30, 1.99, 2.35, 2.47, 2.74, 3.06, 3.46, 3.89, 5.41, 5.80, 7.18, 7.35, 7.51; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 456.1609, found 456.1617.

- 20 **Example 50**
- Preparation of racemic mixture of 5-(2,4-dichlorophenyl)-N-[(*cis*)-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (*cis*)-

2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.14, 1.20, 1.29, 1.95, 2.31, 2.45, 2.73, 2.82, 3.12, 3.48, 3.74, 3.99, 5.42, 5.75, 7.12-7.21, 7.36, 7.51; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 456.1609, found 456.1617.

5 Preparation 55

Preparation of 4,5,6,7-tetrahydro-1-benzothiophen-4-amine




Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 6,7-dihydro-1-benzothiophen-4(5H)-one and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3)

10 δ 7.09, 7.02, 3.95, 2.79, 2.03, 1.85, 1.62; ^{13}C NMR (100 MHz, CDCl_3) δ 140.51, 137.18, 126.77, 122.66, 47.96, 34.24, 25.48, 21.48;

Preparation 56

Preparation of 3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine




15

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 4,5,6,7-tetrahydro-1-benzothiophen-4-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.67 (s, 1 H), 7.10 (d, J = 5.2 Hz, 1 H), 6.93 (d, J = 5.2 Hz, 1 H), 5.40 (m, 1 H), 4.50 (bs, 1 H), 2.83 (m, 2 H), 2.66 (q, J = 7.5 Hz, 2 H), 2.56 (q, J = 7.5 Hz, 2 H), 2.10 (m, 1 H), 1.96 (m, 3 H), 1.29 (m, 6 H); (MS/CI) calcd for $\text{C}_{16}\text{H}_{21}\text{N}_3\text{S}+\text{H}$ 287.4, found 287.9.

Preparation 57

Preparation of 5-bromo-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-


25 2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.10, 6.91, 5.32, 4.47, 2.83, 2.53, 2.10, 1.93, 1.27; (MS/CI) calcd for $\text{C}_{16}\text{H}_{20}\text{BrN}_3\text{S}+\text{H}$ 369.9, found 369.9.

Example 51

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine




10

Following the procedure for the preparation of (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.51, 7.39, 7.12, 6.99, 5.45, 4.64, 2.90, 2.65, 2.51, 2.20, 1.99, 1.27, 1.20; ^{13}C NMR (100 MHz, CDCl_3) δ 151.51, 150.78, 140.47, 139.15, 137.82, 137.21, 135.35, 134.47, 132.93, 128.78, 127.51, 127.37, 123.01, 117.71, 46.74, 29.97, 27.62, 26.36, 25.53, 21.37, 12.32, 11.63; HRMS (FAB) calcd for $\text{C}_{22}\text{H}_{23}\text{Cl}_2\text{N}_3\text{S}+\text{H}$ 432.1068, found 432.1073.

15

Preparation 58

Preparation of 5-methyl-6,7-dihydro-1-benzothiophen-4(5H)-one



To a solution of 6,7-dihydro-1-benzothiophen-4(5H)-one (1.63 g) in tetrahydrofuran (90 ml) at -78°C under N_2 was added lithium diisopropyl amide (5.89 ml, 2 M).


20

After 30 min, iodomethane (0.732 ml) was added and the reaction was allowed to warm to ambient temperature. After 2 h, the reaction mixture was poured into saturated sodium bicarbonate (100ml), extracted methylene chloride (3 x 100ml), dried MgSO_4 , filtered and concentrated. MPLC was run on a biotage 40M column

with 4-6% ethyl acetate/heptane to provide the title compound as an oil (560 mg, 32%): ^1H NMR (300 MHz, CDCl_3) δ 7.41, 7.08, 3.15-2.99, 2.61-2.53, 2.33-2.25, 2.06-1.92, 1.28; HRMS (FAB) calcd for $\text{C}_9\text{H}_{10}\text{OS}+\text{H}$ 167.0531, found 167.0527.


Preparation 59

- 5 Preparation of 5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-ylamine




Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 5-methyl-6,7-dihydro-1-benzothiophen-4(5H)-one and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.12-6.99, 4.13, 3.89, 3.51, 2.86-2.74, 2.13-1.98, 1.75, 1.65, 1.15, 1.07.

- 10 Preparation of 3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine



- 15 Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-ylamine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.66, 7.07, 6.91, 6.83, 5.62, 5.15, 4.46, 4.35, 3.09, 2.65-2.55, 2.28, 2.06-1.97, 1.80, 1.29, 1.11, 1.01; (MS/CI) calcd for $\text{C}_{17}\text{H}_{23}\text{N}_3\text{S}+\text{H}$ 301.6, found 301.9.

- 20 Preparation of 5-bromo-3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine




- 25 Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-

(5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ) 7.08, 6.87, 6.80, 5.55, 5.08, 4.45, 4.40, 2.91-2.78, 2.58, 2.22, 2.05-1.98, 1.79, 1.28, 1.10, 1.00.

5 Example 52


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine



- Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-
10 3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-
3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine,
ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making
non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz,
 CDCl_3) δ) 7.51, 7.33, 7.11, 6.96, 5.66, 4.52, 2.95-2.62, 2.55, 2.38, 2.05, 1.97, 1.79,
15 1.26, 1.20, 1.07; HRMS (FAB) calcd for $\text{C}_{23}\text{H}_{25}\text{Cl}_2\text{N}_3\text{S}+\text{H}$ 446.1224, found 446.1224.

Example 53

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




- 20 Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-
3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-
3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine,
ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making
non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz,
 CDCl_3) δ) 7.50, 7.35-7.30, 7.10, 6.90, 5.18, 4.60, 2.85, 2.66, 2.49, 2.05, 1.82, 1.29-
25 1.12; HRMS (FAB) calcd for $\text{C}_{23}\text{H}_{25}\text{Cl}_2\text{N}_3\text{S}+\text{H}$ 446.1224, found 446.1230. Anal.

Calcd for C₂₃ H₂₅ Cl₂ N₃ S: C, 61.88; H, 5.64; N, 9.41; Cl, 15.88; S, 7.18. Found: C, 62.04; H, 5.77; N, 9.04.

Preparation 62

Preparation of 5-ethyl-6,7-dihydro-1-benzothiophen-4(5H)-one




5

Following the procedure for the preparation of 5-methyl-6,7-dihydro-1-benzothiophen-4(5H)-one but substituting iodoethane and making non-critical variations provided the title compound as a oil: ¹H NMR (300 MHz, CDCl₃) δ 7.40, 7.07, 3.18-2.96, 2.43-2.27, 2.09-1.94, 1.59, 1.02. HRMS (FAB) calcd for C₁₀H₁₂OS+H 181.0687, found 181.0684. Anal. Calcd for C₁₀ H₁₂ O S: C, 66.63; H, 6.71. Found: C, 66.50; H, 6.75.

Preparation 63


Preparation of 5-ethyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine



15 Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 5-ethyl-6,7-dihydro-1-benzothiophen-4(5H)-one and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.10, 7.05, 6.99, 3.98, 3.65, 2.87-2.73, 2.06-1.90, 1.74-1.19, 1.05-0.97. (MS/CI) calcd for C₁₀H₁₅NS+H 182.3, found 181.9.

Example 54

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




25 Following the procedure for the preparation of (1R,2S)-1-[3,6-diethylpyrazin-2-yl]amino]-2,3-dihydro-1H-inden-2-ol but substituting cis-5-ethyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine and 2-bromo-5-(2,4-dichlorophenyl)-3,6-diethylpyrazine and making non-critical variations provided the title compound as a oil: ¹H NMR (400

MHz, CDCl₃) δ; 7.50, 7.32, 7.08, 6.98, 5.77, 4.42, 2.99, 2.95, 2.62, 2.50, 1.98, 1.73, 1.39-1.18, 1.00; HRMS (FAB) calcd for C₂₄H₂₇Cl₂N₃S+H 460.1381, found 460.1376.

Example 55

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-ethyl-4,5,6,7-tetrahydro-5-benzothien-4-yl]pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting trans-5-ethyl-4,5,6,7-tetrahydro-5-benzothienophen-4-amine and 2-bromo-5-(2,4-dichlorophenyl)-3,6-diethylpyrazine

and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.50, 7.35-7.28, 7.11, 6.91, 5.27, 4.58, 2.85, 2.64, 2.49, 2.08, 1.93, 1.84, 1.66, 1.41, 1.26, 1.18, 1.06; HRMS (FAB) calcd for C₂₄H₂₇Cl₂N₃S+H 460.1381, found 460.1398. Anal. Calcd for C₂₄H₂₇Cl₂N₃S: C, 62.60; H, 5.91; N, 9.13. Found: C, 62.36; H, 5.94; N, 8.91.

Preparation 64

Preparation of (4E)-2,3-dihydro-4H-chromen-4-one oxime




To a solution of 2,3-dihydro-4H-chromen-4-one (3.00 g) in ethanol (15 ml)/water (3 ml) was added sodium acetate (6.64 g) and hydroxyl amine hydrochloride (5.52 g).

The reaction mixture was heated at 70 °C for 1 h, poured into saturated sodium bicarbonate (50 ml), extracted methylene chloride (3 x 50ml), dried MgSO₄, filtered and concentrated to provide the title compound as a solid (3.22 g, 99%): ¹H NMR (300 MHz, CDCl₃) δ 7.86, 7.28, 7.00-6.91, 4.27, 3.02; HRMS (FAB) calcd for C₉H₉NO₂+H 164.0712, found 164.0703. Anal. Calcd for C₉H₉NO₂: C, 66.25; H, 5.56; N, 8.58. Found: C, 66.21; H, 5.58; N, 8.57.

Preparation 65


Preparation of 3,4-dihydro-2H-chromen-4-ylamine



To a solution of (4E)-2,3-dihydro-4H-chromen-4-one oxime (3.20 g) in tetrahydrofuran (50 ml) under N₂ atmosphere was added lithium aluminum hydride (1M THF, 50 ml). The reaction mixture stirred at ambient temperature for 16 h and was quenched with 10 ml of water, 10 ml of 2 N NaOH and 20 ml of water. The reaction mixture was filtered through celite, acidified with 1 N HCl (50 ml), washed with ethyl ether (2 x 50ml), basified with 2 N NaOH, extracted methylene chloride (3 x 100 ml), dried MgSO₄, filtered and concentrated. MPLC was run on a biotage 40S column with 2-4% methanol/methylene chloride with 0.5% ammonium hydroxide to provide the title compound as an oil (728 mg, 25%): ¹H NMR (300 MHz, CDCl₃) δ 7.34, 7.17, 6.92, 6.85, 4.31-4.24, 4.09, 2.18, 1.91-1.86; HRMS (FAB) calcd for C₉H₁₁NO+H 150.0919, found 150.0910.

Preparation 66

Preparation of N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine



15

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,4-dihydro-2H-chromen-4-ylamine and making non-critical variations provided the title compound as a oil: ¹H NMR (300 MHz, CDCl₃) δ 7.71, 7.31-7.21, 6.95, 6.91, 5.34, 4.54, 4.32-4.24, 2.71, 2.56, 2.25, 1.36-1.26; HRMS (FAB) calcd for C₁₇H₂₁N₃O+H 284.1763, found 284.1768.

Preparation 67

Preparation of 5-bromo-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine




25 Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting N-(3,4-

dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.28-7.21, 6.96-6.89, 5.26, 4.54, 4.29-4.22, 2.84, 2.57, 2.22, 1.32-1.24; HRMS (FAB) calcd for $\text{C}_{17}\text{H}_{20}\text{BrN}_3\text{O}+\text{H}$ 362.0868, found 362.0861.

- 5 Anal. Calcd for $\text{C}_{17}\text{H}_{20}\text{BrN}_3\text{O}$: C, 56.36; H, 5.56; N, 11.60. Found: C, 56.10; H, 5.56; N, 11.35.

Example 56

Preparation of 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine




10

Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ ; 7.51, 7.36-7.23, 6.98-6.90, 5.37, 4.69, 4.32, 2.66, 2.51, 2.31, 1.29-1.17; HRMS (EI) calcd for $\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}$ 427.1218, found 427.1224.

Example 57

Preparation of 5-(2-chloro-4-methylphenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine, ethylene glycol dimethyl ether, 2-chloro-4-methyl phenyl boronic acid and tetrakis(triphenylphosphine) palladium and making non-critical variations provided


the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.37-7.13, 6.99-6.90, 5.37, 4.64, 4.31, 2.69, 2.54, 2.40, 2.30, 1.29-1.17; HRMS (FAB) calcd for $\text{C}_{24}\text{H}_{26}\text{ClN}_3\text{O}+\text{H}$ 408.1842, found 408.1848.

Anal. Calcd for $\text{C}_{24}\text{H}_{26}\text{ClN}_3\text{O}$: C, 70.66; H, 6.42; N, 10.30.

5 Found: C, 70.93; H, 6.78; N, 10.01.

Example 58

Preparation of N-(3,4-dihydro-2H-chromen-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethylpyrazin-2-amine




10 Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine, ethylene glycol dimethyl ether, 2, 4-dimethyl phenyl boronic acid and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ^1H

15 NMR (300 MHz, CDCl_3) δ 7.38, 7.22, 7.11-6.90, 5.38, 4.58, 4.31, 2.68, 2.53, 2.37, 2.26, 2.14, 1.25-1.15; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{29}\text{N}_3\text{O}+\text{H}$ 388.2389, found 388.2383.

Preparation 68

Preparation of 5-propyl-6,7-dihydro-1-benzothiophen-4(5H)-one




20 To a solution of KH (30%, 11.44 g) in tetrahydrofuran (160 ml) under N₂ was added dropwise 6,7-dihydro-1-benzothiophen-4(5H)-one (8 g) in tetrahydrofuran (40 ml). After 30 min, a triethyl borane (97 ml, 1 M THF) solution was added dropwise over 5 min. After 10 min, iodopropane was added and the reaction stirred for 16h. The reaction mixture was cooled to 0 °C and 1 N NaOH (250 ml) and hydrogen peroxide (12ml, 30%) was added. The reaction mixture stirred for 1 h and was extracted with 400 ml ethyl acetate. The organic layer was washed with saturated sodium thiosulfate, dried MgSO_4 , filtered and concentrated. MPLC chromatography on a biotage 40 L with 4%

ethyl acetate/heptane provided the title compound as an oil (8.21 g, 80%): ^1H NMR (300 MHz, CDCl_3) δ 7.40, 7.07, 3.15-3.01, 2.47, 2.32, 2.07-1.88, 1.53-1.30, 1.27, 0.99-0.88; HRMS (FAB) calcd for $\text{C}_{11}\text{H}_{14}\text{OS}+\text{H}$ 195.0844, found 195.0835.

Preparation 69

- 5 Preparation of (4Z)-5-propyl-6,7-dihydro-1-benzothiophen-4(5H)-one oxime




Following the procedure for the preparation of (4E)-2,3-dihydro-4H-chromen-4-one oxime but substituting 5-propyl-6,7-dihydro-1-benzothiophen-4(5H)-one and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz,

- 10 CDCl_3) 7.98, 7.28, 7.15, 7.10, 3.55, 2.99-2.81, 2.21-1.83, 1.59-1.31, 0.95-0.90; (MS/CI) calcd for $\text{C}_{10}\text{H}_{13}\text{NOS}+\text{H}$ 195.3, found 195.7.

Preparation 70


- Preparation of Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine



- 15 To a solution of sodium borohydride (4.63 g) in ethylene glycol dimethyl ether (150 ml) at 0 °C under N_2 was added titanium tetrachloride (6.89 ml). After 5 min, (4Z)-5-propyl-6,7-dihydro-1-benzothiophen-4(5H)-one oxime (6.25 g) in 50 ml of ethylene glycol dimethyl ether was added dropwise to a blue solution. The reaction mixture was stirred at ambient temperate for 24 h and carefully quenched at 0 °C with 2 N NaOH. The aqueous layer was extracted with methylene chloride (3 x 200ml), dried MgSO_4 , filtered and concentrated. MPLC chromatography on a biotage 40 L column with 2-4% methanol/methylene chloride with 0.5% ammonium hydroxide provided Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine (2.2 g): ^1H NMR (300 MHz, CDCl_3) δ 7.10, 6.96, 3.92, 2.90-2.72, 1.72, 1.47-1.36, 0.98; HRMS (FAB) calcd for $\text{C}_{11}\text{H}_{17}\text{NS}+\text{H}$ 196.1160, found 196.1164. and trans-5-propyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine (2.68 g) as an oil: ^1H NMR (300 MHz, CDCl_3) δ 7.10, 7.02, 3.59, 2.78, 2.07, 1.66-1.48, 1.38-1.24, 0.96; HRMS (FAB) calcd for $\text{C}_{11}\text{H}_{17}\text{NS}+\text{H}$ 196.1160, found 196.1157.

Preparation 71

Preparation of 3,6-diethyl-N-[Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting cis-5-propyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.65, 7.05, 6.92, 5.68, 4.31, 2.97-2.80, 2.68, 2.53, 2.05, 1.97, 1.71, 1.51-1.25, 0.86; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{27}\text{N}_3\text{S}+\text{H}$ 330.2004, found 330.2001. Anal. Calcd for $\text{C}_{19}\text{H}_{27}\text{N}_3\text{S}$: C, 69.26; H, 8.26; N, 12.75; S, 9.73.

Found: C, 69.21; H, 8.28; N, 12.35.

Preparation 72


Preparation of 3,6-diethyl-N-[Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting trans-5-propyl-4,5,6,7-tetrahydro-1-benzothiophen-4-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.66, 7.08, 6.44, 5.19, 4.46, 2.82, 2.68-2.52, 2.03, 1.94, 1.78, 1.53-1.48, 1.26, 0.92; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{27}\text{N}_3\text{S}+\text{H}$ 330.2004, found 330.1993.

Preparation 73


Preparation of 5-bromo-3,6-diethyl-N-[Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-[Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.06, 6.88, 5.61, 4.28, 2.97-2.80, 2.54, 2.05-1.92, 1.74, 1.49-1.21, 0.87; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{26}\text{BrN}_3\text{S}+\text{H}$ 408.1109, found 408.1108.
Anal. Calcd for $\text{C}_{19}\text{H}_{26}\text{BrN}_3\text{S}$: C, 55.88; H, 6.42; N, 10.29. Found: C, 55.62; H, 6.45; N, 10.18.

10 Preparation 74


Preparation of 5-bromo-3,6-diethyl-N-[Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-[Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.07, 6.82, 5.12, 4.41, 2.82, 2.56, 2.15-1.71, 1.68-1.40, 1.28, 0.92; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{26}\text{BrN}_3\text{S}+\text{H}$ 408.1109, found 408.1123.

20 Example 59


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-[Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making
5 non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl₃) δ 7.50, 7.32, 7.08, 6.98, 5.73, 4.43, 2.98, 2.82, 2.62, 2.50, 2.10, 1.95, 1.76, 1.57-1.44, 1.42-1.18, 0.89; HRMS (FAB) calcd for C₂₅H₂₉Cl₂N₃S+H 474.1537, found 474.1544. Anal. Calcd for C₂₅H₂₉Cl₂N₃S: C, 63.28; H, 6.16; N, 8.86;. Found: C, 63.61; H, 6.33; N, 8.65.

10 Example 60


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-[Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making
15 non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl₃) δ 7.50, 7.35-7.31, 7.11, 6.91, 5.21, 4.59, 2.82, 2.64, 2.48, 2.05, 1.82, 1.43-1.35, 1.25, 1.18, 0.94; HRMS (FAB) calcd for C₂₅H₂₉Cl₂N₃S+H 474.1537, found 474.1526.

20 Preparation 75

Preparation of (1R,2S)-1-[(3,6-dimethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol




25

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3-chloro-2,5-dimethylpyrazine

and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.68, 7.32-7.28, 5.59, 4.80, 3.27, 3.09, 2.92, 2.38; HRMS (FAB) calcd for $\text{C}_{15}\text{H}_{17}\text{N}_3\text{O}+\text{H}$ 256.1450, found 256.1460.

Preparation 76


- 5 Preparation of (1R,2S)-1-[(5-bromo-3,6-dimethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



- Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(3,6-dimethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.32-7.28, 5.58, 4.92, 4.77, 3.28, 3.07, 2.51, 2.38, 2.28; HRMS (FAB) calcd for $\text{C}_{15}\text{H}_{16}\text{BrN}_3\text{O}+\text{H}$ 334.0555, found 334.0557. Anal. Calcd for $\text{C}_{15}\text{H}_{16}\text{BrN}_3\text{O}$: C, 53.91; H, 4.83; N, 12.57. Found: C, 53.55; H, 4.88; N, 12.27.

15 **Preparation 77**


- Preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



- Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(5-bromo-3,6-dimethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.51, 7.36-7.28, 5.66, 4.98, 4.82, 3.25, 3.11, 2.75, 2.42, 2.26; HRMS (FAB) calcd for $\text{C}_{21}\text{H}_{19}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 400.0983, found 400.0995.
- 25 Anal. Calcd for $\text{C}_{21}\text{H}_{19}\text{Cl}_2\text{N}_3\text{O}$: C, 63.01; H, 4.78; N, 10.50. Found: C, 62.86; H, 4.80; N, 10.39.

Example 61

Preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and methyl iodide, and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.51, 7.43, 7.37-7.25, 5.86, 5.40, 4.28, 3.43, 3.23, 3.06, 2.42, 2.25; HRMS (FAB) calcd for $\text{C}_{22}\text{H}_{21}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 414.1140, found 414.1143.

Anal. Calcd for $\text{C}_{22}\text{H}_{21}\text{Cl}_2\text{N}_3\text{O}$: C, 63.78; H, 5.11; N, 10.14. Found: C, 63.86; H, 5.21; N, 10.07.

Example 62

Preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ ; 7.50-7.48, 7.32-7.28, 5.81, 5.48, 4.38, 3.70, 3.52, 3.14, 2.41, 2.26, 1.20; HRMS (FAB) calcd for $\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 428.1296, found 428.1288.

Anal. Calcd for $\text{C}_{23}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}$: C, 64.49; H, 5.41; N, 9.8. Found: C, 64.49; H, 5.48; N, 9.74.

Example 63


Preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and 2-iodopropane, and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.50-7.46, 7.34-7.26, 5.76, 5.43, 4.47, 3.72, 3.14-3.11, 2.41, 2.26, 1.20, 1.12; HRMS (FAB) calcd for $\text{C}_{24}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 442.1453, found 442.1441. Anal. Calcd for $\text{C}_{24}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}$: C, 65.16; H, 5.70; N, 9.50. Found: C, 65.33; H, 5.83; N, 9.34.

Preparation 78


Preparation of 8-methoxy-1,2,3,4-tetrahydronaphthalen-1-amine



Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 8-methoxy-3,4-dihydronaphthalen-1(2H)-one and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.13, 6.73, 4.21, 3.87, 2.78-2.72, 1.88; HRMS (FAB) calcd for $\text{C}_{11}\text{H}_{15}\text{NO}+\text{H}$ 178.1232, found 178.1232.

Preparation 79

Preparation of 3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 8-methoxy-1,2,3,4-

tetrahydronaphthalen-1-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.63, 7.22, 6.78, 5.40, 4.31, 3.71, 2.86-2.65, 2.53-2.38, 1.88-1.67, 1.32, 1.21; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{25}\text{N}_3\text{O}+\text{H}$ 312.2076, found 312.2077.

5 Preparation 80

Preparation of 5-bromo-3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[{(5-bromo-3,6-diethylpyrazin-2-yl)amino}-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.23, 6.78, 5.32, 4.31, 3.71, 2.89-2.77, 2.50-2.35, 1.81-1.65, 1.32, 1.18; HRMS (FAB) calcd for $\text{C}_{19}\text{H}_{24}\text{BrN}_3\text{O}+\text{H}$ 390.1181, found 390.1172.

Anal. Calcd for $\text{C}_{19}\text{H}_{24}\text{BrN}_3\text{O}$: C, 58.47; H, 6.20; N, 10.77. Found: C, 58.07; H, 6.13; N, 10.51.

Example 64


Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.50, 7.34-7.22, 6.83, 5.46, 4.45, 3.75, 2.94-2.79, 2.60-2.53, 1.92-1.77, 1.28-1.16; HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}+\text{H}$ 456.1609, found 456.1602.

Preparation 81


Preparation of 6-methoxyindan-1-amine



Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but substituting 8-methoxy-3,4-dihydronaphthalen-1(2H)-one and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.72, 2.54, 2.74, 2.90, 3.83, 4.34, 6.78, 6.91, 7.13; MS (FAB) m/z (rel. intensity) 164 (MH^+ , 17), 308 (8), 164 (17), 163 (7), 162 (19), 148 (18), 147 (99), 146 (18), 145 (9), 121 (11), 115 (8). HRMS (FAB) calcd for $\text{C}_{10}\text{H}_{13}\text{NO}+\text{H}$ 164.1075, found 164.1071.

10 Preparation 82


Preparation of 3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 6-methoxyindan-1-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.31, 1.87, 2.59, 2.67, 2.75, 2.87, 2.95, 3.79, 4.55, 5.75, 6.83, 7.19, 7.70; HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}+\text{H}$ 298.1919, found 298.1909. Anal. Calcd for $\text{C}_{18}\text{H}_{23}\text{N}_3\text{O}$: C, 72.70; H, 7.80; N, 14.13. Found: C, 72.19; H, 7.76; N, 13.84.

Preparation 83

20 Preparation of 5-bromo-3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (CDCl_3) δ 1.27-1.31, 1.86, 2.58, 2.75, 2.83, 2.85, 2.97, 3.80, 4.54, 5.67, 6.83-6.88, 7.20; HRMS (FAB) calcd for

$C_{18}H_{22}BrN_3O+H$ 376.1025, found 376.1020. Anal. Calcd for $C_{18}H_{22}BrN_3O$: C, 57.45; H, 5.89; N, 11.17; Br, 21.23. Found: C, 56.15; H, 5.65; N, 10.83.

Example 65

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-

5 inden-1-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine, ethylene

10 glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 1.21, 1.29, 1.94, 2.51, 2.67, 2.80, 2.92, 3.01, 3.81, 4.69, 5.80, 6.86, 6.95, 7.22, 7.29-7.36, 7.51; HRMS (FAB) calcd for $C_{24}H_{25}Cl_2N_3O+H$ 442.1453, found 442.1443.

Preparation 84

15 Preparation of 2-ethyl-6-methoxyindan-1-one




Following the procedure for the preparation of 5-propyl-6,7-dihydro-1-benzothiophen-4(5H)-one but substituting 6-methoxy 1-tetralone and ethyl iodide, and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 1.02,

20 1.55, 1.99, 2.68, 2.77, 3.27, 3.86, 7.21, 7.37; HRMS (FAB) calcd for $C_{12}H_{14}O_2+H$ 191.1072, found 191.1075.

Preparation 85

Preparation of 2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-one oxime




25 Following the procedure for the preparation of (4E)-2,3-dihydro-4H-chromen-4-one oxime but substituting 2-ethyl-6-methoxyindan-1-one and making non-critical variations provided the title compound as a oil: HRMS (FAB) calcd for

$C_{12}H_{15}NO_2 + H$ 206.1181, found 206.1175. Anal. Calcd for $C_{12}H_{15}NO_2$: C, 70.22; H, 7.37; N, 6.82. Found: C, 69.90; H, 7.48; N, 6.64.

Preparation 86

Preparation of cis-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-amine




5

Following the procedure for the preparation of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine but substituting 2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-one oxime and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 1.03, 1.39, 2.30, 2.63, 2.86, 3.82, 4.26, 6.77, 7.12;

10 Preparation 87


Preparation of 3,6-diethyl-N-[(cis)-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting cis-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-amine and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 0.93, 1.27-1.34, 2.58, 2.68, 3.00, 3.79, 4.44, 5.83, 6.80, 6.92, 7.17, 7.68; HRMS (EI) calcd for $C_{20}H_{27}N_3O$ 325.2154, found 325.2157.

20 Preparation 88

Preparation of 5-bromo-3,6-diethyl-N-[(cis)-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-[(cis)-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 0.93, 1.21-1.34, 2.57, 2.73, 2.82, 3.00, 3.79, 4.41, 5.76, 6.82, 7.17; HRMS (FAB) calcd for

$C_{20}H_{26}BrN_3O + H$ 404.1338, found 404.1317. Anal. Calcd for $C_{20}H_{26}BrN_3O$: C, 59.41; H, 6.48; N, 10.39; Br, 19.76. Found: C, 59.05; H, 6.42; N, 10.13.

Example 66

Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(*cis*)-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




Following the procedure for the preparation of (1*R*,2*S*)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-

10 3,6-diethyl-N-[(*cis*)-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 0.97, 1.22, 1.28, 2.52, 2.65, 2.75, 3.04, 3.81, 4.57, 5.87, 6.84, 6.98, 7.18, 7.34, 7.50; HRMS (FAB) calcd for $C_{26}H_{29}Cl_2N_3O + H$ 470.1766, found 470.1747

Preparation 89

15 Preparation of 5-methoxyindan-1-one oxime




Following the procedure for the preparation of (4*E*)-2,3-dihydro-4H-chromen-4-one oxime but substituting 5-methoxyindan-1-one and making non-critical variations

provided the title compound as a oil: HRMS (EI) calcd for $C_{10}H_{11}O_2$ 177.0790, found 20 177.0783. Anal. Calcd for $C_{10}H_{11}NO_2$: C, 67.78; H, 6.26; N, 7.90. Found: C, 67.73; H, 6.34; N, 7.77.

Preparation 90

Preparation of 5-methoxyindan-1-amine




25 Following the procedure for the preparation of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine but substituting 5-methoxyindan-1-one oxime and making non-critical variations provided the title compound as a oil: 1H NMR ($CDCl_3$) δ 1.73, 2.75, 2.80,

2.94, 3.82, 4.34, 6.80, 7.25; HRMS (FAB) calcd for C₁₀H₁₁NO+H 162.0919, found 162.0922.

Preparation 91

Preparation of 3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine




5

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 5-methoxyindan-1-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.31, 1.89, 2.58, 2.67, 2.73, 2.91, 3.00, 3.83, 4.51, 5.69, 6.79, 6.85, 7.26, 7.69; ¹³C

10 NMR (CDCl₃) δ 11.08, 13.97, 26.04, 28.55, 30.84, 35.35, 55.79, 55.87, 110.39, 113.15, 125.21, 130.10, 137.12, 140.93, 145.91, 151.82, 153.69, 160.25; HRMS (FAB) calcd for C₁₈H₂₃N₃O+H 298.1919, found 298.1900. Anal. Calcd for C₁₈H₂₃N₃O: C, 72.70; H, 7.80; N, 14.13. Found: C, 72.51; H, 8.00; N, 13.82.

Preparation 92


15 Preparation of 5-bromo-3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.29, 1.89, 2.56, 2.70, 2.83, 2.87, 3.00, 3.83, 4.49, 5.61, 6.81, 6.85, 7.23; HRMS (FAB) calcd for C₁₈H₂₂BrN₃O+H 376.1025, found 376.1008.

Example 67

25 Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 5-bromo-3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ¹H NMR (CDCl₃) δ 1.28,

5 1.95, 2.51, 2.65, 2.80, 2.95, 3.02, 3.85, 4.14, 4.65, 5.73, 6.82, 6.87, 7.28-7.35, 7.5; HRMS (FAB) calcd for C₂₄H₂₅Cl₂N₃O+H 442.1453, found 442.1450.

Preparation 93


10 Preparation of 6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine



Following the procedure for the preparation of 4,5,6,7-tetrahydro-1-benzofuran-4-amine but 5,6-dihydro-7H-cyclopenta[b]pyridin-7-one and making non-critical variations provided the title compound as a oil: ¹H NMR (300 MHz, DMSO) δ 8.49, 7.79, 7.36, 4.65, 3.38, 3.01-2.90, 2.55, 1.93; (MS/CI) calcd for C₈H₁₀N₂+H 135.2, found 135.2.

Preparation 94

Preparation of N-(3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine



20


Following the procedure for the preparation of (1R,2S)-1-{[3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting 6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (300 MHz, CDCl₃) δ 8.46, 7.60, 7.17, 5.37, 5.25, 3.11-

2.95, 2.75-2.61, 1.94-1.81, 1.36-1.26; (MS/CI) calcd for C₁₆H₂₀N₄+H 269.4, found 269.3.

Preparation 95

Preparation of N-(5-bromo-3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-

5 cyclopenta[b]pyridin-7-amine




Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting N-(3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (300 MHz, CDCl₃)

10 δ) 8.47, 7.61, 7.18, 5.30, 3.05, 2.81, 2.78, 1.98, 1.33-1.19; (MS/CI) calcd for C₁₆H₁₉N₄Br+H 348.3, found 347.1.

Example 68

Preparation of N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-

15 cyclopenta[b]pyridin-7-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting N-(5-bromo-3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine,


20 ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ¹H NMR (300 MHz, CDCl₃) δ) 8.48, 7.62, 7.50, 7.34-7.19, 5.41, 3.07-3.02, 2.75, 2.48, 1.97, 1.33, 1.17; HRMS (FAB) calcd for C₂₂H₂₂Cl₂N₄+H 413.1299, found 413.1285.

Anal. Calcd for C₂₂H₂₂Cl₂N₄: C, 63.93; H, 5.36; N, 13.555. Found: C, 63.70; H,

25 5.57; N, 13.15.

Preparation 96


Preparation of (5Z)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one oxime



Following the procedure for the preparation of (4E)-2,3-dihydro-4H-chromen-4-one oxime but substituting 6,7-dihydro-5H-cyclopenta[b]pyridin-5-one and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, DMSO- d_6) δ 11.11, 8.50, 7.89, 7.27, 3.04, 2.81; HRMS (EI) calcd for $\text{C}_8\text{H}_8\text{N}_2\text{O}$ 148.0637, found 148.0628.

Preparation 97


Preparation of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine



To a solution of (5Z)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-one oxime (320 mg) in methanol (20 ml) under N_2 was added nickel chloride hexahydrate. The reaction mixture was cooled to -40°C and sodium borohydride (817 mg) was slowly added over 30 min. The reaction mixture was warmed to ambient temperature for 1 h and silica gel was added. The reaction mixture was concentrated. MPLC chromatography was run using a biotage 25S column with 5-8% methanol/methylene chloride with 0.5% ammonium hydroxide to provide the title compound as an oil (197 mg, 68%): ^1H NMR (400 MHz, CDCl_3) δ 8.43, 7.66, 7.28, 7.15, 4.42, 3.13-3.00, 2.97-2.91, 2.63-2.55, 1.81-1.72.

Preparation 98


Preparation of N-(3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 8.48, 7.73, 7.66, 7.14, 5.82, 4.54, 3.22-3.07, 2.79, 2.70-2.57, 1.94, 1.36-1.27; HRMS (FAB) calcd for $\text{C}_{16}\text{H}_{20}\text{N}_4+\text{H}$ 269.1766, found 269.1763.

Preparation 99


Preparation of N-(5-bromo-3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine



- 5 Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting N-(3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 8.49, 7.67, 7.17, 5.77, 4.55, 3.21, 3.09, 2.85-2.75, 2.58, 1.97, 1.31-1.25; HRMS (FAB) calcd for $\text{C}_{16}\text{H}_{19}\text{BrN}_4+\text{H}$ 347.0872, found 347.0878.
- 10

Example 69


Preparation of N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine



- 15 Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting N-(5-bromo-3,6-diethylpyrazin-2-yl)-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine, ethylene glycol dimethyl ether and tetrakis(triphenylphosphine) palladium and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 8.50, 7.73, 7.51, 7.36-7.28, 7.17, 5.88, 4.67, 3.26-3.08, 2.86, 2.70, 2.51, 2.05-1.96, 1.29, 1.12; HRMS (FAB) calcd for $\text{C}_{22}\text{H}_{22}\text{Cl}_2\text{N}_4+\text{H}$ 413.1299, found 413.1286.
- 20

Preparation 100

Preparation of 6-ethyl-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one




Following the procedure for the preparation of 5-methyl-6,7-dihydro-1-benzothiophen-4(5H)-one but substituting 6,7-dihydro-5H-cyclopenta[b]pyridin-5-one and iodoethane, and making non-critical variations provided the title compound as a oil:

- 5 ¹H NMR (400 MHz, CDCl₃) δ 8.75, 7.86, 7.44, 3.33, 2.81, 2.64, 2.02, 1.58, 1.03; HRMS (FAB) calcd for C₁₀H₁₁NO+H 162.0919, found 162.0913.

Preparation 101


Preparation of (7Z)-6-ethyl-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one oxime



- 10 Following the procedure for the preparation of (4E)-2,3-dihydro-4H-chromen-4-one oxime but substituting 6-ethyl-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, DMSO-d₆) δ 11.21, 8.45, 7.74, 7.29, 3.27, 3.11, 2.65, 1.84, 1.46, 0.85; HRMS (FAB) calcd for C₁₀H₁₂N₂O+H 177.1028, found 177.1029.

15 **Preparation 102**


Preparation of 6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine



- Following the procedure for the preparation of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine but substituting (7Z)-6-ethyl-5,6-dihydro-7H-cyclopenta[b]pyridin-7-one oxime and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 8.40, 7.51, 7.10, 4.30, 3.95, 3.07, 2.95, 2.74, 2.50, 2.38, 2.03-1.93, 1.75, 1.57, 1.40, 1.09-0.97; HRMS (FAB) calcd for C₁₀H₁₄N₂+H 163.1235, found 163.1229.

Preparation 103


- 25 Preparation of N-(3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 8.43, 7.68, 7.59, 7.16, 5.44, 5.19, 5 3.12-3.02, 2.82-2.63, 1.43-1.25, 0.88; HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{24}\text{N}_4+\text{H}$ 297.2079, found 297.2080.

Preparation 104

Preparation of N-(3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine




10

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 8.41, 7.66, 7.58, 7.15, 5.53, 4.89, 15 3.15, 2.71-2.57, 2.31, 2.01, 1.99, 1.65, 1.34, 1.22, 1.04; HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{24}\text{N}_4+\text{H}$ 297.2079, found 297.2080.

Preparation 105

Preparation of N-(5-bromo-3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine




20

Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting N-(3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 8.43, 7.62, 7.19, 5.37, 5.28, 3.11, 3.08, 2.87-2.69, 1.41-1.26, 0.86; HRMS (FAB) calcd for $\text{C}_{18}\text{H}_{23}\text{BrN}_4+\text{H}$ 375.1185, found 375.1189.

Preparation 106


Preparation of N-(5-bromo-3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting N-(3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 8.37, 7.78, 7.31, 5.42-5.25, 3.28, 2.75-2.48, 1.96, 1.62, 1.34, 1.05; HRMS (FAB) calcd for C₁₈H₂₃BrN₄+H 375.1185, found 375.1193.

Example 70


Preparation of N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting N-(5-bromo-3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and, tris(2-chloro-4-methoxyphenyl)boroxin, and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 8.45, 7.61, 7.28, 7.19, 7.03, 6.90, 5.50, 5.31, 3.85, 3.14, 3.06, 2.87-2.78, 2.51, 1.52, 1.34, 1.17, 0.97-0.87; HRMS (FAB) calcd for C₂₅H₂₉ClN₄O+H 437.2108, found 437.2103.

Example 71


Preparation of N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting N-(5-bromo-3,6-diethylpyrazin-2-yl)-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine and, tris(2-chloro-4-methoxyphenyl)boroxin, and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 8.43, 7.60, 7.19, 7.01, 6.89, 5.59, 5.08, 3.85, 3.20, 2.77, 2.66, 2.44, 2.06, 1.69, 1.33, 1.07; IR (diffuse reflectance) 2961, 2354 (w), 2063 (w), 1947 (w), 1906 (w), 1577 (s), 1550, 1519, 1491 (s), 1461, 1428 (s), 1397 (s), 1289, 1228, 1196, cm^{-1} HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{29}\text{ClN}_4\text{O}+\text{H}$ 437.2108, found 437.2109.

Preparation 107


Preparation of (+/-)-2-ethyl-2,3-dihydro-1H-inden-1-one



Following the procedure for the preparation of 5-propyl-6,7-dihydro-1-benzothiophen-4(SH)-one but substituting 1-tetralone and ethyl iodide, and making non-critical variations provided the title compound as a colorless mobile oil. IR (liq.) 2963, 2933, 2875, 2860, 1712, 1610, 1588, 1475, 1464, 1327, 1296, 1278, 1205, 749, 718 cm^{-1} ; MS (EI) m/z 160 (M^+); Anal. Calcd for $\text{C}_{11}\text{H}_{12}\text{O}$: C, 82.46; H, 7.55. Found: C, 82.16; H, 7.57.

Preparation 108


Preparation of 2-ethyl-2,3-dihydro-1H-inden-1-one oxime



Following the procedure for the preparation of (4E)-2,3-dihydro-4H-chromen-4-one oxime but substituting (+/-)-2-ethyl-2,3-dihydro-1H-inden-1-one and making non-critical variations provided the title compound as a colorless syrup. MS (ESI+) for m/z 176.1 ($\text{M}+\text{H}$)⁺.

Preparation 109


Preparation of 2-ethylindan-1-amine



Following the procedure for the preparation of 6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine but substituting 2-ethyl-2,3-dihydro-1H-inden-1-one oxime and making non-critical variations provided the title compound as a colorless oil.

Preparation 110


Preparation of 3,6-diethyl-N-(2-ethyl-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine



10 Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 2-ethylindan-1-amine and making non-critical variations provided the title compound as a yellow oil. MS (ESI+) for m/z 296.2 ($M+H$)⁺.

Preparation 111 and 112

15 Preparation of (+/-)-5-bromo-3,6-diethyl-N-[cis-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine and (+/-)-5-bromo-3,6-diethyl-N-[trans-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3,6-diethyl-N-(2-ethyl-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine and making non-critical variations provided the title compounds. Analytical data for (+/-)-5-bromo-3,6-diethyl-N-[cis-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine: IR (liq.) 3435, 2967, 2935, 2874, 1560, 1539, 1479, 1460, 1446, 1416, 1390, 1243, 1177, 751, 731 cm⁻¹; MS (EI) m/z 373 (M^+); Anal. Calcd for C₁₉H₂₄BrN₃: C, 60.97; H, 6.46; N, 11.23. Found: C, 61.01; H, 6.53; N, 11.22. Analytical data for (+/-)-5-bromo-3,6-diethyl-N-[trans-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine: IR (liq.) 2967, 2935, 2874, 2856, 1561, 1537, 1478, 1460, 1447, 1416, 1388, 1186, 1176, 1164, 746

cm^{-1} ; OAMS supporting ions at: ESI+ 373.8; MS (EI) m/z 373 (M^+); Anal. Calcd for $\text{C}_{19}\text{H}_{24}\text{BrN}_3$: C, 60.97; H, 6.46; N, 11.23. Found: C, 60.97; H, 6.51; N, 11.16.

Example 72


Preparation of (+/-)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-[cis-2-ethyl-2,3-dihydro-
5 1H-inden-1-yl]pyrazin-2-amine.



Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-
3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting (+/-)-5-
10 bromo-3,6-diethyl-N-[cis-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine and
making non-critical variations provided the title compound as a light yellow semi-
solid. IR (liq.) 3452, 2965, 2934, 2874, 1589, 1566, 1551, 1495, 1470, 1392, 1377,
1203, 1175, 1101, 752 cm^{-1} ; OAMS supporting ions at: ESI+ 439.8; HRMS (FAB)
calcd for $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3 + \text{H}_1$ 440.1660, found 440.1648. Anal. Calcd for
 $\text{C}_{25}\text{H}_{27}\text{Cl}_2\text{N}_3$: C, 68.18; H, 6.18; N, 9.54. Found: C, 68.33; H, 6.36; N, 9.30.

Example 73

Preparation of (+/-)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-[trans-2-ethyl-2,3-dihydro-
1H-inden-1-yl]pyrazin-2-amine.




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-
3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting (+/-)-5-
10 bromo-3,6-diethyl-N-[trans-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine and
making non-critical variations provided the title compound as a light yellow semi-
solid. IR (liq.) 3443, 2965, 2934, 2874, 1588, 1566, 1551, 1497, 1470, 1390, 1203,
1186, 1173, 1101, 747 cm^{-1} ; OAMS supporting ions at: ESI+ 440.0; MS (EI) m/z

439 (M^+); Anal. Calcd for $C_{25}H_{27}Cl_2N_3$: C, 68.18; H, 6.18; N, 9.54. Found: C, 68.11; H, 6.17; N, 9.29.

Preparation 113

Preparation of benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate




5

To a solution of the olefin (10.0g, 49 mmol) in CH_2Cl_2 (250 ml, 0.2M) was added MCPBA (22g, 2.0 eq.). The reaction was stirred for 48h and 200ml of saturated sodium thiosulfate was added. After 20 min, the layers were separated and the organic layer was washed with 2N NaOH (2 x 100ml). The organic layer was dried $MgSO_4$, filtered and concentrated to provide the title compound as an oil (10.79 g, 99%): 1H NMR (300 MHz, $CDCl_3$) δ 7.35, 5.13, 3.93-3.84, 3.71, 3.43-3.38; IR (liq.) 2209 (w), 2068 (w), 1958 (w), 1706 (s), 1455, 1448, 1428 (s), 1397 (s), 1364, 1327 (s), 1214, 1206, 1107 (s), 848 (s), 699, cm^{-1} Anal. Calcd for $C_{12}H_{13}NO_3$: C, 65.74; H, 5.98; N, 6.39. Found: C, 65.45; H, 6.07; N, 5.99.

15 Preparation 114


Preparation of benzyl (trans)-3-amino-4-hydroxypyrrolidine-1-carboxylate



benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate (10.5 g) was stirred in 200 ml of saturated ammonium hydroxide at 35 °C for 40 h. The reaction mixture was poured into 100 ml of 2 N NaOH, extracted methylene chloride (4 x 200 ml), dried $MgSO_4$, filtered and concentrated to provide the title compound as an oil (10.15 g, 95%): 1H NMR (300 MHz, $CDCl_3$) δ 7.34, 5.14, 3.99, 3.78, 3.37, 3.19, 1.77; HRMS (FAB) calcd for $C_{12}H_{16}N_2O_3+H$ 237.1239, found 237.1244.

Preparation 115

25 Preparation of benzyl (trans)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate




Following the procedure for the preparation of benzyl (3*R*,4*S*)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate but substituting benzyl (trans)-3-amino-4-hydroxypyrrolidine-1-carboxylate and making non-critical variations

5 provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.78, 7.39, 6.41, 6.22, 5.18, 4.51-3.95, 3.40, 2.65, 1.31-1.26; (MS/CI) calcd for $\text{C}_{20}\text{H}_{26}\text{N}_4\text{O}_3+\text{H}$ 371.4, found 370.9.

Preparation 116

Preparation of benzyl (trans)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-

10 hydroxypyrrolidine-1-carboxylate




Following the procedure for the preparation of (1*R*,2*S*)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1*H*-inden-2-ol but substituting benzyl (trans)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate and making

15 non-critical variations provided the title compound as a oil: ^1H NMR (300 MHz, CDCl_3) δ 7.38, 5.17, 4.48, 4.38, 4.28, 4.12, 3.91, 3.42, 2.86-2.78, 2.58, 1.32-1.24; HRMS (FAB) calcd for $\text{C}_{20}\text{H}_{25}\text{BrN}_4\text{O}_3+\text{H}$ 449.1189, found 449.1175.

Preparation 117

Preparation of benzyl (trans)-3-{{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-

20 yl]amino}-4-hydroxypyrrolidine-1-carboxylate




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting benzyl (trans)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate and making non-critical variations provided the title compound as a oil:

5 ^1H NMR (300 MHz, CDCl_3) δ 7.49-7.11, 5.97, 5.17, 4.78, 4.67, 4.33-4.26, 4.16-3.96, 3.46, 2.69, 2.49, 1.46-1.24, 1.14; HRMS (FAB) calcd for $\text{C}_{26}\text{H}_{28}\text{Cl}_2\text{N}_4\text{O}_3+\text{H}$ 515.1616, found 515.1606.

Preparation 118

Preparation of benzyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-


10 yl]amino}-4-[(4-nitrobenzoyl)oxy]pyrrolidine-1-carboxylate



To a solution of benzyl (trans)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate (2.93 g) in tetrahydrofuran (100 ml) was added *p*-nitrobenzoic acid (1.89 g), triphenyl phosphine (2.23 g) and di-*tert*-butyl azodicarboxylate (1.95 g). The reaction mixture was heated at 40 °C for 18h and was poured into saturated sodium bicarbonate (200 ml). The aqueous layer was extracted with ethyl acetate (2 x 200 ml), dried MgSO_4 , filtered and concentrated. MPLC chromatography on a biotage 40 M column with 15-20% ethyl acetate/heptane provided the title compound as an oil (3.19 g, 84%): ^1H NMR (400 MHz, CDCl_3) δ 8.35, 8.20, 7.49-7.22, 6.23, 5.81, 5.32, 5.20, 5.05, 4.83, 4.27, 3.95-3.85, 3.51, 2.58-2.41, 1.63, 1.32-1.14; (MS/CI) calcd for $\text{C}_{33}\text{H}_{31}\text{Cl}_2\text{N}_5\text{O}_3+\text{H}$ 664.5, found 664.1.

Preparation 119

benzyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate




25

To a solution of benzyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-[(4-nitrobenzoyl)oxy]pyrrolidine-1-carboxylate (3.17 g) in tetrahydofuran (38 ml) and methanol (3 ml) was added LiOH (1M_(aq), 38 ml). The reaction mixture stirred 45 min and was poured into saturated sodium bicarbonate (100 ml). The aqueous layer was extracted ethyl acetate (2 x 200 ml), dried MgSO₄, filtered and concentrated. MPLC chromatography on a biotage 40M column with 20-60% ethyl acetate/heptane provided the title compound as an oil (1.225 g, 50%): ¹H NMR (400 MHz, CDCl₃) δ 7.50, 7.46-7.25, 5.18, 4.99, 4.89, 4.70, 4.51, 4.04, 3.75-3.59, 3.42-3.35, 2.70, 2.47, 2.19, 1.14; HRMS (FAB) calcd for C₂₆H₂₈Cl₂N₄O₃+H 515.1616, found 515.1641. Anal. Calcd for C₂₆H₂₈Cl₂N₄O₃: C, 60.59; H, 5.48; N, 10.87. Found: C, 60.32; H, 5.79; N, 10.54.

Example 74

benzyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




15

Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting benzyl (cis)-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate and making non-critical variations provided the title compound as an oil: ¹H NMR (400 MHz, CDCl₃) δ 7.49, 7.40-7.25, 5.20-5.13, 4.73, 4.10, 3.98, 3.77-3.59, 3.53-3.30, 2.70, 2.46, 1.27, 1.15; HRMS (FAB) calcd for C₂₈H₃₂Cl₂N₄O₃+H 543.1929, found 543.1913. Anal. Calcd for C₂₈H₃₂Cl₂N₄O₃: C, 61.88; H, 5.93; N, 10.31. Found: C, 62.07; H, 6.14; N, 10.16.

Example 75


25 5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine



To a solution of benzyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate (900 mg) in methylene chloride (16.5 ml) was added palladium dichloride (30 mg) and triethylamine (0.229 ml). Triethyl silane was added (2 x 0.395 ml) over 2h. The reaction mixture stirred 1 h and 2 ml of 5 trifluoroacetic acid was added. After 30 min the reaction was basified with 2 N NaOH, extracted methylene chloride (3 x 100 ml), dried MgSO₄, filtered and concentrated. MPLC chromatography was run on a biotage 40S column with 3-5% methanol/methylene chloride with 0.5% ammonium hydroxide to provide the title compound as an oil (501 mg, 74%): ¹H NMR (400 MHz, CDCl₃) δ 7.49, 7.33-7.26, 10 5.38, 4.54, 4.07, 3.68, 3.52, 3.22, 2.95, 2.71, 2.46, 1.29, 1.15; HRMS (FAB) calcd for C₂₀H₂₆Cl₂N₄O+H 409.1562, found 409.1567. Anal. Calcd for C₂₀H₂₆Cl₂N₄O: C, 58.68; H, 6.40; N, 13.69. Found: C, 58.42; H, 6.43; N, 13.50.

Example 76


15 N-[(cis)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine



To a solution of 5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine (105 mg) in methylene chloride (5 ml) under N₂ was added 20 acetyl chloride (0.027 ml). The reaction mixture stirred for 30 min and was poured into saturated sodium bicarbonate (20 ml), extracted methylene chloride (2 x 20 ml), dried MgSO₄, filtered and concentrated. MPLC chromatography was run on a biotage 25 S column with 60% ethyl acetate/heptane to provide the title compound as an oil (79 mg, 69%): ¹H NMR (400 MHz, CDCl₃) δ 7.50, 7.34-7.26, 5.30, 5.12, 4.81, 4.19, 4.01, 3.87-3.67, 3.61-3.37, 2.72, 2.48, 1.33-1.26, 1.14; HRMS (FAB) calcd for 25 C₂₂H₂₈Cl₂N₄O₂+H 451.1667, found 451.1667.

Example 77

5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxy-1-propionylpyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting propionyl chloride and making non-critical variations provided the title compound as an oil:

- ¹H NMR (400 MHz, DMSO) δ 7.71, 7.50, 7.41, 6.00, 5.98, 4.68, 4.52, 4.22, 4.11, 3.85-3.39, 2.68, 2.37, 2.25, 1.24-0.85; HRMS (FAB) calcd for C₂₃H₃₀Cl₂N₄O₂+H 465.1824, found 465.1825.

Example 78

Preparation of methyl (*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-

- 10 yl]amino}-4-ethoxypyrrolidine-1-carboxylate




Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting methyl chloroformate and making non-critical variations provided the title compound as an

- 15 oil:

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.72, 7.50, 7.41, 6.03, 4.59, 4.17, 3.69, 3.56-3.50, 3.39, 2.67, 2.37, 1.16, 1.09-1.02; HRMS (FAB) calcd for C₂₂H₂₈Cl₂N₄O₃+H 467.1617, found 467.1621.

Example 79

- 20 Preparation of 5-(2,4-dichlorophenyl)-N-[(*cis*)-4-ethoxy-1-(methylsulfonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting methanesulfonyl chloride and making non-critical variations provided the title

5 compound as an oil:

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.72, 7.51, 7.42, 6.05, 4.62, 4.18, 3.66-3.57, 3.49, 3.38, 2.92, 2.69, 2.38, 1.18, 1.10-1.05; HRMS (FAB) calcd for C₂₁H₂₈Cl₂N₄O₃S+H 487.1337, found 487.1328.

Example 80

10 Preparation of ethyl (*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate



Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting ethyl


15 chloroformate and making non-critical variations provided the title compound as an oil:

¹H NMR (400 MHz, DMSO-*d*₆) δ 7.72, 7.50, 7.41, 6.04, 4.59, 4.16, 4.04, 3.70, 3.56-3.39, 2.67, 2.35, 1.21-1.02; HRMS (FAB) calcd for C₂₃H₃₀Cl₂N₄O₃+H 481.1773, found 481.1772. Anal. Calcd for C₂₃H₃₀Cl₂N₄O₃: C, 57.38; H, 6.28; N, 11.64.

20 Found: C, 57.71; H, 6.55; N, 11.44.

Example 81

Preparation of (*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N,N-dimethylpyrrolidine-1-carboxamide




Following the procedure for the preparation of N-[((cis)-1-acetyl-4-ethoxypyrrolidin-3-yl)-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]dimethylcarbamyl chloride and making non-critical variations provided the title compound as an oil:

^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ 7.72, 7.50, 7.41, 5.98, 4.52, 4.12, 4.00, 3.61-3.39, 2.74, 2.68, 2.37, 1.23-1.05; HRMS (FAB) calcd for $\text{C}_{23}\text{H}_{31}\text{Cl}_2\text{N}_5\text{O}_2+\text{H}$ 480.1933, found 480.1927.

Example 82

- Preparation of (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N,N-dimethylpyrrolidine-1-carbothioamide




Following the procedure for the preparation of N-[((cis)-1-acetyl-4-ethoxypyrrolidin-3-yl)-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]dimethylcarbamyl chloride and making non-critical variations provided the title compound as an oil:

^1H NMR (400 MHz, CDCl_3) δ 7.50, 7.34-7.25, 5.23, 4.78, 4.11, 3.97, 3.83, 3.74, 3.56-3.45, 2.71, 2.46, 1.33-1.25, 1.14; HRMS (FAB) calcd for $\text{C}_{23}\text{H}_{31}\text{Cl}_2\text{N}_5\text{OS}+\text{H}$ 496.1704, found 496.1691.

Example 83

- Preparation of isopropyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting isopropyl chloroformate and making non-critical variations provided the title compound as an

5 oil: ^1H NMR (400 MHz, CDCl_3) δ 7.49, 7.34-7.26, 5.22, 4.95, 4.75, 4.08, 3.96, 3.73, 3.60, 3.50, 3.38, 3.25, 2.71, 2.47, 1.32-1.25, 1.16; HRMS (FAB) calcd for $\text{C}_{24}\text{H}_{32}\text{Cl}_2\text{N}_4\text{O}_3+\text{H}$ 495.1929, found 495.1909. Anal. Calcd for $\text{C}_{24}\text{H}_{32}\text{Cl}_2\text{N}_4\text{O}_3$: C, 58.18; H, 6.51; N, 11.31. Found: C, 58.43; H, 6.64; N, 11.25.

Example 84

10 Preparation of (*cis*)-3-{{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N-methylpyrrolidine-1-carbothioamide



Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting methyl


15 thiocyanate and making non-critical variations provided the title compound as an oil:

^1H NMR (400 MHz, CDCl_3) δ 7.50, 7.35-7.25, 5.31, 4.87, 4.15-4.05, 3.88, 3.76, 3.51, 3.40, 2.70, 2.47, 1.32-1.25, 1.15; IR (diffuse reflectance) 2970, 2933, 2351 (w), 2338 (w), 1549 (s), 1536 (s), 1498 (s), 1467 (s), 1392 (s), 1353 (s), 1200, 1122, 1101, 1058, 1048, cm^{-1} HRMS (FAB) calcd for $\text{C}_{22}\text{H}_{29}\text{Cl}_2\text{N}_5\text{OS}+\text{H}$ 482.1548, found

20 482.1559.

Example 85


Preparation of 5-(2,4-dichlorophenyl)-N-[(*cis*)-4-ethoxy-1-(morpholin-4-ylcarbonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine



Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting 4-morpholinecarbonyl chloride and making non-critical variations provided the title compound as an oil: ^1H NMR (400 MHz, CDCl_3) δ 7.50, 7.34, 7.28, 5.23, 4.69, 4.10, 3.90, 3.80-3.68, 3.58-3.28, 2.70, 2.49, 1.33-1.26, 1.16; IR (liq.) 2970 (s), 2934 (s), 2874 (s), 2353 (w), 1996 (w), 1956 (w), 1642 (s), 1567 (s), 1552 (s), 1500 (s), 1469 (s), 1414 (s,b), 1397 (s), 1118 (s), 1102 (s), cm^{-1} HRMS (FAB) calcd for $\text{C}_{25}\text{H}_{33}\text{Cl}_2\text{N}_5\text{O}_3+\text{H}$ 522.2039, found 522.2038.

10 Example 86


Preparation of 2-fluoroethyl (*cis*)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate



Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting 2-fluoroethyl chloroformate and making non-critical variations provided the title compound as an oil: ^1H NMR (400 MHz, CDCl_3) δ 7.49, 7.34-7.26, 5.21, 4.70-4.58, 4.56, 4.42, 4.34, 4.10, 3.99, 3.75-3.30, 2.71, 2.47, 1.32-1.26, 1.15; IR (liq.) 2973 (s), 2347 (b), 2181 (w), 1709 (s), 1567 (s), 1553 (s), 1500 (s), 1470 (s), 1445 (s), 1426 (s), 1396 (s), 1347 (s), 1140 (s), 1103 (s), 1060 (s), cm^{-1} HRMS (FAB) calcd for $\text{C}_{23}\text{H}_{29}\text{Cl}_2\text{FN}_4\text{O}_3+\text{H}$ 499.1679, found 499.1673. Anal. Calcd for $\text{C}_{23}\text{H}_{29}\text{Cl}_2\text{FN}_4\text{O}_3$: C, 55.32; H, 5.85; N, 11.22. Found: C, 55.20; H, 5.91; N, 10.95.

Preparation 120

Preparation of benzyl (*3R,4R*)-3-(2lambda~5~-triaza-1,2-dienyl)-4-[(trimethylsilyl)oxy]pyrrolidine-1-carboxylate




To benzyl 6-oxa-3-azabicyclo[3.1.0]hexane-3-carboxylate (10.4g, 48 mmole) was added TMSN₃ (6.65ml, 1.05eq.) and 1S,2S-(-)-[1,2-cyclohexanediamino-N,N'-bis(3,5-di-t-butylsalicylidene)] chromium(III) chloride (STREM 24-0851) (904mg, 0.03 eq.). The reaction was stirred for 18h under N₂. The red oil was used as is in the next step. ¹H NMR (400 MHz, CDCl₃) δ 7.18 (m, 5 H), 4.98 (s, 2 H), 3.99 (m, 1 H), 3.69 (m, 1 H), 3.61-3.51 (m, 2 H), 3.31-3.05 (m, 2 H).

5

Preparation 121

Preparation of benzyl (3R,4R)-3-amino-4-hydroxypyrrolidine-1-carboxylate



10

Benzyl (3R,4R)-3-(2lambda~5~-triaza-1,2-dienyl)-4-[(trimethylsilyl)oxy]pyrrolidine-1-carboxylate (23.6g) in MeOH (250 ml, 0.3M) was treated with TFA (15 ul) for 1.5 hr. Lindlar's catalyst (10g) was added under 1 atmosphere of H₂. It was stirred for 6 days. (Another batch of Lindlar's catalyst 5 g was added on the 4th day). The Pd catalyst was filtered through celite. The filtrate was concentrated, diluted with Et₂O (250ml) and 1N HCl (250ml). The separated 1N HCl phase was basified with NaOH (solid) to pH 12. It was extracted with CH₃Cl: iPrOH (9:1 mixture 4 x 300ml) and EtOAC (3 x 300ml). It was dried (MgSO₄) and used as is. ¹H NMR (CDCl₃) δ 3.22 (m, 1 H), 3.38 (m, 2 H), 3.78 (m, 2 H), 4.02 (m, 1 H), 5.15 (s, 2 H), 7.37 (m, 5 H);


15

(Another batch of Lindlar's catalyst 5 g was added on the 4th day). The Pd catalyst was filtered through celite. The filtrate was concentrated, diluted with Et₂O (250ml) and 1N HCl (250ml). The separated 1N HCl phase was basified with NaOH (solid) to pH 12. It was extracted with CH₃Cl: iPrOH (9:1 mixture 4 x 300ml) and EtOAC (3 x 300ml). It was dried (MgSO₄) and used as is. ¹H NMR (CDCl₃) δ 3.22 (m, 1 H), 3.38 (m, 2 H), 3.78 (m, 2 H), 4.02 (m, 1 H), 5.15 (s, 2 H), 7.37 (m, 5 H);

20

Preparation 122

Preparation of benzyl (3R,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate




A 50ml oven-dried r.b.flask was charged with benzyl (3R,4R)-3-amino-4-hydroxypyrrolidine-1-carboxylate (4.235g, 17.93mmol) and dissolved in 60ml of THF. Trifluoroacetic anhydride (2.54 ml, 17.93mmol) and TEA (3ml, 21.52mmol) were added sequentially at 0°C. The rxn was allowed to warm to r.t., and stirred for O/N. The reaction was diluted with H₂O (250ml), extracted with 250ml (CHCl₃: iPrOH 9:1 mixture, x 4), dried (MgSO₄), filtered, concentrated *in vacuo*.

This crude trifluoroamide product (confirmed by LC-MS) was dissolved in 90ml of CH₂Cl₂ (0.2M) and cooled to 0°C under N₂ followed by addition of TEA (21.52mmol, 3ml) and MsCl (1.63ml, 19.72mmol). The reaction was stirred for 15 min at 0°C and 1hr at r.t followed by addition of DBU (5.39ml, 53.79mmol) with subsequent stirring overnight. The reaction mixture was filtered through silica and washed with (80% EtOAc in Heptane,) 800ml. The filtrate was collected and concentrated.

The oxazoline was hydrolyzed by addition of K₂CO₃ (14.87g) in 80ml MeOH/40ml H₂O for 18 hr. It was reduced in volume and extracted with (9:1 CHCl₃: iPrOH) 200ml x 5. The combined organic solvent was dried (K₂CO₃), filtered, concentrated, purified by biotage chromatography (1% to 5 % MeOH in CH₂Cl₂, 0.5 % NH₄OH) to give the title compound as a solid. ¹H NMR (CDCl₃) δ 3.22 (m, 1 H), 3.38 (m, 2 H), 3.79 (m, 2 H), 4.02 (m, 1 H), 5.15 (s, 2 H), 7.40 (m, 5 H); IR (diffuse reflectance) 3374, 2949, 2316 (w), 1966 (w), 1947 (w), 1686 (s), 1450 (s), 1423 (s), 1354, 1321, 1144, 1096, 1084, 765, 695, cm⁻¹ HRMS (FAB) calcd for C₁₂H₁₆N₂O₃+H 237.1239, found 237.1236. Specific Rotation (25 C D) = -17 (c 0.97, chloroform).

Preparation 123


Preparation of benzyl (3R,4S)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate



To an 250ml r.b-flask was sequentially added benzyl (3R,4S)-3-amino-4-hydroxypyrrolidine-1-carboxylate (4.9714g, 21.04mmol), chloride (3.949g, 23.15mmol), Pd₂(dba)₃ (10 mol %, 1.926g), 2-dicyclohexylphosphino-2'-(N, N-dimethyl amino)biphenyl (20 mol%, 1.656g), and DME (110ml). Cs₂CO₃ (9.57g) was then added and the reaction mixture was stirred at 80°C for 20 hr. It was cooled, diluted with Et₂O (100ml), poured into NaHCO₃ (80ml), extracted with CH₂Cl₂ (150ml x 3), dried (MgSO₄), and concentrated. Purification via biotage chromatography (35% EtOAc in heptane) provided the title compound. ¹H NMR (CDCl₃) δ 1.28 (m, 6 H), 2.65 (m, 4 H), 3.36 (m, 1 H), 3.63 (m, 1 H), 3.73 (m, 1 H), 4.00 (m, 1 H), 4.51 (m, 1 H), 4.64 (m, 1 H), 4.80 (m, 1 H), 5.18 (s, 2 H), 7.38 (m, 6 H), 7.74 (d, 1H); IR (liq.) 2969, 2344 (w), 1996 (w), 1952 (w), 1703 (s), 1691 (s), 1546, 1499 (s), 1449 (s), 1426 (s), 1395, 1359 (s), 1175, 1133, 1095, cm⁻¹ HRMS (FAB) calcd for C₂₀H₂₆N₄O₃+H 371.2083, found 371.2089.

15 Preparation 124


Preparation of benzyl (3R,4S)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting benzyl (3R,4S)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, CDCl₃) δ 7.38, 5.16, 4.91, 4.82, 4.59, 4.48, 4.59, 4.48, 4.01, 3.72-3.58, 3.36-3.25, 2.81, 2.69, 2.54, 2.46, 1.31-1.23.

25 Preparation 125

Preparation of benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting benzyl (3R,4S)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate and making non-critical variations provided the title compound as a oil:

1 ^1H NMR (400 MHz, CDCl_3) δ 7.49, 7.39-7.25, 5.18, 4.99, 4.89, 4.71, 4.55, 4.04, 3.75-3.58, 3.36, 2.69, 2.49, 1.30, 1.15; HRMS (FAB) calcd for $\text{C}_{26}\text{H}_{28}\text{Cl}_2\text{N}_4\text{O}_3+\text{H}$ 515.1616, found 515.1641.

Example 87

Preparation of benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




15 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting benzyl (3R,4S)-3-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.49, 7.40-7.25, 5.20-5.13, 4.76, 4.11, 3.98, 3.73-3.60, 3.51-3.31, 2.70, 2.47, 1.31-1.24, 1.15; IR (liq.) 2972, 2342 (w), 1948 (w), 1709 (s), 1567, 1552, 1498 (s), 1470 (s), 1449 (s), 1420 (s), 1397 (s), 1350, 1126, 1100 (s), 1080, cm^{-1}

20 HRMS (FAB) calcd for $\text{C}_{28}\text{H}_{32}\text{Cl}_2\text{N}_4\text{O}_3+\text{H}$ 543.1929, found 543.1929. Anal. Calcd for $\text{C}_{28}\text{H}_{32}\text{Cl}_2\text{N}_4\text{O}_3$: C, 61.88; H, 5.93; N, 10.31. Found: C, 61.73; H, 6.08; N, 10.04.

Example 88

Preparation of 5-(2,4-dichlorophenyl)-N-[(3R,4S)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine




- 5 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(*cis*)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine but substituting benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate and making non-critical variations provided the title compound as an oil:
¹H NMR (400 MHz, CDCl₃) δ 7.49, 7.33-7.26, 5.38, 4.54, 4.07, 3.68, 3.52, 3.22,
10 2.95, 2.71, 2.46, 1.29, 1.15; HRMS (FAB) calcd for C₂₀H₂₆Cl₂N₄O+H 409.1562, found 409.1567. Anal. Calcd for C₂₀H₂₆Cl₂N₄O: C, 58.68; H, 6.40; N, 13.69. Found: C, 58.42; H, 6.43; N, 13.50.

Example 89

Preparation of methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-


- 15 **yl]amino}-4-ethoxypyrrolidine-1-carboxylate**



- Following the procedure for the preparation of N-[(*cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting 5-(2,4-dichlorophenyl)-N-[(3R,4S)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine and methyl chloroformate, and making non-critical variations provided the title compound as an oil: ¹H NMR (400 MHz, CDCl₃) δ 7.49, 7.34-7.26, 5.20, 4.73, 4.09, 3.95, 3.74, 3.60, 3.50, 3.39, 3.31, 3.26, 2.69, 2.47, 1.32-1.25, 1.15; IR (diffuse reflectance) 2971 (s), 2350 (w), 2341 (w), 2063 (w), 1940 (w), 1921 (w), 1710 (s), 1568, 1551, 1499, 1466 (s), 1452 (s), 1392 (s), 1373, 1102, cm⁻¹; HRMS (FAB) calcd for C₂₂H₂₈Cl₂N₄O₃+H 467.1617, found 467.1619. Anal. Calcd for C₂₂H₂₈Cl₂N₄O₃: C, 56.54; H, 6.04; N, 11.99. Found: C, 56.64; H, 6.27; N, 11.92.

Example 90


Preparation of benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate



- 5 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate and 2-fluoro-1-bromo ethane, and making non-critical variations provided the title compound as a oil: ^1H NMR (400 MHz, CDCl_3) δ 7.49, 7.41-7.25, 5.18, 4.81, 4.67, 4.55, 4.17, 4.06, 3.80-3.62, 3.39-3.29, 2.69, 2.47, 1.28, 1.15; IR (diffuse reflectance) 2971, 2386 (w), 2350 (w), 2338 (w), 2039 (w), 2014 (w), 1710 (s), 1699 (s,b), 1569, 1499, 1467 (s), 1450, 1428, 1420, 1397, cm^{-1} ; HRMS (FAB) calcd for $\text{C}_{28}\text{H}_{31}\text{Cl}_2\text{FN}_4\text{O}_3+\text{H}$ 561.1835, found 561.1808.

Example 91

- 15 Preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine




- Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine but substituting benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate and making non-critical variations provided the title compound as an oil: ^1H NMR (400 MHz, CDCl_3) δ 7.49, 7.35-7.26, 5.38, 4.68-4.53, 4.11, 3.88, 3.80, 3.74, 3.46, 3.24-3.16, 2.93, 2.70, 2.62, 2.29, 2.00, 1.33-1.24, 1.15; IR (liq.) 2971 (s), 2936 (s), 2874, 2359 (w), 2342 (w), 1566 (s), 1552 (s),

1500 (s), 1470 (s), 1396 (s), 1200 (s), 1129 (s), 1102 (s), 1046 (s), 868, cm⁻¹; HRMS (FAB) calcd for C₂₀H₂₅Cl₂FN₄O+H 427.1468, found 427.1474.

Example 92

Preparation of methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-

5 yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate



Following the procedure for the preparation of N-[(cis)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting 5-(2,4-


10 dichlorophenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-

amine and methyl chloroformate, and making non-critical variations provided the title compound as an oil: ¹H NMR (400 MHz, DMSO-d₆) δ 7.71, 7.50, 7.41, 6.04, 4.61, 4.54, 4.42, 4.25, 3.78-3.70, 3.60, 3.54, 3.37, 2.65, 2.37, 1.15, 1.08; IR (diffuse

reflectance) 2970, 2934, 2350 (w), 2341 (w), 2039 (w), 1940 (w), 1921 (w), 1710 (s), 1569, 1551, 1499, 1466 (s), 1452 (s), 1393 (s), 1373, cm⁻¹; HRMS (FAB) calcd for C₂₂H₂₇Cl₂FN₄O₃+H 485.1522, found 485.1541. Anal. Calcd for C₂₂H₂₇Cl₂FN₄O₃: C, 54.44; H, 5.61; N, 11.54. Found: C, 54.73; H, 5.76; N, 11.46.

Preparation 126

Preparation of benzyl (3R,4S)-3-{[(3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate}




20

Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting benzyl (3R,4S)-3-{[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate and 2-fluoro-1-bromo ethane, and making non-critical variations provided the title

compound as a oil: ^1H NMR (400 MHz, DMSO- d_6) δ 7.61, 7.38-7.36, 5.85, 5.08, 4.52, 4.50, 4.38, 4.22, 3.75-3.40, 2.60, 2.53, 1.19-1.13; IR (liq.) 2970 (s), 2937 (s), 2340 (w), 2068 (w), 1996 (w), 1954 (w), 1705 (s), 1546 (s), 1499 (s), 1448 (s), 1422 (s), 1395 (s), 1351 (s), 1136 (s), 1107 (s), cm $^{-1}$; HRMS (FAB) calcd for C₂₂H₂₉FN₄O₃+H 417.2302, found 417.2299.

Preparation 127


Preparation of 3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine but substituting benzyl (3R,4S)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate and making non-critical variations provided the title compound as an oil: ^1H NMR (400 MHz, CDCl₃) δ 7.65, 5.21, 4.64, 4.53, 4.07, 3.81-3.61, 3.40, 3.22, 3.14, 2.82, 2.62, 1.33-1.25; IR (liq.) 3437, 2969 (s), 2936 (s), 2874, 2348 (w), 1580 (s), 1546 (s), 1498 (s), 1464, 1449 (s), 1395, 1162, 1129, 1043 (s), 870, cm $^{-1}$; HRMS (FAB) calcd for C₁₄H₂₃FN₄O+H 283.1934, found 283.1928.

Preparation 128

Preparation of methyl (3R,4S)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




Following the procedure for the preparation of N-[(cis)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting 3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine and methyl chloroformate, and making non-critical variations provided the title compound as an oil: ^1H NMR (400 MHz, DMSO- d_6) δ 7.61, 5.82, 4.55, 4.51, 4.39, 4.19, 3.73-3.48, 2.64-2.49, 1.20-1.14; IR (diffuse reflectance) 2967, 2934, 2873, 2450 (w), 2407 (w),

2350 (w), 2334 (w), 2226 (w), 1699 (s), 1499, 1457 (s), 1392 (s), 1158, 1142, 768, cm⁻¹; HRMS (FAB) calcd for C₁₆H₂₅FN₄O₃+H 341.1989, found 341.1988.

Preparation 129

Preparation of methyl (3R,4S)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-(2-

- 5 fluoroethoxy)pyrrolidine-1-carboxylate



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting methyl (3R,4S)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-


- 10 carboxylate and making non-critical variations provided the title compound as a oil:

¹H NMR (400 MHz, DMSO-d₆) δ 6.12, 4.49, 4.37, 4.21, 3.69-3.39, 2.71-2.55, 1.20-1.12; IR (liq.) 2973 (s), 2957, 2068 (b), 1996, 1705 (s), 1561 (s), 1541 (s), 1481 (s), 1454 (s), 1392 (s), 1191 (s), 1175, 1140 (s), 1114 (s), 1048, cm⁻¹; HRMS (FAB) calcd for C₁₆H₂₄BrFN₄O₃+H 419.1094, found 419.1112. Anal. Calcd for

- 15 C₁₆H₂₄BrFN₄O₃: C, 45.83; H, 5.77; N, 13.36. Found: C, 45.49; H, 5.81; N, 13.03.

Example 93

Preparation of methyl(3R,4S)-3-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




- 20 Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting methyl (3R,4S)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate and tris(4-methoxy-2-methylphenyl)boroxin, and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, DMSO-d₆) δ

7.12, 6.80, 5.12, 5.08, 4.80, 4.66, 4.54, 4.16, 3.99-3.60, 3.36, 3.27, 2.70, 2.48, 2.12, 1.28; HRMS (FAB) calcd for C₂₄H₃₃FN₄O₄+H 461.2564, found 461.2570.

Example 94

Preparation of methyl (3R,4S)-3-({5-[2-chloro-4-(dimethylamino)phenyl]-3,6-

5 diethylpyrazin-2-yl}amino)-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting methyl (3R,4S)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-(2-fluoroethoxy)pyrrolidine-1-

10 carboxylate and N-(4-{4,6-bis[2-chloro-4-(dimethylamino)phenyl]boroxin-2-yl}-3-chlorophenyl)-N,N-dimethylamine, and making non-critical variations provided the title compound as a oil: ¹H NMR (400 MHz, DMSO-d₆) δ 7.30, 7.13, 6.76, 5.85, 4.60-4.54, 4.42, 4.28, 3.72-3.53, 2.94, 2.63, 2.38, 1.19-1.13, 1.06; IR (diffuse reflectance) 2963 (b), 2351 (w), 2338 (w), 2054 (w), 1927 (w), 1921 (w), 1710 (s), 1706 (s), 1608, 1568, 1551, 1486 (s), 1451 (s), 1392 (s), 1353, cm⁻¹; HRMS (FAB) calcd for C₂₄H₃₃ClFN₅O₃+H 494.2334, found 494.2340.

Example 95

Preparation of benzyl (3R,4S)-3-{{5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl}amino}-4-hydroxypyrrolidine-1-carboxylate




20

Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting benzyl (3R,4S)-3-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-

carboxylate and 2-chloro-4-methoxy phenyl boronic acid, and making non-critical variations provided the title compound as a oil: ^1H NMR (DMSO- d_6) δ 1.06, 2.35, 2.67, 3.51, 3.57, 3.62, 3.82, 4.35, 4.46, 5.08, 5.42, 5.95, 6.98, 7.11, 7.24, 7.38; IR (diffuse reflectance) 2968, 2351 (w), 2339 (w), 2063 (w), 1951 (w), 1700 (s,b), 1681 (s), 1568 (s), 1482 (s), 1428 (s,b), 1422 (s), 1397, 1359 (s), 1287, 1229, cm^{-1} HRMS (FAB) calcd for $\text{C}_{27}\text{H}_{31}\text{ClN}_4\text{O}_4+\text{H}$ 511.2112, found 511.2115.

Example 96

Preparation of benzyl (3R,4S)-3-{{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate




10

Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but benzyl (3R,4S)-3-{{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate and making non-critical variations provided the title compound as a oil: ^1H NMR (DMSO- d_6) δ 1.04, 1.16, 2.38, 2.68, 3.34, 3.40, 3.54, 3.70, 3.82, 4.18, 4.62, 5.10, 5.95, 6.98, 7.10, 7.26, 7.38; IR (diffuse reflectance) 2971, 2934, 2350 (w), 2338 (w), 2063 (w), 1949 (w), 1710 (s), 1568, 1482 (s), 1419 (s), 1397 (s), 1348, 1287, 1228, 1096, cm^{-1} HRMS (FAB) calcd for $\text{C}_{29}\text{H}_{35}\text{ClN}_4\text{O}_4+\text{H}$ 539.2425, found 539.2436.

20 Anal. Calcd for $\text{C}_{29}\text{H}_{35}\text{ClN}_4\text{O}_4$: C, 64.61; H, 6.54; N, 10.39; Cl, 6.58. Found: C, 64.30; H, 6.56; N, 10.26.

Example 97

Preparation of benzyl (3R,4S)-3-{{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-

- 5 hydroxypyrrolidine-1-carboxylate and 1-bromo-2-fluoro ethane, and making non-critical variations provided the title compound as a oil: ^1H NMR (DMSO-d₆) δ 1.07, 1.14, 2.36, 2.65, 3.60, 3.72, 3.79, 3.82, 4.27, 4.42, 4254, 4.62, 5.09, 5.95, 6.98, 7.11, 7.25, 7.38; IR (diffuse reflectance) 2350 (w), 2337 (w), 2058 (w), 1952 (w), 1940 (w), 1710 (s), 1569, 1552, 1483 (s), 1459, 1419 (s), 1397, 1353, 1287, 1228, cm⁻¹ HRMS (FAB) calcd for C₂₉H₃₄ClFN₄O₄+H 557.2330, found 557.2338.


Anal. Calcd for C₂₉H₃₄ClFN₄O₄: C, 62.53; H, 6.15; N, 10.06; Cl, 6.36; F, 3.41.

Found: C, 62.33; H, 6.32; N, 10.07.

Example 98

Preparation of 5-(2-chloro-4-methoxyphenyl)-N-[(3R,4S)-4-ethoxypyrrolidin-3-yl]-

- 15 3,6-diethylpyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine but substituting (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidin-1-

- 20 carboxylate and making non-critical variations provided the title compound as an oil: ^1H NMR (CDCl₃) δ 1.15, 1.22-1.34, 2.45, 2.71, 2.89, 3.06, 3.22, 3.41, 3.51, 3.65, 3.85, 4.51, 5.32, 6.88, 7.02, 7.24.

Example 99

Preparation of methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-

- 25 2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate



Following the procedure for the preparation of N-[((3R,4S)-4-ethoxypyrrolidin-3-yl)amino]-3,6-diethyl-5-(2,4-dichlorophenyl)pyrazin-2-amine but substituting 5-(2-chloro-4-methoxyphenyl)-N-[((3R,4S)-4-ethoxypyrrolidin-3-yl)amino]-3,6-diethylpyrazin-2-amine and

- 5 methyl chloroformate, and making non-critical variations provided the title compound as an oil: ^1H NMR (DMSO-d₆) δ 1.03-1.09, 1.16, 2.36, 2.67, 3.78, 3.51, 3.60, 3.69, 3.82, 4.15, 4.62, 5.95, 6.98, 7.11, 7.26; IR (diffuse reflectance) 2965 (s,b), 2937, 2351 (w), 2338 (w), 2213 (w), 2158 (w), 2059 (w), 1710 (s), 1568 (s), 1552, 1483 (s), 1456 (s), 1393 (s), 1287 (s), 1228, cm⁻¹ HRMS (FAB) calcd for C₂₃H₃₀ClFN₄O₄+H 10 481.2018, found 481.2026. Anal. Calcd for C₂₃H₃₀ClFN₄O₄: C, 57.44; H, 6.29; N, 11.65; Cl, 7.37; F, 3.95. Found: C, 57.14; H, 6.46; N, 11.37.

Example 100

Preparation of 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[((3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl)amino]-3,6-diethylpyrazin-2-amine




15

Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[((3R,4S)-4-ethoxypyrrolidin-3-yl)amino]-3,6-diethylpyrazin-2-amine but substituting benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate and making non-critical variations provided

- 20 the title compound as an oil: ^1H NMR (CDCl₃) δ 1.15, 1.29, 2.48, 2.70, 2.90, 2.90, 3.15, 3.23, 3.44, 3.85, 4.11, 4.55, 4.66, 5.32, 6.88, 7.02, 7.24.

Example 101


Preparation of methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate



- Following the procedure for the preparation of N-[*(cis*)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine but substituting 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[*(3R,4S*)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine and methyl chloroformate, and making non-critical variations provided the title compound as an oil: ^1H NMR (DMSO-d₆) δ 1.08, 1.15, 2.37, 2.65, 3.54, 3.60, 3.71, 3.82, 4.25, 4.43, 4.54, 5.93, 6.98, 7.10, 7.26; IR (liq.) 2972, 2068 (w), 1996 (w), 1707 (s), 1607, 1566, 1484 (s), 1454 (s), 1393 (s), 1287, 1230, 1197, 1175, 1128, 1104, cm⁻¹
- HRMS (FAB) calcd for C₂₃H₃₁ClN₄O₄+H 463.2112, found 463.2104.

Preparation 130


Preparation of trans-(+/-)-4-[(3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol



- Following the procedure for the preparation of benzyl (*3R,4S*)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate but substituting trans- (+/-)-4-aminotetrahydrofuran-3-ol and making non-critical variations provided the title compound as an orange oil. IR (diffuse reflectance) 3356, 3255, 2972, 2938, 1587, 1511, 1464, 1453, 1396, 1337, 1185, 1099, 1064, 965, 888 cm⁻¹; OAMS supporting ions at: ESI+ 238.1; MS (EI) *m/z* 237 (M⁺); HRMS (FAB) calcd for C₁₂H₁₉N₃O₂+H₁ 238.1555, found 238.1551.

Preparation 131


Preparation of trans-(+/-)-4-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting trans-(+/-)-4-[(3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol and making non-critical variations provided the title compound as a light yellow solid. IR (diffuse reflectance) 3398, 2971, 2938, 1569, 1539, 1490, 1466, 1447, 1413, 1397, 1251, 1232, 1054, 969, 891 cm⁻¹; OAMS supporting ions at: ESI+ 315.9 & ESI- 313.9; MS (EI) m/z 315 (M⁺); HRMS (FAB) calcd for C₁₂H₁₈BRN₃O₂ +H₁ 316.0661, found 316.0656; Anal. Calcd for C₁₂H₁₈BrN₃O₂: C, 45.58; H, 5.74; N, 13.29. Found: C, 45.49; H, 5.84; N, 13.14.

Preparation 132

Preparation of trans-(+/-)-4-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}tetrahydrofuran-3-ol.




Following the procedure for the preparation of (1R,2S)-1-[(5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting trans-(+/-)-4-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol and 2-methyl-4-methoxyphenylboronic acid and making non-critical variations provided the title compound as a light yellow solid. IR (diffuse reflectance) 3363, 1603, 1571, 1490, 1447, 1393, 1303, 1233, 1208, 1177, 1170, 1103, 1059, 887, 849 cm⁻¹; OAMS supporting ions at: ESI+ 358.1; MS (EI) m/z 357 (M⁺); HRMS (FAB) calcd for C₂₀H₂₇N₃O₃ +H₁ 358.2130, found 358.2142.

Example 102

Preparation of trans-(+/-)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethyl-5-(4-methoxy-

2-methylphenyl)pyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting trans-(+/-)-4-((3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-

- 5 yl)amino)tetrahydrofuran-3-ol and making non-critical variations provided the title compound as a light yellow solid. IR (diffuse reflectance) 3354, 2973, 2958, 2938, 1484, 1462, 1446, 1396, 1300, 1239, 1172, 1072, 1050, 1043, 885 cm⁻¹; OAMS supporting ions at: ESI+ 386.1; MS (EI) *m/z* 385 (M⁺); HRMS (FAB) calcd for C₂₂H₃₁N₃O₃ +H₁ 386.2443, found 386.2438. Anal. Calcd for C₂₂H₃₁N₃O₃: C, 68.54;
- 10 H, 8.11; N, 10.90. Found: C, 68.38; H, 7.99; N, 10.85.

Preparation 133


Preparation of cis-(+/-)-4-((3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl)amino)tetrahydrofuran-3-yl 4-nitrobenzoate



- 15 Following the procedure for the preparation of (1S,2S)-1-((5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl)amino)-2,3-dihydro-1H-inden-2-yl 4-nitrobenzoate but substituting trans-(+/-)-4-((3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl)amino)tetrahydrofuran-3-ol and making non-critical variations provided the title compound as a light yellow semi-solid. MS (ESI+) for *m/z* 507.1 (M+H)⁺.

Preparation 134


Preparation of cis-(+/-)-4-((3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl)amino)tetrahydrofuran-3-ol.



Following the procedure for the preparation of (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol, but substituting cis-(+/-)-4-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}tetrahydrofuran-3-yl 4-nitrobenzoate and making non-critical variations provided the title compound as a colorless semi-solid. OAMS supporting ions at: ESI+ 358.2; MS (EI) *m/z* 357 (M^+); HRMS (FAB) calcd for $C_{20}H_{27}N_3O_3 + H_1$ 358.2130, found 358.2125.

Example 103


Preparation of cis-(+/-)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine.



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting of cis-(+/-)-4-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}tetrahydrofuran-3-ol and making non-critical variations provided the title compound as a light yellow solid. IR (liq.) 2972, 2935, 2874, 1609, 1564, 1481, 1395, 1294, 1243, 1204, 1160, 1123, 1077, 1069, 1058 cm^{-1} ; OAMS supporting ions at: ESI+ 386.2; MS (EI) *m/z* 385 (M^+); HRMS (FAB) calcd for $C_{22}H_{31}N_3O_3 + H_1$ 386.2443, found 386.2457. Anal. Calcd for $C_{22}H_{31}N_3O_3$: C, 68.54; H, 8.11; N, 10.90. Found: C, 68.22; H, 8.05; N, 10.76.

Preparation 135


Preparation of cis-(+/-)-4-{(3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol



Following the procedure for the preparation of benzyl (3R,4S)-3-[(3,6-diethylpyrazin-2-yl)amino]-4-hydroxypyrrolidine-1-carboxylate but substituting cis- (+/-)-4-aminotetrahydrofuran-3-ol and making non-critical variations provided the title compound as a light yellow amorphous solid. IR (diffuse reflectance) 3399, 3259, 3223, 3218, 3212, 2969, 2867, 2847, 1582, 1546, 1493, 1465, 1160, 1066, 920 cm⁻¹; MS (EI) *m/z* 237 (M⁺); HRMS (FAB) calcd for C₁₂H₁₉N₃O₂ +H₁ 238.1555, found 238.1558.

Preparation 136


- 10 Preparation of cis-(+/-)-4-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting trans-(+/-)-4-[(3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol and making non-critical variations provided the title compound as a light yellow solid. IR (diffuse reflectance) 3398, 2971, 2938, 1569, 1539, 1490, 1466, 1447, 1413, 1397, 1251, 1232, 1054, 969, 891 cm⁻¹; OAMS supporting ions at: ESI+ 315.9 & ESI- 313.9; MS (EI) *m/z* 315 (M⁺); HRMS (FAB) calcd for C₁₂H₁₈BrN₃O₂ +H₁ 316.0661, found 316.0656; Anal. Calcd for C₁₂H₁₈BrN₃O₂: C, 45.58; H, 5.74; N, 13.29. Found: C, 45.49; H, 5.84; N, 13.14.

Preparation 137

Preparation of cis-(+/-)-4-{{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-ol.




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting cis-(+/-)-4-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol and 2-chloro-4-methoxyphenylboronic acid and making non-critical variations provided the title compound as a light yellow amorphous solid. IR (diffuse reflectance) 3420, 2969,

- 5 2935, 2873, 1604, 1568, 1482, 1439, 1397, 1393, 1287, 1229, 1204, 1181, 1044 cm⁻¹;
- OAMS supporting ions at: ESI+ 378.1; MS (EI) *m/z* 377 (M^+); HRMS (FAB) calcd for C₁₉H₂₄ClN₃O₃ + H₁ 378.1584, found 378.1566. Anal. Calcd for C₁₉H₂₄ClN₃O₃:
- 10 C, 60.39; H, 6.40; N, 11.12. Found: C, 59.97; H, 6.46; N, 10.99.

Example 104


Preparation of cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[4-methoxytetrahydrofuran-3-yl]pyrazin-2-amine.



- 15 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting of cis-(+/-)-4-[(5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl)amino]tetrahydrofuran-3-ol and iodomethane and making non-critical variations provided the title compound as a colorless semi-solid. IR (liq.) 2970, 2936, 2874, 1606, 1566, 1483, 1441, 1397, 1287, 1230, 1203, 1182, 1126, 1076, 1049 cm⁻¹;
- 20 OAMS supporting ions at: ESI+ 392.1; MS (EI) *m/z* 391 (M^+); HRMS (FAB) calcd for C₂₀H₂₆ClN₃O₃ + H₁ 392.1741, found 392.1758. Anal. Calcd for C₂₀H₂₆ClN₃O₃: C, 61.30; H, 6.69; N, 10.72. Found: C, 61.16; H, 6.47; N, 10.65.

Example 105


Preparation of cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethylpyrazin-2-amine.



- 5 Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting of cis-(+/-)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-ol and making non-critical variations provided the title compound as a light yellow oil. IR (liq.) 2973, 2936, 2874, 1606, 1566, 1481, 1441,
10 1396, 1287, 1230, 1203, 1181, 1124, 1078, 1046 cm⁻¹; OAMS supporting ions at:
ESI+ 406.2; MS (EI) *m/z* 405 (M⁺); HRMS (FAB) calcd for C₂₁H₂₈CLN₃O₃ +H₁ 406.1897, found 406.1889.

Example 106


- Preparation of cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine.
15



- Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting of cis-(+/-)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-ol and 1-iodopropane and making non-critical variations provided the title compound as a light yellow oil. IR (liq.) 2967, 2936, 2875, 1606,
20 1566, 1483, 1441, 1396, 1287, 1230, 1203, 1124, 1078, 1058, 1046 cm⁻¹; OAMS supporting ions at: ESI+ 420.2; MS (EI) *m/z* 419 (M⁺); HRMS (FAB) calcd for C₂₂H₃₀CLN₃O₃ +H₁ 420.2054, found 420.2052. Anal. Calcd for C₂₂H₃₀ClN₃O₃: C, 62.92; H, 7.20; N, 10.01. Found: C, 62.78; H, 7.28; N, 10.01.

Example 107 and 108

Preparation of 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine and 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine




5

Chiral HPLC separation of a racemic sample of *cis*-(+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine employing an Chiralcel OJ column eluting with 5% isopropopyl alcohol/heptane (containing 0.1% diethylamine) provided the title compounds. Analytical data for 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4R)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine: OAMS supporting ions at: ESI+ 420.2; MS (EI) *m/z* 419 (M^+); $[\alpha]^{25}_D = 23$ (*c* 1.0, methylene chloride); HRMS (FAB) calcd for $C_{22}H_{30}ClN_3O_3 + H_1$ 420.2054, found 420.2049. Analytical data for 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine: OAMS supporting ions at: ESI+ 420.2; MS (EI) *m/z* 419 (M^+); $[\alpha]^{25}_D = -24$ (*c* 1.0, methylene chloride); HRMS (FAB) calcd for $C_{22}H_{30}ClN_3O_3 + H_1$ 420.2054, found 420.2064. Anal. Calcd for $C_{22}H_{30}ClN_3O_3$: C, 62.92; H, 7.20; N, 10.01. Found: C, 63.00; H, 7.11; N, 9.67.

- 10
- 15

Example 109

- 20 Preparation of (+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[*cis*-4-(3-fluoropropoxy)tetrahydrofuran-3-yl]pyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1*R*,2*S*)-2-ethoxy-2,3-dihydro-1*H*-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting of *cis*-(+/-)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-

- 25

yl]amino}tetrahydrofuran-3-ol and 1-bromo-3-fluoropropane and making non-critical variations provided the title compound as a colorless semi-solid. IR (liq.) 2969, 2936, 2875, 1606, 1565, 1481, 1441, 1397, 1287, 1230, 1203, 1127, 1075, 1059, 1046 cm⁻¹; OAMS supporting ions at: ESI+ 438.2; MS (EI) *m/z* 437 (M⁺); HRMS (FAB) 5 calcd for C₂₂H₂₉ClFN₃O₃ +H₁ 438.1960, found 438.1965. Anal. Calcd for C₂₂H₂₉ClFN₃O₃: C, 60.34; H, 6.67; N, 9.59. Found: C, 60.31; H, 6.78; N, 9.65.

Preparation 138


N-[(1E)-phenylmethylidene]-1H-imidazol-2-amine



10 In order to obtain the free base, 2-aminoimidazole sulfate (5.00 g, 37.8 mmol) was dissolved in water (35mL) and Na₂CO₃ (6.25 g, 59.0 mmol) was added. After 20 minutes, the water was removed under reduced pressure. After the addition of ethanol (100 mL), the salts were removed via filtration. Concentration of the filtrate gave a light brown oil that was dissolved in ethanol (15 mL). Benzaldehyde (4.0 mL, 39.4 15 mmol) was added and the mixture was heated at reflux. After 2 h, the reaction was cooled to rt and concentrated. The crude product was purified by column chromatography (Biotage, 40M) with heptanes/EtOAc (1:1) to give impure product. Crystallization of this material from EtOAc/heptanes gave 2.37 g (first crop, 37%) and 0.78 g (second crop, 12%) of yellow solid: ¹H NMR (400 MHz, CDCl₃) δ 10.33, 9.34, 7.90, 7.48, 7.09, 7.01; IR (diffuse reflectance) 3148, 3134, 3112, 3081, 3063, 20 3029, 2908, 2895, 2881, 1606, 1449, 1108, 753, 738, 687 cm⁻¹; HRMS (FAB) calcd for C₁₀H₉N₃+H 172.0875, found 172.0872; Anal. Calcd for C₁₀H₉N₃: C, 70.16; H, 5.30; N, 24.54, found: C, 70.02; H, 5.32; N, 24.39.

Preparation 139

N-[(1E)-phenylmethylidene]-1-propyl-1H-imidazol-2-amine




To a solution of *N*-[(1E)-phenylmethylidene]-1H-imidazol-2-amine (1.00 g, 5.84 30 mmol) in DMF (20 mL) was added KO*t*-Bu (0.80 g, 7.13 mmol) and 1-iodopropane (0.63 mL, 6.46 mmol). After 3.5 h, the reaction was diluted with water (50 mL) and extracted with EtOAc (3 x 50 mL). The combined organic layers were washed with brine, dried over Na₂SO₄, decanted, and concentrated. The crude product was purified

by column chromatography (Biotage, 40M) with heptanes/EtOAc (2:1) to give 1.12 g (90%) of yellow liquid: ^1H NMR (400 MHz, CDCl_3) δ 9.23, 7.94, 7.47, 7.02, 6.94, 4.14, 1.83, 0.95; IR (liq.) 2966, 2935, 2876, 1612, 1576, 1509, 1477, 1450, 1313, 1282, 1150, 761, 738, 716, 690 cm^{-1} ; HRMS (FAB) calcd for $\text{C}_{13}\text{H}_{15}\text{N}_3+\text{H}$ 214.1344, found 214.1336.

Preparation 140


1-propyl-1H-imidazol-2-amine



A mixture of *N*-[(1E)-phenylmethylidene]-1-propyl-1H-imidazol-2-amine (0.92 g, 4.31 mmol) and 6N HCl (25 mL) was heated at reflux for 2 h. After cooling to rt, the reaction was concentrated to a residue then taken up in 2M aqueous Na_2CO_3 and extracted with CH_2Cl_2 . The combined organic layers were washed with brine, dried over Na_2SO_4 , decanted, and concentrated. The crude product was purified by column chromatography (Biotage, 40M) with $\text{CH}_2\text{Cl}_2/\text{MeOH}/\text{NH}_4\text{OH}$ (gradient, 950:47:3 to 900:90:10) to give 0.30 g (56%) of brown oil: ^1H NMR (400 MHz, CDCl_3) δ 6.63, 6.52, 4.00, 3.65, 1.75, 0.95; MS (ESI+) 126.7.

Example 110

5-(2,4-dichlorophenyl)-3,6-diethyl-*N*-(1-propyl-1H-imidazol-2-yl)pyrazin-2-amine




A mixture of 2-bromo-5-(2,4-dichlorophenyl)-3,6-diethylpyrazine (0.25 g, 0.69 mmol), 1-propyl-1H-imidazol-2-amine (0.15 g, 1.2 mmol), tris(dibenzylideneacetone) dipalladium (0.032 g, 0.032 mmol), 2-dicyclohexylphosphino)biphenyl (0.037 g, 0.12 mmol), and sodium *tert*-butoxide (0.093 g, 0.97 mmol) in dioxane (2.0 mL) was heated at 110 °C for 21 h. After cooling to rt, the reaction was diluted with saturated aqueous NaHCO_3 and extracted with CH_2Cl_2 . The combined organic layers were washed with brine, dried over Na_2SO_4 , decanted, and concentrated. The crude product was purified by column chromatography (Biotage, 40M) with (Biotage, 40S) with heptanes/EtOAc (3:1) to give 0.076 g (27%) of dark yellow oil: ^1H NMR (400 MHz, CDCl_3) δ 12.86, 7.47, 7.31, 6.70, 6.55, 3.94, 2.97, 2.48, 2.97, 2.48, 1.84, 1.30,

1.21, 0.98; IR (liq.) 2968, 2934, 1599, 1556, 1549, 1509, 1460, 1422, 1402, 1384, 1373, 1302, 1174, 1102, 712 cm⁻¹; HRMS (FAB) calcd for C₂₀H₂₃Cl₂N₅+H 404.1408, found 404.1416.

Preparation 141


- 5 methyl amino(cyclopropyl)acetate hydrochloride



To a solution of cyclopropyl glycine (0.50 g, 4.3 mmol) in ice cold MeOH (4.3 mL) was added dropwise SOCl₂ (1.3 g, 0.8 mL, 11 mmol). The ensuing mixture was stirred at 0 °C for 10 min then allowed to warm to rt. Stir at rt overnight, concentrate and dry at rt/0.5 mmHg to provide 0.60 g (85%) of methyl amino(cyclopropyl)acetate hydrochloride as a solid: ¹H NMR (DMSO-d6) δ 0.51-0.69, 1.05-1.17, 3.36-3.39, 3.75, 8.69.

Preparation 142

- methyl 2-aminobutanoate hydrochloride




15

Following the procedure for the preparation of methyl amino(cyclopropyl)acetate hydrochloride but substituting alpha-aminobutyric acid and making non-critical variations provided the title compound as a solid: MS (ESI+) for C₅H₁₁NO₂ m/z 235 (2M+H)⁺.

20 **Preparation 143**

- methyl {[N-(tert-butoxycarbonyl)-L-alanyl]amino}(cyclopropyl)acetate




To an ice cold solution of methyl amino(cyclopropyl)acetate hydrochloride (0.25 g, 1.5 mmol), N-Boc-L-alanine-OH (0.34 g, 1.5 mmol) in DMF (7.5 mL) containing diisopropylethyl amine (0.58 g, 0.8 mL, 4.5 mmol) was added O-(7-azabenzotriazol-1-yl)-N,N,N,N-tetramethyluronium hexafluorophosphate (HATU) (0.57 g, 1.5 mmol). After stirring at rt for 2 days, the mixture was diluted with EtOAc

and sequentially washed with sat. aq. NaHCO₃ and sat. aq. NaCl. The organic extracts were dried over MgSO₄, filtered and concentrated. Purify by biotage MPLC (90 g column, 25-30% ethyl acetate/hexanes) to afford 0.39 g (78%) methyl {[N-(tert-butoxycarbonyl)-L-alanyl]amino}(cyclopropyl)acetate as a solid: ¹H NMR (CDCl₃) δ 5 0.39-0.62, 1.28-1.39, 1.47, 3.77, 4.03-4.19, 4.99, 6.66; MS (ESI+) for C₁₄H₂₄N₂O₅ m/z 301 (M+H)⁺.

Preparation 144


methyl {[2-[(tert-butoxycarbonyl)amino]butanoyl]amino}(cyclopropyl)acetate



10 Following the procedure for the preparation of methyl {[N-(tert-butoxycarbonyl)-L-alanyl]amino}(cyclopropyl)acetate but substituting N-Boc-alpha-aminobutyric acid and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 0.40-0.62, 0.94-0.99, 1.09-1.12, 1.46, 1.63-2.06, 3.77, 4.04, 5.02, 6.54.

Preparation 145


methyl N-{2-[(tert-butoxycarbonyl)amino]butanoyl}alaninate



20 Following the procedure for the preparation of methyl {[N-(tert-butoxycarbonyl)-L-alanyl]amino}(cyclopropyl)acetate but substituting N-Boc-alpha-aminobutyric acid and methyl 2-aminobutanoate hydrochloride and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 0.82-0.91, 1.24-1.38, 1.52, 1.68-2.05, 3.75, 4.20, 4.52-4.59, 5.05, 6.69.

Preparation 146

methyl (L-alanylamino)(cyclopropyl)acetate hydrochloride




25

A solution of methyl {[N-(tert-butoxycarbonyl)-L-alanyl]amino}(cyclopropyl)-acetate (72 mg, 0.24 mmol) in 4 N HCl in dioxane (1 mL) was stirred at rt for 45 min.

Concentrate to afford 57 mg (100%) of methyl (L-alanyl amino)(cyclopropyl)acetate hydrochloride as a solid: ^1H NMR (DMSO-d₆) δ 0.42-0.60, 1.21-1.26, 1.68, 3.65-3.91, 4.60, 8.17; MS (ESI+) for C₈H₁₂N₂O₂ *m/z* 201 (M+H)⁺.

Preparation 147


- 5 methyl [(2-aminobutanoyl)amino](cyclopropyl)acetate hydrochloride



- Following the procedure for the preparation of methyl (L-alanyl amino)(cyclopropyl)acetate hydrochloride but substituting methyl {(2-[(tert-butoxycarbonyl)amino]butanoyl)amino}(cyclopropyl)acetate and making non-critical variations provided the title compound as a solid: ^1H NMR (DMSO-d₆) δ 0.29-0.40, 0.88-0.94, 1.12, 1.37, 1.75-1.82, 3.57, 3.62-3.79, 8.29.

Preparation 148


- methyl N-(2-aminobutanoyl)alaninate hydrochloride



- 15 Following the procedure for the preparation of methyl (L-alanyl amino)(cyclopropyl)acetate hydrochloride but substituting methyl N-{2-[(tert-butoxycarbonyl)amino]butanoyl}alaninate and making non-critical variations provided the title compound as a solid: ^1H NMR (DMSO-d₆) δ 0.86-0.92, 1.39-1.41, 1.62-1.82, 3.64, 3.92, 4.18-4.23, 8.36, 8.92.


20 **Preparation 149**

- 3,6-dicyclopropylpiperazine-2,5-dione




- Following the procedure for the preparation of 3,6-diethylpiperazine-2,5-dione but substituting cyclopropyl glycine (prepared as described in patent US 6,191,306) and making non-critical variations provided the title compound as a solid. ^1H NMR (DMSO-d₆) δ 0.26-0.52, 1.04-1.12, 3.15-3.18, 3.24-3.27, 3.33, 8.06, 8.19.

Preparation 150


3-cyclopropyl-6-methylpiperazine-2,5-dione

A solution of methyl (L-alanyl)amino(cyclopropyl)acetate hydrochloride (230 mg, 0.97 mmol) in 7 N NH₃ in MeOH (6 mL) was heated at reflux for 5 hr. Cool to rt and concentrate. The resulting material was dried at rt/0.5 mm Hg to provide 0.21 g of 3-cyclopropyl-6-methylpiperazine-2,5-dione as a solid: ¹H NMR (CDCl₃) δ 0.26-0.51, 1.06-1.37, 3.16-3.25, 3.50, 3.80, 4.00, 8.13.


Preparation 151**3-cyclopropyl-6-ethylpiperazine-2,5-dione**

10

Following the procedure for the preparation of 3-cyclopropyl-6-methylpiperazine-2,5-dione but substituting methyl [(2-aminobutanoyl)amino](cyclopropyl)acetate hydrochloride and making non-critical variations provided the title compound as a solid: ¹H NMR (DMSO-d6) δ 0.29-0.48, 0.79-1.20, 1.69, 3.20, 3.93, 8.05.

Preparation 152**3-ethyl-6-methylpiperazine-2,5-dione**


Following the procedure for the preparation of 3-cyclopropyl-6-methylpiperazine-2,5-dione but substituting methyl N-(2-aminobutanoyl)alaninate hydrochloride and making non-critical variations provided the title compound as a solid: ¹H NMR (DMSO-d6) δ 0.81-0.86, 1.25-1.27, 1.64-1.76, 3.73-3.91, 7.37, 8.07-8.15.

Preparation 153**25 3-chloro-2,5-dicyclopropylpyrazine**

Following the procedure for the preparation of 3-chloro-2,5-diethylpyrazine but substituting 3,6-dicyclopropylpiperazine-2,5-dione and making non-critical variations provided the title compound as an oil: ^1H NMR (CDCl_3) δ 0.99-1.13, 1.94-2.03, 2.38-2.47; MS (ESI+) for $\text{C}_{10}\text{H}_{11}\text{N}_2$ m/z 195 ($\text{M}+\text{H}$) $^+$.

5 Preparation 154A and 154B


3-chloro-2-cyclopropyl-5-methylpyrazine (A) and 3-chloro-5-cyclopropyl-2-methylpyrazine (B)



10 Following the procedure for the preparation of 3-chloro-2,5-diethylpyrazine but substituting 3-cyclopropyl-6-methylpiperazine-2,5-dione and making non-critical variations provided 3-chloro-2-cyclopropyl-5-methylpyrazine (A) and 3-chloro-5-cyclopropyl-2-methylpyrazine (B) as oils. Analytical data for 3-chloro-2-cyclopropyl-5-methylpyrazine (A): ^1H NMR (CDCl_3) δ 1.44, 2.35, 2.90, 3.07, 8.10; MS (ESI+) for $\text{C}_8\text{H}_9\text{N}_2\text{Cl}$ m/z 169 ($\text{M}+\text{H}$) $^+$; Analytical data for 3-chloro-5-cyclopropyl-2-methylpyrazine (B): ^1H NMR (CDCl_3) δ 1.04, 2.00, 2.57, 8.10; MS (ESI+) for $\text{C}_8\text{H}_9\text{N}_2\text{Cl}$ m/z 169 ($\text{M}+\text{H}$) $^+$.

Preparation 155A and 155B

20 3-chloro-2-cyclopropyl-5-ethylpyrazine (A) and 3-chloro-5-cyclopropyl-2-ethylpyrazine (B)



Following the procedure for the preparation of 3-chloro-2,5-diethylpyrazine but substituting 3-cyclopropyl-6-ethylpiperazine-2,5-dione and making non-critical variations provided 3-chloro-2-cyclopropyl-5-methylpyrazine (A) and 3-chloro-5-cyclopropyl-2-methylpyrazine (B) as oils. Analytical data for 3-chloro-2-cyclopropyl-5-ethylpyrazine (A): ^1H NMR (CDCl_3) δ 1.06-1.10, 1.28-1.33, 2.42-2.51, 2.73-2.81, 8.18; Analytical data for 3-chloro-5-cyclopropyl-2-ethylpyrazine (B): ^1H NMR (CDCl_3) δ 1.04-1.08, 1.24-1.39, 1.97-2.06, 2.88-2.95, 8.31.

30 Preparation 156A and 156B

3-chloro-5-ethyl-2-methylpyrazine (A) and 3-chloro-2-ethyl-5-methylpyrazine (B)




A

B


Following the procedure for the preparation of 3-chloro-2,5-diethylpyrazine
 5 but substituting 3-ethyl-6-methylpiperazine-2,5-dione and making non-critical variations provided a mixture of 3-chloro-5-ethyl-2-methylpyrazine (A) and 3-chloro-2-ethyl-5-methylpyrazine (B) as an oil: ^1H NMR (CDCl_3) δ 1.29-1.39, 2.53, 2.63, 2.77-2.99, 8.27, 8.30.

Preparation 157
 10 (1R,2S)-1-[(3,6-dicyclopropylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3-chloro-2,5-dicyclopropylpyrazine and making non-critical variations provided the title compound 15 as a solid: ^1H NMR (CDCl_3) δ 0.86-0.89, 2.00, 2.89, 3.11, 4.54, 5.17, 5.42, 6.22-6.24, 7.17-7.25, 7.64; MS (ESI+) for $\text{C}_{19}\text{H}_{21}\text{N}_3\text{O}$ m/z 308 ($\text{M}+\text{H}$) $^+$.

Preparation 158
 (1R,2S)-1-[(6-cyclopropyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



20 Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3-chloro-5-cyclopropyl-2-methylpyrazine and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.95, 1.93, 2.38, 2.61, 3.09, 3.22, 4.75, 5.50, 7.30, 7.77; MS (ESI+) for $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}$ m/z 282 ($\text{M}+\text{H}$) $^+$.


25 **Preparation 159**
 (1R,2S)-1-[(3-cyclopropyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3-chloro-2-cyclopropyl-5-methylpyrazine and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.92-1.01, 1.25, 1.76, 2.36, 3.08, 3.24, 4.80, 5.38, 5.59, 7.22-7.49, 7.64; MS (ESI+) for $\text{C}_{17}\text{H}_{19}\text{N}_3\text{O}$ m/z 282 ($\text{M}+\text{H}$) $^+$.

Preparation 160


(1R,2S)-1-[(6-cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3-chloro-5-cyclopropyl-2-ethylpyrazine and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.92-0.95, 1.31-1.35, 1.93, 2.59-2.70, 3.03-3.10, 3.22-3.30, 4.74, 4.91, 5.49-5.52, 7.28-7.32, 7.82; MS (ESI+) for $\text{C}_{18}\text{H}_{21}\text{N}_3\text{O}$ m/z 296 ($\text{M}+\text{H}$) $^+$.

Preparation 161


(1R,2S)-1-[(3-cyclopropyl-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting 3-chloro-2-cyclopropyl-5-ethylpyrazine and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.93-1.02, 1.24-1.30, 1.72-1.81, 2.61-2.68, 3.06-3.30, 4.79-4.84, 5.36, 5.58, 7.24-7.35, 7.66; MS (ESI+) for $\text{C}_{18}\text{H}_{21}\text{N}_3\text{O}$ m/z 296 ($\text{M}+\text{H}$) $^+$.

Preparation 162A and 162B

(1R,2S)-1-[(6-ethyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (A) and
 (1R,2S)-1-[(3-ethyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (B)



5


A**B**

Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting a mixture of 3-chloro-5-ethyl-2-methylpyrazine (A) and 3-chloro-2-ethyl-5-methylpyrazine (B) and making non-critical variations provided a mixture of the title compounds as a solid: ¹H NMR

10 (CDCl₃) δ 1.24-1.34, 2.38, 2.63-2.69, 3.04-3.10, 3.23-3.29, 4.78-4.92, 5.58-5.63, 7.24-7.32, 7.68, 7.73.

Preparation 163

(1S,2S)-1-[(5-bromo-3,6-dicyclopropylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol




15

Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(3,6-dicyclopropylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 0.89-1.03, 1.27-1.30, 1.71-1.75, 2.36-2.39, 3.05-3.09, 3.25-3.30, 4.72-4.75, 5.45-5.46, 7.26-7.33; MS (ESI+) for C₁₉H₂₀BrN₃O m/z 386 (M+H)⁺.

Preparation 164


(1R,2S)-1-[(5-bromo-6-cyclopropyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(6-cyclopropyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making
5 non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.99, 2.08, 2.38, 3.04, 3.25, 4.72, 4.97, 5.45, 7.24-7.31; MS (ESI+) for $\text{C}_{17}\text{H}_{18}\text{BrN}_3\text{O}$ m/z 362 ($\text{M}+\text{H}$) $^+$.

Preparation 165


(1R,2S)-1-[(5-bromo-3-cyclopropyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol
10



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(3-cyclopropyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making
15 non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.95-1.08, 1.69-1.78, 2.49, 3.04, 3.24, 4.78, 5.39, 5.58, 7.24-7.33; MS (ESI+) for $\text{C}_{17}\text{H}_{18}\text{BrN}_3\text{O}$ m/z 360 ($\text{M}+\text{H}$) $^+$.

Preparation 166

(1R,2S)-1-[(5-bromo-6-cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol
20




Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(6-

cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.93-1.09, 1.28-1.39, 2.35-2.43, 2.60-2.67, 2.99-3.05, 3.22-3.29, 4.70, 5.04, 5.44-5.49, 7.23-7.32; MS (ESI+) for $\text{C}_{18}\text{H}_{20}\text{BrN}_3\text{O}$ m/z 374 ($\text{M}+\text{H}$) $^+$.

5 **Preparation 167**


(1R,2S)-1-[(5-bromo-3-cyclopropyl-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-[(5-bromo-3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(3-cyclopropyl-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.86-1.08, 1.23-1.30, 1.70-1.79, 2.77-2.84, 3.03-3.09, 3.23-3.30, 4.77-4.81, 5.44, 5.56, 7.23-7.32; MS (ESI+) for $\text{C}_{18}\text{H}_{20}\text{BrN}_3\text{O}$ m/z 374 ($\text{M}+\text{H}$) $^+$.


15 **Preparation 168**

(1R,2S)-1-[(5-bromo-6-ethyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (A) and (1R,2S)-1-[(5-bromo-3-ethyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (B)



20

A



B

25


Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting a mixture of (1R,2S)-1-[(6-ethyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (A) and (1R,2S)-1-[(3-ethyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (B) and making non-critical variations provided a mixture of the title compound as a solid: ^1H NMR

(CDCl₃) δ 1.11-1.24, 2.26-3.16, 4.63-4.67, 4.94-4.98, 5.20, 5.46-5.50, 7.12-7.30; MS (ESI+) for C₁₆H₁₈BrN₃O m/z 348 (M+H)⁺.

Preparation 169

(1R,2S)-1-{[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]amino}-2,3-

5 dihydro-1H-inden-2-ol




Following the procedure for the preparation of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol but substituting (1S,2S)-1-[(5-bromo-3,6-dicyclopropylpyrazin-2-yl)amino]-2,3-dihydro-10 1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 0.85-0.99, 1.67, 1.82, 2.48, 3.10-3.13, 3.27-3.28, 4.79, 5.40, 5.42, 7.30-7.51; MS (ESI+) for C₂₅H₂₃Cl₂N₃O m/z 452 (M+H)⁺.

Preparation 170

(1R,2S)-1-{[6-cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazin-2-yl]amino}-2,3-

15 dihydro-1H-inden-2-ol




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-[(5-bromo-6-cyclopropyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 0.87-1.03, 1.60-1.69, 2.42, 2.71, 3.03, 3.25, 4.73, 4.99, 5.53, 7.12-7.66; MS (ESI+) for C₂₃H₂₁Cl₂N₃O m/z 426 (M+H)⁺.

Preparation 171

(1R,2S)-1-{[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-methylpyrazin-2-yl]amino}-2,3-


25 dihydro-1H-inden-2-ol



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-[(5-bromo-3-cyclopropyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.96-0.99, 1.58, 1.81, 2.26, 2.85, 3.14, 3.26, 4.86, 5.44, 5.63, 7.26-7.50; MS (ESI+) for $\text{C}_{23}\text{H}_{21}\text{Cl}_2\text{N}_3\text{O}$ m/z 426 ($\text{M}+\text{H}$) $^+$.

Preparation 172


- 10 (1R,2S)-1-{[6-cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-[(5-bromo-6-cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.96-1.00, 1.26-1.32, 2.04, 2.35-2.40, 2.61-2.66, 3.0-3.04, 3.22-3.27, 4.09-4.14, 4.68-4.70, 5.08, 5.45-5.48, 7.23-7.31; MS (ESI+) for $\text{C}_{24}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}$ m/z 440 ($\text{M}+\text{H}$) $^+$.

Preparation 173


- 20 (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1*R*,2*S*)-2-ethoxy-2,3-dihydro-1*H*-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1*R*,2*S*)-1-[(5-bromo-6-cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1*H*-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ ; MS (ESI+) for $\text{C}_{23}\text{H}_{21}\text{Cl}_2\text{N}_3\text{O}$ m/z ($\text{M}+\text{H})^+$.

Preparation 174


(1*R*,2*S*)-1-({6-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-3-ethylpyrazin-2-yl}amino)-2,3-dihydro-1*H*-inden-2-ol



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1*R*,2*S*)-2-ethoxy-2,3-dihydro-1*H*-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1*R*,2*S*)-1-[(5-bromo-6-cyclopropyl-3-ethylpyrazin-2-yl)amino]-2,3-dihydro-1*H*-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ ; MS (ESI+) for $\text{C}_{23}\text{H}_{21}\text{Cl}_2\text{N}_3\text{O}$ m/z ($\text{M}+\text{H})^+$.

Preparation 175


(1*R*,2*S*)-1-{[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazin-2-yl]amino}-2,3-dihydro-1*H*-inden-2-ol



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-[(5-bromo-3-cyclopropyl-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.94-1.02, 1.14-1.19, 1.26-1.30, 1.68-1.86, 2.06, 2.28-2.49, 3.08-3.32, 4.06-4.18, 4.83-4.87, 5.49, 5.62-5.66, 7.27-7.50; MS (ESI+) for $\text{C}_{24}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}$ m/z 440(MH^+).

Preparation 176


(1R,2S)-1-({3-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-6-ethylpyrazin-2-yl}amino)-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-[(5-bromo-3-cyclopropyl-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.88-1.00, 1.13-1.17, 1.25-1.34, 1.77-1.82, 2.11, 2.52-2.58, 3.08-3.12, 3.23-3.28, 4.82-4.85, 5.41, 5.60-5.62, 7.26-7.70, 7.97; MS (ESI+) for $\text{C}_{26}\text{H}_{31}\text{N}_5\text{O}$ m/z 430(MH^+).

Preparation 177


(1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-6-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-[(5-bromo-3-cyclopropyl-6-ethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.95-1.01, 1.14-1.30, 1.80-1.84, 2.52, 2.76-2.84, 3.11-3.16, 3.26-3.31, 3.80-3.88, 4.12-4.17, 4.85-4.88, 5.36, 5.61-5.63, 6.88-7.03, 7.21-7.46; MS (ESI+) for $\text{C}_{25}\text{H}_{26}\text{ClN}_3\text{O}_2$ m/z 436(MH^+).

Preparation 178


(1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-ethyl-3-methylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(5-bromo-6-ethyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (A) and (1R,2S)-1-[(5-bromo-3-ethyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (B) and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 1.06-1.09, 1.13-1.20, 2.36-2.38, 3.00-3.22, 4.76, 5.57, 7.19-7.42.


Preparation 179

(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3-ethyl-6-methylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol




Following the procedure for the preparation of (1R,2S)-1-[(3,6-diethylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol but substituting (1R,2S)-1-[(5-bromo-6-ethyl-3-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (A) and (1R,2S)-1-[(5-bromo-3-ethyl-6-methylpyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (B) and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 1.15-1.28, 2.36-2.52, 2.74, 3.09-3.30, 4.85, 5.68, 7.28-7.68.

Example 111
 3,6-dicyclopethyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[3,6-dicyclopethyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.80-1.07, 1.17-1.20, 1.67, 1.79, 3.14-3.20, 3.46-3.50, 3.70-3.72, 4.35, 5.72, 5.97, 7.24-7.50; MS (ESI+) for $\text{C}_{27}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}$ m/z 480 ($\text{M}+\text{H}$) $^+$.


Example 112
 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-methylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[6-cyclopropyl-5-(2,4-dichlorophenyl)-3-methylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.75-1.13, 1.53-1.59, 2.31, 2.98-3.09, 3.35-3.40, 3.57-3.65, 4.23-4.25, 5.37, 5.62, 7.12-7.42; MS (ESI+) for $\text{C}_{25}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}$ m/z 454 ($\text{M}+\text{H})^+$.

Example 113


3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-methylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.87-1.07, 1.18-1.23, 1.82, 2.27, 3.10-3.16, 3.47-3.57, 3.66-3.76, 4.40, 5.83, 5.98, 7.25-7.50; MS (ESI+) for $\text{C}_{25}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}$ m/z 454 ($\text{M}+\text{H})^+$.

Example 114

6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[6-cyclopropyl-5-(2,4-dichlorophenyl)-3-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the

title compound as a solid: ^1H NMR (CDCl_3) δ 0.82-1.33, 1.58-1.71, 2.68-2.76, 3.06-3.19, 3.41-3.51, 3.65-3.75, 4.32-4.36, 5.52-5.54, 5.71-5.76, 7.23-7.52; MS (ESI+) for $\text{C}_{26}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}$ m/z 469 ($\text{M}+\text{H}$) $^+$.

Example 115


- 5 5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-3-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: MS (ESI+) for $\text{C}_{27}\text{H}_{30}\text{ClN}_3\text{O}_2$ m/z 465 ($\text{M}+\text{H}$) $^+$.

Example 116


- 6-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[6-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-3-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.81-1.19, 1.28-1.33, 2.67-2.73, 3.11-3.14, 3.42-3.51, 3.65-3.73, 4.32-4.35, 5.40-5.42, 5.72-5.75, 6.49-7.22, 7.39, 8.19; MS (ESI+) for $\text{C}_{28}\text{H}_{35}\text{N}_5\text{O}$ m/z 458 ($\text{M}+\text{H}$) $^+$.

Example 117


3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.87-1.21, 1.58, 1.80-1.85, 2.51, 3.15-3.17, 3.46-3.56, 3.66-3.76, 4.40-4.45, 5.88, 6.04, 7.21-7.34, 7.47-7.50; MS (ESI+) for $\text{C}_{26}\text{H}_{27}\text{Cl}_2\text{N}_3\text{O}$ m/z 469 ($\text{M}+\text{H}$) $^+$.

Example 118


3-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.85-0.95, 1.16-1.34, 1.80-1.83, 2.53-2.58, 3.49-3.55, 3.68-3.72, 4.39-4.42, 5.32, 5.81-5.88, 6.46, 7.24-7.28, 7.51-7.53, 8.01; MS (ESI+) for $\text{C}_{28}\text{H}_{35}\text{N}_5\text{O}$ m/z 458 ($\text{M}+\text{H}$) $^+$.

Example 119


5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.77-0.86, 0.97-1.23, 1.70-1.76, 2.42, 2.67-2.69, 3.00-3.11, 3.38-3.45, 3.57-3.64, 3.76-3.78, 4.30-4.34, 5.73-5.84, 6.78-6.92, 7.13-7.19, 7.37-7.42; MS (ESI+) for $\text{C}_{27}\text{H}_{30}\text{ClN}_3\text{O}_2$ m/z 465($\text{M}+\text{H}$) $^+$.

Example 120


10 5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[3-cyclopropyl-5-(2,4-dichlorophenyl)-6-ethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.77-0.86, 0.97-1.23, 1.70-1.78, 2.42, 2.63-2.75, 3.00-3.11, 3.58-3.64, 3.76-3.78, 4.30-4.34, 5.73-5.84, 6.76-6.93, 7.13-7.19, 7.37-7.42; MS (ESI+) for $\text{C}_{27}\text{H}_{30}\text{ClN}_3\text{O}_2$ m/z 465 ($\text{M}+\text{H}$) $^+$.


20 **Example 121**

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methylpyrazin-2-amine



- Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-ethyl-3-methylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 0.76-0.82, 1.02-1.34, 1.56-1.58, 2.24, 2.62, 3.38-3.55, 3.90-3.95, 5.22, 5.50-5.54, 6.14-6.16, 6.70-6.72, 7.04-7.62; MS (ESI+) for $\text{C}_{24}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}$ m/z 443 ($\text{M}+\text{H}$) $^+$.


- Example 122**
- 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methylpyrazin-2-amine



- Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3-ethyl-6-methylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: MS (ESI+) for $\text{C}_{24}\text{H}_{25}\text{Cl}_2\text{N}_3\text{O}$ m/z 443 ($\text{M}+\text{H}$) $^+$.

Preparation 180


- N-[(1R,2R)-2-azido-2,3-dihydro-1H-inden-1-yl]-3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-amine



To a solution of (1R,2S)-1-{[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol (0.76 g, 1.7 mmol) in toluene (10 mL) and THF (10 mL) was added PPh₃ (1.14 g, 4.57 mmol). The solution was cooled to 0 °C and HN₃ (5.6 mL, 6.38 mmol) and a solution of diethylazodicarboxylate (0.69 mL, 4.37 mmol) in toluene (10 mL) were added. The reaction was stirred at rt overnight. The precipitates were removed by filtration and the filtrate was concentrated. Dissolve residue in 1 N HCl and EtOAc. Extract with EtOAc (3 x 30 mL). The aqueous phase was neutralized with sat. aq. NaHCO₃ to pH 7.5 followed by a small amount of 6 N NaOH to pH 9. The aqueous phase was extracted with CH₂Cl₂ (3 x 30 mL). The combined organic extracts were dried over MgSO₄, filtered and concentrated. Purify by biotage MPLC (90 g column, 29 - 39% ethyl acetate/hexanes) to afford 0.8 g (78%) of N-[(1R,2R)-2-azido-2,3-dihydro-1H-inden-1-yl]-3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-amine as a solid: ¹H NMR (CDCl₃) δ 0.74-1.10, 1.63-1.71, 2.97-3.03, 3.36-3.42, 4.09-4.13, 4.26-4.29, 5.05, 5.57, 7.25-7.53; MS (ESI+) for C₂₅H₂₂Cl₂N₆ m/z 477 (M+H)⁺.

Preparation 181

(1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-2,3-dihydro-1H-indene-1,2-diamine




To a solution of N-[(1R,2R)-2-azido-2,3-dihydro-1H-inden-1-yl]-3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-amine (0.55 g, 1.15 mmol) in anhydrous THF (30 mL) was added PPh₃ (0.396 g, 1.51 mmol). The resulting mixture was stirred at rt for 3 hr. To the solution was added water (0.25 mL, 13.9 mmol). The reaction is then allowed to stir overnight at rt. The mixture is concentrated, and the resulting solid is dissolved in MeOH. Purify by passage over Biorad acidic resin by applying the MeOH solution onto the resin and rinsing the resin with MeOH. The resin was then rinsed with 5% triethylamine/MeOH solution to afford 0.52 g (75%) of (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-2,3-dihydro-1H-indene-1,2-diamine as a solid: ¹H NMR (CDCl₃) δ 0.85-1.12, 1.64-1.76, 1.89, 2.68-

2.82, 3.31-3.39, 3.66-3.72, 5.16, 5.33, 7.28-7.53; MS (ESI+) for $C_{25}H_{24}Cl_2N_4$ m/z 451 ($M+H$)⁺.

Example 123


(1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-ethyl-2,3-dihydro-1H-indene-1,2-diamine



To a solution of (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-2,3-dihydro-1H-indene-1,2-diamine (0.15 g, 0.33 mmol) in MeOH (3.3 mL) was sequentially added acetaldehyde (22 mg, 0.5 mmol) and 10 AcOH (5 drops). This mixture was stirred for 30 min before addition of NaBH₃CN (1 M solution in THF, 0.6 mL, 0.6 mmol). Stir at rt overnight. Add additional acetic acid (2 drops), acetaldehyde (29 μ L, 0.5 mmol) and NaBH₃CN (1 M solution in THF, 0.6 mL, 0.6 mmol). After 2 hr, add additional acetic acid (2 drops), acetaldehyde (29 μ L, 0.5 mmol) and NaBH₃CN (1 M solution in THF, 0.6 mL, 0.6 mmol). After 3 hr, dilute mixture with EtOAc and wash with sat. aq. NaHCO₃ and extract with EtOAc (3 x 40 mL). The combined organic extracts were dried over MgSO₄, filtered and concentrated. Purify by biotage MPLC (90 g column, 100% ethyl acetate) to afford 15 0.16 g (44%) of (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-ethyl-2,3-dihydro-1H-indene-1,2-diamine as a solid: ¹H NMR (CDCl₃) δ 0.84-20 1.05, 1.62-1.75, 2.78-2.86, 3.31-3.37, 3.52, 5.22, 5.52, 7.28-7.51; MS (ESI+) for C₂₇H₂₈Cl₂N₄ m/z 479 ($M+H$)⁺.

Example 124

N-((1R,2R)-1-{[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)acetamide




25 To a solution of (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-2,3-dihydro-1H-indene-1,2-diamine (0.10 g, 0.22 mmol)

in CHCl₃ (1 mL) at 0 °C under N₂ was added trichloroacetone (30 µL, 0.26 mmol). The mixture was allowed to slowly warm to rt for 1.5 hr. The reaction was then heated at 60 °C for 1.5 h. Cool to rt, add additional trichloroacetone (10 µL) and continue heating at 60 °C for 2 hr. The reaction was concentrated and purified by 5 biotage MPLC (90 g column, 80% ethyl acetate/hexanes) to afford 0.11 g (55%) of N-((1R,2R)-1-{[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)acetamide as a solid: ¹H NMR (CDCl₃) δ 0.84-1.01, 1.61-1.81, 2.04, 2.80-2.86, 3.58-3.64, 4.07-4.13, 4.46, 5.56, 6.56, 7.28-7.51; MS (ESI+) for C₂₇H₂₆Cl₂N₄O m/z 493 (M+H)⁺.

10 Example 125


(1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-(2-methoxyethyl)-2,3-dihydro-1H-indene-1,2-diamine



To a solution of (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-2,3-dihydro-1H-indene-1,2-diamine (0.10 g, 0.22 mmol) in MeOH (2 mL) containing acetic acid (2 drops) and methoxyacetaldehyde (49 mg, 0.66 mmol) was added NaBH₃CN (1 M solution in THF, 0.8 mL, 0.8 mmol). The mixture was stirred at rt overnight. Dilute with sat. aq. NaHCO₃ and extract ED with EtOAc (3 x 30 mL). The combined organic extracts were dried over MgSO₄, filtered and concentrated to afford an oil that was purified by biotage MPLC (90 g column, 10% ethyl acetate/hexanes) to afford 0.11 g (20%) of (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-(2-methoxyethyl)-2,3-dihydro-1H-indene-1,2-diamine as a solid: ¹H NMR (CDCl₃) δ 0.60-1.01, 1.45-1.70, 2.83-2.99, 3.22-3.33, 3.47-3.56, 5.19, 5.53, 7.11-7.42; MS (ESI+) for C₂₈H₃₀Cl₂N₄O m/z 509 (M+H)⁺.

25 Example 126


5-(2,4-dichlorophenyl)-N-[(1S,2R)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine but substituting (1S,2R)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and iodoethane and making non-critical variations provided the title compound as a solid: MS (ESI+) for C₂₅H₂₇Cl₂N₃O m/z 457 (M+H)⁺.

Example 127

5-(2,4-dichlorophenyl)-N-[(1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine




10

Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine but substituting (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and iodoethane and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 0.81, 1.17-1.21, 1.30-1.34, 1.51-1.59, 1.98, 3.90-3.96, 4.02-4.08, 6.71-6.73, 7.04-7.07, 7.19; MS (ESI+) for C₂₅H₂₇Cl₂N₃O m/z 457 (M+H)⁺.

Example 128

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine




Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine but substituting (1S,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-

dihydro-1H-inden-2-ol and 1-bromo-2-fluoroethane and making non-critical variations provided the title compound as a solid: MS (ESI+) for $C_{25}H_{26}Cl_2FN_3O$ *m/z* 475 ($M+H$)⁺.

Preparation 182


- 5 (1R,2S)-1-[(6-chloropyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



To a solution of 2,6-dichloropyrazine (5.0 g, 34 mmol) in n-BuOH (30 mL) was added triethylamine (6.8 g, 9.4 mL, 67 mmol) and (1R,2S)-(+)-cis-1-amino-2-indanol (5.0 g, 34 mmol). The mixture was heated at 115 °C overnight. The solution 10 was cooled to rt and concentrated. Dissolve material in EtOAc (200 mL) and remove insoluble material by vacuum filtration. Wash filtrate sequentially with 4 N NaOH and sat. aq. NaCl. Dry organic extract over MgSO₄, filter and concentrate. Purify by biotage MPLC (90 g column, 10% ethyl acetate/hexanes) to afford 4.85 g (57%) of (1R,2S)-1-[(6-chloropyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol as a solid: ¹H 15 NMR (CDCl₃) δ 2.83-2.87, 3.08-3.13, 3.32, 4.54, 5.11, 5.28-5.31, 7.18-7.28, 7.73, 8.12; MS (ESI+) for $C_{13}H_{12}ClN_3O$ *m/z* 262 ($M+H$)⁺.

Preparation 183

methyl 6-{{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate




20

An autoclave was charged with (1R,2S)-1-[(6-chloropyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (1.7 g, 6.5 mmol), MeOH (20 mL), triethylamine (1.1 mL, 7.8 mmol), bis(diphenylphosphino)ferrocene (21.6 mg, 39 μmol), PdCl₂(PhCN)₂ (12.5 mg, 32.5 μmol) and dried, powdered 4 Å molecular sieves (2.8 g). Evacuate and 25 charge (3x) with carbon monoxide (350 psi). Heat at 145 °C for 18 hours. Cool to rt, release pressure and remove solids by filtration. The mixture was diluted with CH₂Cl₂ and washed with water. The organic extract was dried over MgSO₄, filtered and concentrated. Purify by biotage MPLC (90 g column, 50% ethyl acetate/hexanes) to afford 1.4 g (77%) of methyl 6-{{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-

yl]amino}pyrazine-2-carboxylate as a solid: ^1H NMR (CDCl_3) δ 2.84-2.88, 3.09-3.14, 3.85, 4.55-4.57, 5.41-5.44, 7.14-7.28, 7.61-7.63, 8.30, 8.39; MS (ESI+) for $\text{C}_{15}\text{H}_{15}\text{N}_3\text{O}_3$ m/z 286 ($\text{M}+\text{H})^+$.

Preparation 184

- 5 methyl 3-bromo-6-{{(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate



To a solution of methyl 6-{{(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate (1.0 g, 3.5 mmol) in CH_2Cl_2 (35 mL) was added N-bromosuccinimide (0.69 g, 3.86 mmol). Stir at t for 2 hr. Wash the reaction with sat. aq. NaHCO_3 . The organic extract was dried over MgSO_4 , filtered and concentrated. Purify by biotage MPLC (90 g column, 20% ethyl acetate/hexanes) to afford 380 mg (30%) of methyl 3-bromo-6-{{(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate as a solid: ^1H NMR (CDCl_3) δ 3.01-3.06, 3.24-3.29, 4.00, 4.75-4.78, 5.45-5.46, 7.25-7.32, 7.94; MS (ESI+) for $\text{C}_{15}\text{H}_{14}\text{BrN}_3\text{O}_3$ m/z 386 ($\text{M}+\text{H})^+$.

Preparation 185

methyl 3-(2,4-dichlorophenyl)-6-{{(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate



20

Charge a Kimble vial with methyl 3-bromo-6-{{(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate (0.45 g, 1.14 mmol), $\text{Pd}(\text{PPh}_3)_4$ (198 mg, 0.17 mmol), and 2,4-dichlorophenylboronic acid (325 mg, 1.71 mmol). Flush with N_2 and add DMF (4 mL) and 2 M Na_2CO_3 (1.1 mL). The resulting mixture was heated at 85 °C overnight. The mixture was diluted with sat. aq. NaHCO_3 . Extract with Et_2O . The organic extract was dried over MgSO_4 , filtered and concentrated. Purify by biotage MPLC (90 g column, 30% ethyl acetate/hexanes) to afford 290 mg (59%) of methyl 3-(2,4-dichlorophenyl)-6-{{(1R,2S)-2-hydroxy-2,3-

dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate as a solid: ^1H NMR (CDCl_3) δ 3.06-3.09, 3.27-3.32, 3.80, 4.09-4.15, 4.84, 5.58, 7.28-7.49, 8.25; MS (ESI+) for $\text{C}_{21}\text{H}_{17}\text{Cl}_2\text{N}_3\text{O}_3$ m/z 430 ($\text{M}+\text{H})^+$.

Preparation 186

- 5 methyl 5-bromo-3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate




Following the procedure for the preparation of methyl 3-bromo-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate but substituting

- 10 methyl 3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 2.99-3.04, 3.20-3.25, 3.70, 3.99-4.08, 4.77, 5.59-5.62, 6.11, 7.24-7.38; MS (ESI+) for $\text{C}_{21}\text{H}_{16}\text{BrCl}_2\text{N}_3\text{O}_3$ m/z 509 ($\text{M}+\text{H})^+$.

Preparation 187


- 15 ethyl 3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxylate



To a solution of methyl 5-bromo-3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate (0.19 g, 0.37 mmol) in MeOH (3.7 mL) was added NaOMe (60 mg, 1.1 mmol). The mixture was heated at reflux for 3 hr. Cool to rt, and dilute with EtOAc. Wash with sat. aq. NaHCO_3 . Dry organic extract over MgSO_4 , filter and concentrate. Purify by biotage MPLC (90 g column, 25% ethyl acetate/hexanes) to afford 0.15 g (73%) of ethyl 3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxylate as a solid: ^1H NMR (CDCl_3) δ 3.07-3.12, 3.25-3.31, 3.76, 4.04, 4.85-4.89, 5.68-5.76, 7.28-7.49; MS (ESI+) for $\text{C}_{22}\text{H}_{19}\text{Cl}_2\text{N}_3\text{O}_4$ m/z 460 ($\text{M}+\text{H})^+$.

Example 129


methyl 3-(2,4-dichlorophenyl)-6-{{(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxylate



Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine but substituting methyl 3-(2,4-dichlorophenyl)-6-{{(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxylate and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 1.13-2.20, 3.15, 3.55-3.58, 3.66-3.70, 3.76, 4.02, 4.41, 5.75-5.79, 6.16, 7.25-7.34, 7.48, 7.59-7.61; MS (ESI+) for $\text{C}_{24}\text{H}_{23}\text{Cl}_2\text{N}_3\text{O}_4$ m/z 488 ($\text{M}+\text{H}$)⁺.

Example 130


methyl 6-{{(1R,2S)-2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]amino}-3-(2,4-dichlorophenyl)-5-methoxypyrazine-2-carboxylate



Following the procedure for the preparation of (1R,2S)-1-{{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate but substituting methyl 3-(2,4-dichlorophenyl)-6-{{(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxylate and making non-critical variations provided the title compound as a solid: ^1H NMR (CDCl_3) δ 2.03, 3.10-3.14, 3.31-3.36, 3.75, 4.05, 5.68-5.77, 6.07-6.11, 7.31-7.48; MS (ESI+) for $\text{C}_{24}\text{H}_{21}\text{Cl}_2\text{N}_3\text{O}_5$ m/z 502 ($\text{M}+\text{H}$)⁺.

Preparation 186


(1R,2S)-1-[(6-methoxypyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol



To a solution of (1R,2S)-1-[(6-chloropyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (2 g, 7.6 mmol) in MeOH (26 mL) was added a solution of NaOMe (1.3 g, 23 mmol) in MeOH (40 mL). The mixture was heated at reflux for 24 hr. Additional NaOMe (1.3 g) was added. Continue heating at reflux for 24 hr, and then add 5 additional NaOMe (1.3 g). Continue heating at reflux for 24 hr and cool to rt. Dilute with EtOAc and wash with sat. aq. NaHCO₃. The solids were removed by filtration. Separate phases and wash organic extract with additional sat. aq. NaHCO₃. Dry organic extracts over MgSO₄, filter and concentrate. Purify by biotage MPLC (90 g column, 25% ethyl acetate/hexanes) to afford 1.4 g (71%) of (1R,2S)-1-[(6-methoxypyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol as an oil: ¹H NMR (CDCl₃) δ 3.04-3.08, 3.23-3.29, 3.91, 4.75-4.78, 5.18, 5.42-5.45, 7.25-7.34, 7.57-7.61; MS (ESI+) for C₁₄H₁₅N₃O₂ m/z 258 (M+H)⁺.

Preparation 187

(1R,2S)-1-[(5-bromo-6-methoxypyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol




15

Following the procedure for the preparation of methyl 3-bromo-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate but substituting methyl (1R,2S)-1-[(6-methoxypyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 2.07, 3.03-3.07, 3.25-3.30, 3.98, 4.76, 5.38, 7.26-7.32, 7.45; MS (ESI+) for C₁₄H₁₄BrN₃O₂ m/z 336 (M+H)⁺.

Preparation 188

(1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol




25

A Kimble vial was charged with (1R,2S)-1-[(5-bromo-6-methoxypyrazin-2-yl)amino]-2,3-dihydro-1H-inden-2-ol (0.55 g, 1.63 mmol), Pd₂(dba)₃ (33 mg, 35 μmol), dicyclohexyl[2-(9-phenanthryl)phenyl]phosphine (64 mg), 2,4-

dichlorophenylboronic acid (567 mg, 2.67 mmol), K₃PO₄ (1.13 g, 5.34 mmol) and toluene (15 mL). The vial was flushed with N₂, sealed and heated at 110 °C for 6 hr. Cool to rt, add additional Pd₂(dba)₃ (33 mg) and 2,4-dichlorophenylboronic acid (0.5 g, 2.7 mmol). Continue heating overnight. Add additional Pd₂(dba)₃ (33 mg) and 2,4-dichlorophenylboronic acid (0.5 g, 2.7 mmol) and continue heating for 5 hr. Add additional Pd₂(dba)₃ (33 mg) and 2,4-dichlorophenylboronic acid (0.5 g, 2.7 mmol) and continue heating overnight. The reaction was cooled to rt, diluted with CH₂Cl₂, washed with sat. aq NaHCO₃ and sat. aq. NaCl. Dry organic extract over MgSO₄, filter and concentrate. Purify by biotage MPLC (90 g column, 30% ethyl acetate/hexanes) to afford 0.2 g (31%) of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol as an oil: ¹H NMR (CDCl₃) δ 3.06-3.10, 3.26-3.32, 3.92, 4.79, 5.33, 5.49-5.50, 7.28-7.41, 7.50, 7.74; MS (ESI+) for C₂₀H₁₇Cl₂N₃O₂ m/z 402 (M+H)⁺.

Preparation 189


(1R,2S)-1-{[3-bromo-5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



Following the procedure for the preparation of methyl 3-bromo-6-{[(1R,2S)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]amino}pyrazine-2-carboxylate but substituting (1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 3.09-3.13, 3.29-3.34, 3.92, 4.81, 5.60-5.63, 5.99, 7.33-7.42, 7.49; MS (ESI+) for C₂₀H₁₆BrCl₂N₃O₂ m/z 479 (M+H)⁺.

Preparation 190


(1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-methoxy-3-vinylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol



To a solution of (1R,2S)-1-{[3-bromo-5-(2,4-dichlorophenyl)-6-methoxypyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol (150 mg, 0.31 mmol) in DMF (1.6 mL) is added Pd(PPh₃)₄ (7 mg, 6 µmol), and tributyl vinyl tin (114 mg, 0.36 mmol). The reaction is heated at 120 °C overnight. Sat. aq. KF (15 mL) is added and the mixture is stirred at rt for 1 hr. Extract with CH₂Cl₂ (5 x 30 mL). The combined organic extracts were dried over MgSO₄, filtered and concentrated. Purify by biotage MPLC (90 g column, 15% ethyl acetate/hexanes) to afford 132 mg (38%) of (1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-methoxy-3-vinylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol as a solid: ¹H NMR (CDCl₃) δ 3.08-3.12, 3.28-3.34, 3.93, 4.82, 5.46-5.49, 5.54-5.67, 6.09-6.13, 6.77-6.84, 7.28-7.50; MS (ESI+) for C₂₀H₁₇Cl₂N₃O₂ m/z 402 (M+H)⁺.

Example 131

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy-3-vinylpyrazin-2-amine



15


Following the procedure for the preparation of 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine but substituting (1R,2S)-1-{[5-(2,4-dichlorophenyl)-6-methoxy-3-vinylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-ol and making non-critical variations provided the title compound as a solid: ¹H NMR (CDCl₃) δ 1.11-1.14, 3.04-3.08, 3.37-3.44, 3.60-3.68, 3.84, 4.28-4.30, 5.34-5.37, 5.68-5.71, 5.90-5.99, 6.66-6.73, 7.14-7.26, 7.32-7.40; MS (ESI+) for C₂₄H₂₃Cl₂N₃O₂ m/z 456 (M+H)⁺.

25

CLAIMS

WHAT IS CLAIMED IS:

- 5 1. A compound of Formula I



Formula I

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula I,


- 10 X is selected from -NR₃R₄, -OR₃, -CR₃R₅R₅, -C(O)R₃, -S(O)_mR₃, -NR₃C(O)R₄, or -NR₃S(O)_mR₄,
m is 0,1 or 2;
- Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
R₁, R₂, and R₅ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a,
15 -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;
- 20 R₃ and R₄ are independently selected from R_a, heterocycloalkyl, substituted heterocycloalkyl, substituted heteroaryl, substituted aryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, substituted heteroaryl heterocycloalkyl, heteroaryl heterocycloalkyl, or substituted heteroaryl heterocycloalkyl provided at least one of R₃ or R₄ are heteroaryl, substituted heteroaryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl,
25 substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, substituted heteroaryl heterocycloalkyl, heterocycloalkyl or substituted heterocycloalkyl;
- 30 R_a each is selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

- R_t each is selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen,
- 5

provided that the compound is not:

- 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-methylpiperidin-4-yl)oxy]pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-(tetrahydrofuran-3-yl)oxy]pyrazine
 10 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-(tetrahydro-2H-pyran-4-yloxy)pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-methylpiperidin-3-yl)oxy]pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-ethylpiperidin-3-yl)oxy]pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-(1-piperidin-4-yl)oxy]pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-piperidin-3-yl)oxy]pyrazine
 15 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-ethylpyrrolidin-3-yl)oxy]pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(1-methylpyrrolidin-3-yl)oxy]pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(pyrrolidin-3-yl)oxy]pyrazine
 2,5-dimethyl-3-(2,4-dichlorophenyl)-6-[(pyridin-4-yl)oxy]pyrazine.

20 2. A compound of Formula II



Formula II

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula II,

- 25 Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
 m is 0,1 or 2;
 R₁ and R₂ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a,
 -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -


$\text{NR}_a\text{C(O)OR}_a$, $-\text{OC(O)NR}_a\text{R}_a$, $-\text{NR}_a\text{C(O)NR}_a\text{R}_a$, $-\text{NR}_a\text{C(S)NR}_a\text{R}_a$, $-\text{C(O)OR}_a$, $-\text{C(S)OR}_a$, or $-\text{OC(O)OR}_a$;

R_3 and R_4 are independently selected from R_a , heterocycloalkyl, substituted heterocycloalkyl, substituted heteroaryl, substituted aryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, or substituted heteroaryl heterocycloalkyl provided at least one of R_3 or R_4 are heteroaryl, substituted heteroaryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, substituted heteroaryl heterocycloalkyl, heterocycloalkyl or substituted heterocycloalkyl;

R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t , $-\text{OR}_t$, $-\text{S(O)}_m\text{R}_t$, NR_tR_t , oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t ; and

R_t each is independently selected from H, halogen, $-\text{NO}_2$, $-\text{NH}_2$, $-\text{OH}$, $-\text{SH}$, $-\text{CN}$, $-\text{C(O)NH}_2$, $-\text{C(O)-NHalkyl}$, $-\text{C(O)Nalkylalkyl}$, $-\text{Oalkyl}$, NHalkyl , Nalkylalkyl , $-\text{S(O)}_m\text{alkyl}$, SO_2NH_2 , $\text{SO}_2\text{NHalkyl}$ and $\text{SO}_2\text{Nalkylalkyl}$, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

3. A compound of Formula III



Formula III

25

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula III,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; m is 0, 1 or 2;

R_1 and R_2 are independently selected from halogen, $-NO_2$, $-CN$, $-R_a$, $-OR_a$, $-S(O)_mR_a$, $-NR_aR_a$, $-C(O)NR_aR_a$, $-C(S)NR_aR_a$, $-S(O)_mNR_aR_a$, $-NR_aS(O)_mR_a$, $-NR_aC(O)OR_a$, $-OC(O)NR_aR_a$, $-NR_aC(O)NR_aR_a$, $-NR_aC(S)NR_aR_a$, $-C(O)OR_a$, $-C(S)OR_a$, or $-OC(O)OR_a$;


5 R_3 is selected from heteroaryl, substituted heteroaryl, aryl cycloalkyl, substituted aryl cycloalkyl, heteroaryl cycloalkyl, substituted heteroaryl cycloalkyl, aryl heterocycloalkyl, substituted aryl heterocycloalkyl, heteroaryl heterocycloalkyl, substituted heteroaryl heterocycloalkyl, heterocycloalkyl or substituted heterocycloalkyl;

10 R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t , $-OR_t$, $-S(O)_mR_t$, NR_tR_t , oxo ($=O$), thione ($=S$), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t ; and

15 R_t each is independently selected from H, halogen, $-NO_2$, $-NH_2$, $-OH$, $-SH$, $-CN$, $-C(O)NH_2$, $-C(O)-NHalkyl$, $-C(O)Nalkylalkyl$, $-Oalkyl$, $NHalkyl$, $Nalkylalkyl$, $-S(O)_malkyl$, SO_2NH_2 , $SO_2NHalkyl$ and $SO_2Nalkylalkyl$, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

20

4. A compound of Formula IV



Formula IV

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug

25 thereof, wherein in Formula IV,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl; m is 0,1 or 2;

R_1 and R_2 are independently selected from halogen, $-NO_2$, $-CN$, $-R_a$, $-OR_a$, $-S(O)_mR_a$, $-NR_aR_a$, $-C(O)NR_aR_a$, $-C(S)NR_aR_a$ $-S(O)_mNR_aR_a$, $-NR_aS(O)_mR_a$, $-NR_aC(O)OR_a$, $-OC(O)NR_aR_a$, $-NR_aC(O)NR_aR_a$, $-NR_aC(S)NR_aR_a$, $-C(O)OR_a$, $-C(S)OR_a$, or $-OC(O)OR_a$;


5 R_s each is independently selected from halogen, $-NO_2$, $-CN$, $-R_a$, $-OR_a$, $-S(O)_mR_a$, $-NR_aR_a$, $-C(O)NR_aR_a$, $-C(S)NR_aR_a$ $-S(O)_mNR_aR_a$, $-NR_aS(O)_mR_a$, $-NR_aC(O)OR_a$, $-OC(O)NR_aR_a$, $-NR_aC(O)NR_aR_a$, $-NR_aC(S)NR_aR_a$, $-C(O)OR_a$, $-C(S)OR_a$, or $-OC(O)OR_a$;

10 R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t , $-OR_t$, $-S(O)_mR_t$, NR_tR_t , oxo ($=O$), thione ($=S$), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t ; and

15 R_t each is independently selected from H, halogen, $-NO_2$, $-NH_2$, $-OH$, $-SH$, $-CN$, $-C(O)NH_2$, $-C(O)-NHalkyl$, $-C(O)Nalkylalkyl$, $-Oalkyl$, $NHalkyl$, $Nalkylalkyl$, $-S(O)_malkyl$, SO_2NH_2 , $SO_2NHalkyl$ and $SO_2Nalkylalkyl$, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

20 5. A compound of claim 4 which is $(+/-)$ -5-(2,4-dichlorophenyl)-3,6-diethyl-N-[*cis*-2-ethyl-2,3-dihydro-1*H*-inden-1-yl]pyrazin-2-amine, or $(+/-)$ -5-(2,4-dichlorophenyl)-3,6-diethyl-N-[*trans*-2-ethyl-2,3-dihydro-1*H*-inden-1-yl]pyrazin-2-amine, or a pharmaceutically acceptable salt of either said compound.

25 6. A compound of Formula V



Formula V

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula V,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
m is 0,1 or 2;

5 R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;

10 R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

15 R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

20 7. A compound of claims 6 which is 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine,

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine,

25 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine,

30 N-[(1R,2S)-2-(cyclopropylmethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine,

5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine, or

5-[2-chloro-4-(dimethylamino)phenyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine, or a pharmaceutically acceptable salt of any said compound.

5


5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(prop-2-nyloxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine.

10 N-[(1R,2S)-2-(allyloxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine.

15 N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine, or a pharmaceutically acceptable salt of any said compound.

15

8. A compound of Formula VI



Formula VI

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug

20 thereof, wherein in Formula VI,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

m is 0,1 or 2;

R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -

S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -

25 NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -

C(S)OR_a, or -OC(O)OR_a;

R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t;

5 R_m is C₁-C₆ alkyl substituted with from 1-2 of halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, oxo (=O), thione (=S), heterocycloalkyl, or substituted heterocycloalkyl; and

10 R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

15

9. A compound of claim 8 which is 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine,

20 2-[((1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)oxy]ethanol,

(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate,

25 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine,

(1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate,


30

5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine,

(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl dimethylcarbamate.

5 5-(2,4-dimethoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine, or a pharmaceutically acceptable salt of any said compound.

10. A compound of Formula VII



Formula VII

10

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula VII,

Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;

W is O, NR_p, or S(O)_m;

15 m is 0,1 or 2;

R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;

20 R₁ and R₂ are independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;


25 R_p each is independently selected from -R_a, -S(O)_mR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -C(O)OR_a, or -C(S)OR_a;

R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl,

heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

- R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

11. A compound of Formula VIII



Formula VIII

10

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula VIII,

- Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
- 15 W is O, NR_p, or S(O)_m;
- m is 0,1 or 2;
- R_s each is independently selected from halogen, -NO₂, -CN, -R_a, -OR_a, -S(O)_mR_a, -NR_aR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -NR_aS(O)_mR_a, -NR_aC(O)OR_a, -OC(O)NR_aR_a, -NR_aC(O)NR_aR_a, -NR_aC(S)NR_aR_a, -C(O)OR_a, -C(S)OR_a, or -OC(O)OR_a;
- 20 R_p is independently selected from -R_a, -S(O)_mR_a, -C(O)NR_aR_a, -C(S)NR_aR_a -S(O)_mNR_aR_a, -C(O)OR_a, or -C(S)OR_a;
- R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

5 12. A compound of claim 11 which is 5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxy-1-propionylpyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine,

10 10 ethyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate,

benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate,


15 15 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate,

20 methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate,

benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate,

25 25 cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine, or a pharmaceutically acceptable salt thereof.

13. A compound of Formula IX



Formula IX

or a stereoisomer thereof, a pharmaceutically acceptable salt thereof, or a prodrug thereof, wherein in Formula IX,

5 Ar is selected from aryl, substituted aryl, heteroaryl, or substituted heteroaryl;
m is 0,1 or 2;

Y= O or S

R_m is C₁-C₆ alkyl substituted with from 1-2 of halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl,

10 Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, oxo (=O), thione (=S), heterocycloalkyl, or substituted heterocycloalkyl;

15 R_a each is independently selected from H, alkyl, cycloalkyl, haloalkyl, aryl, heteroaryl, or heterocycloalkyl optionally substituted with 1 to 5 of R_t, -OR_t, -S(O)_mR_t, NR_tR_t, oxo (=O), thione (=S), phenyl, heteroaryl, or heterocycloalkyl where phenyl, heteroaryl, and heterocycloalkyl are optionally substituted with 1 to 5 independently taken from R_t; and

20 R_t each is independently selected from H, halogen, -NO₂, -NH₂, -OH, -SH, -CN, -C(O)NH₂, -C(O)-NHalkyl, -C(O)Nalkylalkyl, -Oalkyl, NHalkyl, Nalkylalkyl, -S(O)_malkyl, SO₂NH₂, SO₂NHalkyl and SO₂Nalkylalkyl, alkyl, cycloalkyl, haloalkyl, phenyl, benzyl, heteroaryl, or heterocycloalkyl where phenyl, benzyl heteroaryl and heterocycloalkyl may be optionally substituted with alkyl or halogen.

14. A compound of claim 13 which is benzyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate,

25

methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate,

benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate,

5 methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate,

methyl (3S,4R)-3-(acetyloxy)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}pyrrolidine-1-carboxylate,

10 methyl (3S,4R)-3-(acetyloxy)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}pyrrolidine-1-carboxylate,

ethy1 (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate, or

15 ethy1 (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate, or a pharmaceutically acceptable salt of any said compound.

20 15. A compound of claim 1 wherein, in Formula I, X is NR₃R₄.

16. A compound of claim 15 wherein in Formula I one of R₃ or R₄ is aryl cycloalkyl or heteroaryl cycloalkyl.

25 17. A compound of claim 16 wherein in Formula I one of R₃ or R₄ is aryl cycloalkyl or heteroaryl cycloalkyl and the point of attachment is the cycloalkyl ring.

18. A compound of claim 17 wherein in Formula I R₃ is aryl cycloalkyl and R₄ is hydrogen, or R₄ is aryl cycloalkyl and R₃ is hydrogen.

30 19. A compound of claim 15 wherein in Formula I R₃ is heterocycloalkyl and R₄ is hydrogen, or R₄ is heterocycloalkyl and R₃ is hydrogen.

20. A compound of claim 15 wherein in Formula I R3 is hydrogen and R4 is substituted aryl cycloalkyl or substituted heteroaryl cycloalkyl and the point of attachment is the cycloalkyl ring, or R4 is hydrogen and R3 is substituted aryl cycloalkyl or substituted heteroaryl cycloalkyl and the point of attachment is the
5 cycloalkyl ring.
- 10 21. A compound of claim 20 wherein, in the substituted aryl cycloalkyl or substituted heteroaryl cycloalkyl, the substituent is either alkyl or alkoxy and is on the cycloalkyl ring.
22. A compound of claim 15 wherein one of R3 or R4 is substituted heterocycloalkyl where the substituent is either alkyl or alkoxy.
- 15 23. A compound of claim 22 wherein in the substituted heterocycloalkyl the absolute stereochemistry of the ring substituent is either (R,R), (R,S), (S,R), or (S,S).
24. A compound of claim 21 wherein one of R3 or R4 is substituted aryl cycloalkyl where the substituent is either alkyl or alkoxy and is on the cycloalkyl ring and the absolute stereochemistry of the ring substituent is either (R,R), (R,S), (S,R), or (S,S).
- 20 25. A compound of claim 21 wherein R3 is 2-substituted-1-indanyl and R4 is hydrogen.
26. A compound of claim 25 wherein R3 is 2-alkoxy-1-indanyl and R4 is hydrogen;
- 25 27. A compound of claim 26 wherein R3 is 2(S)-alkoxy-1(R)-indanyl and R4 is hydrogen;
28. A compound of claim 22 wherein R3 is 4-substituted-3-pyrrolidinyl and R4 is hydrogen;
- 30 29. A compound of claim 28 wherein R3 is 4-alkoxy-3-pyrrolidinyl and R4 is hydrogen.

30. A compound of claim 29 wherein R3 is 4(S)-alkoxy-3(R)-pyrrolidinyl-1-carboxylate and R4 is hydrogen.

5 31. A compound of claim 1 which is:

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

10 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R)-2-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

15 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-methoxyethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-propoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

20 3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine;

25 5-(2,4-dimethoxyphenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine;

5-[2-chloro-4-(dimethylamino)phenyl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine;

30 5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-(2,3-dihydro-1H-inden-1-yl)-3,6-dimethylpyrazin-2-amine;

- N-(2,3-dihydro-1H-inden-1-yl)-5-(4-methoxy-2-methylphenyl)-3,6-dimethylpyrazin-2-amine;
- 5 5-(2,4-dichlorophenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine;
- 10 5-(4-methoxy-2-methylphenyl)-3,6-dimethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine;
- 15 N-[5-(2,4-dichlorophenyl)-3,6-dimethylpyrazin-2-yl]isoquinolin-1-amine;
- 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(3-ethyl-6-methylpyridin-2-yl)pyrazin-2-amine;
- 15 5-(2,4-dichlorophenyl)-N-(4,6-dimethylpyridin-2-yl)-3,6-diethylpyrazin-2-amine;
- 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine;
- 20 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl)pyrazin-2-amine;
- 25 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(*cis*)-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl]pyrazin-2-amine;
- 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(*cis*)-5-ethyl-4,5,6,7-tetrahydro-1-benzofuran-4-yl]pyrazin-2-amine;
- 30 5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-thiochromen-4-yl)-3,6-diethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine;

2-(2,4-dichlorophenyl)-3,6-diethyl-5-(1,2,3,4-tetrahydronaphthalen-1-yloxy)pyrazine;

5

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine;

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-(7-methoxy-1,2,3,4-

10 tetrahydronaphthalen-1-yl)pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine;

15 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(6-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2R) and (1S,2S)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine;

20

5-(2,4-dichlorophenyl)-N-[(1R,2R) and (1S,2S)-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-diethylpyrazin-2-amine;

cis-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-1,2,3,4-

25 tetrahydronaphthalen-2-ol;

(*cis*)-2-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(*cis*)-2-ethoxy-1,2,3,4-tetrahydronaphthalen-1-yl]-3,6-

30 diethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(4,5,6,7-tetrahydro-1-benzothien-4-yl)pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine;

5 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-methyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine;

10

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-ethyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine;

15

5-(2-chloro-4-methylphenyl)-N-(3,4-dihydro-2H-chromen-4-yl)-3,6-diethylpyrazin-2-amine;

N-(3,4-dihydro-2H-chromen-4-yl)-5-(2,4-dimethylphenyl)-3,6-diethylpyrazin-2-

20 amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Cis-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine;

25 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[Trans-5-propyl-4,5,6,7-tetrahydro-1-benzothien-4-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-methoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine;

30

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-isopropoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(8-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(6-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine;

10 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(cis)-2-ethyl-6-methoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(5-methoxy-2,3-dihydro-1H-inden-1-yl)pyrazin-2-amine;

15 N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine;

20 N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-6,7-dihydro-5H-cyclopenta[b]pyridin-5-amine;

N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine;

25 N-[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]-6-ethyl-6,7-dihydro-5H-cyclopenta[b]pyridin-7-amine;

(+/-)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-[cis-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

30 (+/-)-5-(2,4-dichlorophenyl)-3,6-diethyl-N-[trans-2-ethyl-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

benzyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate;

5
5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine;

N-[(cis)-1-acetyl-4-ethoxypyrrolidin-3-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine;

10
methyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate;

5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxy-1-(methylsulfonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine;

15
(cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N,N-dimethylpyrrolidine-1-carboxamide;

(cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N,N-dimethylpyrrolidine-1-carbothioamide;

20
isopropyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate;

(cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-N-methylpyrrolidine-1-carbothioamide;

5-(2,4-dichlorophenyl)-N-[(cis)-4-ethoxy-1-(morpholin-4-ylcarbonyl)pyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine;

30
2-fluoroethyl (cis)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carboxylate;

5-(2,4-dichlorophenyl)-N-[(3R,4S)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine;

5 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine;

10 methyl(3R,4S)-3-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

15 methyl (3R,4S)-3-({5-[2-chloro-4-(dimethylamino)phenyl]-3,6-diethylpyrazin-2-yl}amino)-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

benzyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-hydroxypyrrolidine-1-carboxylate;

20 15 5-(2-chloro-4-methoxyphenyl)-N-[(3R,4S)-4-ethoxypyrrolidin-3-yl]-3,6-diethylpyrazin-2-amine;

25 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3R,4S)-4-(2-fluoroethoxy)pyrrolidin-3-yl]pyrazin-2-amine;

trans-(+/-)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine;

30 25 cis-(+/-)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-amine;

cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[4-methoxytetrahydrofuran-3-yl]pyrazin-2-amine;

35 30 cis-(+/-)-5-(2-chloro-4-methoxyphenyl)-N-[4-ethoxytetrahydrofuran-3-yl]-3,6-diethylpyrazin-2-amine;

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine;

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(3S,4S)-4-propoxytetrahydrofuran-3-yl]pyrazin-2-amine;

(+/-)-5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[cis-4-(3-fluoropropoxy)tetrahydrofuran-3-yl]pyrazin-2-amine;

10 5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-propyl-1H-imidazol-2-yl)pyrazin-2-amine;

3,6-dicyclopethyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

15 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-methylpyrazin-2-amine;

3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methylpyrazin-2-amine;

20 6-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine;

25 5-(2-chloro-4-methoxyphenyl)-6-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine;

6-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethylpyrazin-2-amine;

30 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine;

3-cyclopropyl-5-[6-(dimethylamino)-4-methylpyridin-3-yl]-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine;

5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine;

5-(2-chloro-4-methoxyphenyl)-3-cyclopropyl-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethylpyrazin-2-amine;

10 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methylpyrazin-2-amine;

15 (1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-ethyl-2,3-dihydro-1H-indene-1,2-diamine;

20 N-((1R,2R)-1-{[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)acetamide;

(1R,2R)-N¹-[3,6-dicyclopropyl-5-(2,4-dichlorophenyl)pyrazin-2-yl]-N²-(2-methoxyethyl)-2,3-dihydro-1H-indene-1,2-diamine;

25 5-(2,4-dichlorophenyl)-N-[(1S,2R)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(1S,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-diethylpyrazin-2-amine;

30 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1S,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

methyl 3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxylate;

- 5 methyl 6-{[(1R,2S)-2-(acetyloxy)-2,3-dihydro-1H-inden-1-yl]amino}-3-(2,4-dichlorophenyl)-5-methoxypyrazine-2-carboxylate;
- 10 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxy-3-vinylpyrazin-2-amine;
- 15 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-propoxypyrrolidine-1-carboxylate;
- 20 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate;
- 25 methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate;
- 30 methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionyloxy)pyrrolidine-1-carboxylate;
- 35 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionyloxy)pyrrolidine-1-carboxylate;
- 40 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionylamino)pyrrolidine-1-carboxylate;
- 45 methyl (3S,4R)-3-(acetylamino)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}pyrrolidine-1-carboxylate;

methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(ethylamino)pyrrolidine-1-carboxylate;

5 methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propylamino)pyrrolidine-1-carboxylate;

O-methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carbothioate;

10 O-methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidine-1-carbothioate;

O-methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carbothioate;

15 pyridin-2-ylmethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

20 pyridin-3-ylmethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

pyridin-4-ylmethyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

25 2-piperidin-1-ylethyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

2-morpholin-4-ylethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

30 2-morpholin-4-ylethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(propionyloxy)pyrrolidine-1-carboxylate;

2-(dimethylamino)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate;

5 2-pyrrolidin-1-ylethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)pyrrolidine-1-carboxylate;

2-(1H-imidazol-1-yl)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

10 2-(methylamino)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

2-aminoethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

15 2-hydroxyethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

20 2-methoxyethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

2-(2-oxopyrrolidin-1-yl)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrrolidine-1-carboxylate;

25 2-(2-oxopyridin-1(2H)-yl)ethyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrrolidine-1-carboxylate;

(3S,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxypyrrolidin-2-one;

30 (3S,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-ethoxy-1-methylpyrrolidin-2-one;

(3S,4S)-1-benzyl-3-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidin-2-one;

5 (3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-3-(2-fluoroethoxy)pyrrolidin-2-one;

(3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-3-(2-fluoroethoxy)-1-methylpyrrolidin-2-one;

10 (3R,4R)-1-benzyl-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-3-(2-fluoroethoxy)pyrrolidin-2-one;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-(1-ethyl-1H-imidazol-2-yl)pyrazin-2-amine;

15 ethyl (2S,3S)-3-{[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]amino}-2,3-dihydrofuro[2,3-b]pyridine-2-carboxylate;

(2S,3S)-N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]-2-(ethoxymethyl)-2,3-dihydrofuro[2,3-b]pyridin-3-amine;

20 (2R,3S)-N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]-2-ethyl-2,3-dihydrofuro[2,3-b]pyridin-3-amine;

25 (2R,3S)-N-[3,6-diethyl-5-(4-methoxy-2-methylphenyl)pyrazin-2-yl]-2-propyl-2,3-dihydrofuro[2,3-b]pyridin-3-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2S)-2-(methoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine;

30 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(methoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine;

\

5-(2,4-dichlorophenyl)-N-[(2R)-2-(ethoxymethyl)pyrrolidin-1-yl]-3,6-diethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(2R)-2-(propoxymethyl)pyrrolidin-1-yl]pyrazin-2-amine;

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(2R)-2-[(2-fluoroethoxy)methyl]pyrrolidin-1-yl]pyrazin-2-amine;

10 5-(2-chloro-4-methoxyphenyl)-N-[(2R)-2-(ethoxymethyl)pyrrolidin-1-yl]-3,6-diethylpyrazin-2-amine;

5-(2-chloro-4-methoxyphenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)pyrazin-2-amine;

15 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methoxymethyl)pyrazin-2-amine;

methyl (3R,4S)-3-{[5-(2,4-dichlorophenyl)-3,6-bis(methoxymethyl)pyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

methyl (3R,4S)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-bis(methoxymethyl)pyrazin-2-yl]amino}-4-(2-fluoroethoxy)pyrrolidine-1-carboxylate;

25 5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

30 (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl hydroxyacetate;

(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl hydroxyacetate;

5 (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl methoxyacetate;

(1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl methoxyacetate;

10 N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-amine;

N-[(1R,2S)-2-(2-aminoethoxy)-2,3-dihydro-1H-inden-1-yl]-5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-amine;

15 (1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl glycinate;

20 (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl glycinate;

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

25 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

(1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N-methylglycinate;

30 (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N-methylglycinate;

5-(2-chloro-4-methoxyphenyl)-N-{(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl}-3,6-diethylpyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-{(1R,2S)-2-[2-(dimethylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl}-3,6-diethylpyrazin-2-amine;

(1R,2S)-1-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate;

10 (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl N,N-dimethylglycinate;

5-(2-chloro-4-methoxyphenyl)-3,6-diethyl-N-{(1R,2S)-2-[2-(methylamino)ethoxy]-2,3-dihydro-1H-inden-1-yl}pyrazin-2-amine;

15 (1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl methylcarbamate;

20 5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

5-(3,5-dichloropyridin-2-yl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

25 5-(3-chloro-5-methoxypyridin-2-yl)-3,6-diethyl-N-[(1R,2S)-2-(2-fluoroethoxy)-2,3-dihydro-1H-inden-1-yl]pyrazin-2-amine;

(1R,2S)-1-{[5-(4-chloro-2-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate;

30 (1R,2S)-1-{[5-(3,5-dichloropyridin-2-yl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate;

(1R,2S)-1-{[5-(3-chloro-5-methoxypyridin-2-yl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl acetate

5-(4-chloro-2-methoxyphenyl)-3,6-diethyl-N-[(1R,2S)-2-(3-fluoropropoxy)-2,3-

5 dihydro-1H-inden-1-yl]pyrazin-2-amine;

(3R,4R)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-

yl]amino}tetrahydrofuran-3-yl acetate;

10 (3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-yl acetate;

(3R,4R)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-
yl]amino}tetrahydrofuran-3-yl propionate;

15 (3R,4R)-4-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}tetrahydrofuran-3-
yl propionate;

20 5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-propoxytetrahydrofuran-3-
yl]pyrazin-2-amine;

5-(2,4-dichlorophenyl)-3,6-diethyl-N-[(3R,4R)-4-(3-fluoropropoxy)tetrahydrofuran-3-
yl]pyrazin-2-amine;

25 (3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(2-
fluoroethoxy)dihydrofuran-2(3H)-one;

(3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-
ethoxydihydrofuran-2(3H)-one;

30 (3R,4S)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-5-
oxotetrahydrofuran-3-yl acetate;

(3R,4S)-4-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-5-oxotetrahydrofuran-3-yl propionate;

5 (3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-propoxydihydrofuran-2(3H)-one;

(3S,4R)-3-{[5-(2-chloro-4-methoxyphenyl)-3,6-diethylpyrazin-2-yl]amino}-4-(3-fluoropropoxy)dihydrofuran-2(3H)-one;

10 (1R,2S)-N-[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]-N'-ethyl-2,3-dihydro-1H-indene-1,2-diamine;

N-((1R,2S)-1-{[5-(2,4-dichlorophenyl)-3,6-diethylpyrazin-2-yl]amino}-2,3-dihydro-1H-inden-2-yl)acetamide;

15 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-dimethoxypyrazin-2-amine;

20 3-cyclopropyl-5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-methoxypyrazin-2-amine;

3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-ethylpyrazine-2-carboxamide;

25 3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxamide;

3-(2,4-dichlorophenyl)-6-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-(methylthio)pyrazine-2-carboxamide;

30 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-(methylthio)pyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-3-methoxypyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-methoxypyrazin-2-amine;

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3-ethyl-6-(methylthio)pyrazin-2-amine;

10 5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-3,6-bis(methylthio)pyrazin-2-amine;

6-(2,4-dichlorophenyl)-3-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-ethylpyrazine-2-carboxamide;

15 6-(2,4-dichlorophenyl)-3-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-methoxypyrazine-2-carboxamide;

20 6-(2,4-dichlorophenyl)-3-{[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]amino}-5-(methylthio)pyrazine-2-carboxamide;

5-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-6-ethyl-N'-methylpyrazine-2,3-diamine;

25 6-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-N',N"-dimethylpyrazine-2,3,5-triamine; or

3-(2,4-dichlorophenyl)-N-[(1R,2S)-2-ethoxy-2,3-dihydro-1H-inden-1-yl]-5-ethyl-N'-methylpyrazine-2,6-diamine, or

30 a pharmaceutically acceptable salt of any said compound.

32. A compound of claim 1 wherein the compound exhibits an IC₅₀ for CRF binding of 1 micromolar or less in a standard CRF binding assay.

33. A compound of claim 32 wherein the compound exhibits an IC₅₀ for CRF binding of 100 nanomolar or less.

34. A compound of claim 32 wherein the compound exhibits an IC₅₀ for CRF binding of 10 nanomolar or less.

10 35. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.

15 36. A method of inhibiting the binding of CRF to the CRF₁ receptor, the method comprising contacting, in the presence of CRF, a solution comprising a compound of claim 1 with cells expressing the CRF₁ receptor, wherein the compound is present in the solution at a concentration sufficient to reduce levels of CRF binding to the cells *in vitro*.

20 37. A method of antagonizing a CRF₁ receptor in a mammal, comprising administering to the mammal, a therapeutically effective amount of a compound of claim 1.

38. A method of treating a disorder manifesting hypersecretion of CRF in mammal, comprising administering to the animal a therapeutically effective amount of a compound of claim 1.

25 39. A method for the treatment of a disorder, the treatment of which can be effected or facilitated by antagonizing CRF in a mammal, comprising administering to the mammal a therapeutically effective amount of a compound of claim 1.

30 40. A method for screening for ligands for CRF₁ receptors, which method comprises: a) carrying out a competitive binding assay with a CRF₁ receptor, a compound of claim 1, which is labelled with a detectable label, and a candidate ligand; and b) determining the ability of said candidate ligand to displace said labelled compound.

41. A method for detecting CRF₁ receptors in tissues comprising: a) contacting a compound of claim 1, which is labelled with a detectable label, with a tissue, under conditions that permit binding of the compound to the tissue; and b) detecting the labelled compound bound to the tissue.
- 5 42. An article of manufacture comprising: a) a packaging material; b) a compound of claim 1, and c) a label or package insert contained within said packaging material indicating that said compound is effective for treating affective disorder, anxiety or depression.
- 10 43. A method of promoting smoking cessation in a human, comprising administering to the human in need thereof an effective amount of a compound of claim 1.
- 15 44. A method of treating a disorder in a mammal, comprising administering to the human in need thereof an effective amount of a compound of claim 1, wherein the disorder is selected from social anxiety disorder; panic disorder; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; affective disorder; anxiety; depression; irritable bowel syndrome; post-traumatic stress disorder; supranuclear palsy; immune suppression; gastrointestinal disease; anorexia nervosa or other feeding disorder; drug or alcohol withdrawal symptoms; substance abuse disorder; inflammatory disorder; fertility problems; inflammatory disorders; pain; asthma; psoriasis; allergies; generalized anxiety disorder; panic, phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; fibromyalgia; mood disorders; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; human immunodeficiency virus infections; neurodegenerative diseases; gastrointestinal diseases; eating disorders; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone; obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; cardiovascular and hear related disorders; stroke; immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions; osteoporosis; psychosocial dwarfism; and hypoglycemia.
- 20 45. The method of claim 44 wherein the mammal is a human.

46. The method according to claim 45 wherein the disorder is selected from affective disorder; anxiety; depression; irritable bowel syndrome; post-traumatic stress disorder; supranuclear palsy; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; Alzheimer's disease; gastrointestinal disease; skin disorders;
- 5 anorexia nervosa; social anxiety disorder; bulimia nervosa or other feeding disorder; drug or alcohol withdrawal symptoms; substance abuse disorder; inflammatory disorder; pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder; sleep disorders induced by stress; fibromyalgia; mood disorders; dysthymia; bipolar disorders; cyclothymia; fatigue
- 10 syndrome; stress-induced headache; cancer; neurodegenerative diseases; gastrointestinal diseases; syndrome of inappropriate antidiarrhetic hormone; cardiovascular and heart related disorders; stroke; senile dementia of the Alzheimer's type; multiinfarct dementia; and amyotrophic lateral sclerosis.
- 15 47. The method according to claim 46 wherein the disorder is selected from affective disorder; anxiety; depression; generalized anxiety disorder; social anxiety disorder; anxiety; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; panic disorder; mood disorders; bipolar disorders; post-traumatic stress disorder; substance abuse disorders; inflammatory disorders; gastrointestinal diseases; and skin disorders.
48. The method according to claim 47 wherein the disorder is selected from affective disorder, anxiety, and depression.
- 25 49. A compound of claim 1 for use as an active pharmaceutical substance.
50. Use of a compound of claim 1 for the preparation of a pharmaceutical composition.
51. Use of a compound of claim 1 for the preparation of a medicament for treating
- 30 a disorder manifesting hypersecretion of CRF in mammal.
52. Use of a compound of claim 1 for the preparation of a medicament for treating a disorder the treatment of which can be effected or facilitated by antagonizing CRF in a mammal.

53. Use of a compound of claim 1 for the preparation of a medicament for treating a disorder in a mammal, wherein the disorder is selected from social anxiety disorder; panic disorder; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; affective disorder; anxiety; depression; irritable bowel syndrome; post-traumatic stress disorder; supranuclear palsy; immune suppression; gastrointestinal disease; anorexia nervosa or other feeding disorder; drug or alcohol withdrawal symptoms; substance abuse disorder; inflammatory disorder; fertility problems; inflammatory disorders; pain; asthma; psoriasis; allergies; generalized anxiety disorder; panic, phobias; obsessive-compulsive disorder; post-traumatic stress disorder; sleep disorders induced by stress; fibromyalgia; mood disorders; dysthemia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; human immunodeficiency virus infections; neurodegenerative diseases; gastrointestinal diseases; eating disorders; hemorrhagic stress; stress-induced psychotic episodes; euthyroid sick syndrome; syndrome of inappropriate antidiarrhetic hormone; obesity; infertility; head traumas; spinal cord trauma; ischemic neuronal damage; excitotoxic neuronal damage; epilepsy; cardiovascular and hear related disorders; stroke; immune dysfunctions; muscular spasms; urinary incontinence; senile dementia of the Alzheimer's type; multiinfarct dementia; amyotrophic lateral sclerosis; chemical dependencies and addictions; osteoporosis; psychosocial dwarfism; and hypoglycemia.

54. The use according to claim 53 wherein the mammal is a human.
55. The use according to claim 54 wherein the disorder is selected from affective disorder; anxiety; depression; irritable bowel syndrome; post-traumatic stress disorder; supranuclear palsy; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; Alzheimer's disease; gastrointestinal disease; skin disorders; anorexia nervosa; social anxiety disorder; bulimia nervosa or other feeding disorder; drug or alcohol withdrawal symptoms; substance abuse disorder; inflammatory disorder; pain, asthma, psoriasis and allergies; generalized anxiety disorder; panic disorder; phobias; obsessive-compulsive disorder; sleep disorders induced by stress; fibromyalgia; mood disorders; dysthymia; bipolar disorders; cyclothymia; fatigue syndrome; stress-induced headache; cancer; neurodegenerative diseases; gastrointestinal diseases; syndrome of inappropriate antidiarrhetic hormone;

cardiovascular and hear related disorders; stroke; senile dementia of the Alzheimer's type; multiinfarct dementia; and amyotrophic lateral sclerosis.

56. The use according to claim 55 wherein the disorder is selected from affective disorder; anxiety; depression; generalized anxiety disorder; social anxiety disorder; anxiety; obsessive-compulsive disorder; anxiety with co-morbid depressive illness; panic disorder; mood disorders; bipolar disorders; post-traumatic stress disorder; substance abuse disorders; inflammatory disorders; gastrointestinal diseases; and skin disorders.

10

57. The use according to claim 57 wherein the disorder is selected from affective disorder, anxiety, and depression.

15

INTERNATIONAL SEARCH REPORT

PCT/US 02/33642

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 7	C07D241/20	C07D241/18	C07D241/26	C07D401/12	C07D403/12
	C07D405/12	C07D491/04	C07D409/12	C07D401/04	C07D401/14
	A61K31/4965	A61K31/497	G01N33/74	A61P25/00	

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 C07D G01N A61K A61P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

CHEM ABS Data, PAJ

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	H. NAKAMURA: "SYNTHESIS A. CHEMIOLUMINESCENCE OF 5-'PYRIDYL-, 2-PYRAZINYL-, AND (SUBSTIT. 2-PYRAZINYL)AMINO!-1,2,4-TRIOXANES." BULLETIN OF THE CHEMICAL SOCIETY OF JAPAN., vol. 61, no. 10, 1988, pages 3776-8, XP002233212 JAPAN PUBLICATIONS TRADING CO. TOKYO., JP ISSN: 0009-2673 page 3376 ---	1
A	WO 98 38174 A (GLAXO) 3 September 1998 (1998-09-03) page 1 -page 11; claims ---	1-3, 35-39, 42-57 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 March 2003	19/03/2003
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040. Tx. 31 651 epo nl. Fax: (+31-70) 340-3016	Authorized officer Francois, J

INTERNATIONAL SEARCH REPORT

PCT/US 02/33642

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 01 60806 A (NEUROGEN CORP.) 23 August 2001 (2001-08-23) cited in the application the whole document ---	1-3, 35-39, 42-57
A	CHEMICAL ABSTRACTS, vol. 121, no. 28, 1994 Columbus, Ohio, US; abstract no. 83374r, page 1111; column 2; XP002233213 abstract & JP 00 601776 A (NIPPON SODA) 11 January 1994 (1994-01-11) ---	1
A	CHEMICAL ABSTRACTS, vol. 127, no. 2, 1997 Columbus, Ohio, US; abstract no. 17644b, FOKS,H.: "STUDIES ON PYRAZINE DERIVATIVES.XXX" page 559; XP002233214 abstract & ACTA POL. PHARM., vol. 54, no. 1, 1997, pages 55-62, POL. -----	1

INTERNATIONAL SEARCH REPORT

PCT/US 02/33042

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
Although claims 36 to 39, 43 to 48 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

PCT/US02/33642

Patent document cited in search report		Publication date		Patent family member(s)		Publication date
WO 9838174	A	03-09-1998	AU	732915 B2		03-05-2001
			AU	6823798 A		18-09-1998
			BG	103723 A		31-05-2001
			BR	9807814 A		22-02-2000
			CN	1253551 T		17-05-2000
			EA	2102 B1		24-12-2001
			EE	9900376 A		17-04-2000
			WO	9838174 A1		03-09-1998
			EP	0966448 A1		29-12-1999
			HR	980107 A1		31-12-1998
			HU	0001802 A2		28-05-2001
			JP	3369189 B2		20-01-2003
			JP	2000511203 T		29-08-2000
			NO	994213 A		29-10-1999
			NZ	337121 A		30-03-2001
			PL	335441 A1		25-04-2000
			SK	117399 A3		12-06-2000
			TR	9902082 T2		21-04-2000
			US	6255307 B1		03-07-2001
			US	2002169172 A1		14-11-2002
			ZA	9801624 A		26-08-1999
			JP	2002308773 A		23-10-2002
-----	-----	-----	-----	-----	-----	-----
WO 0160806	A	23-08-2001	AU	3849401 A		27-08-2001
			EP	1255740 A2		13-11-2002
			NO	20023869 A		11-09-2002
			WO	0160806 A2		23-08-2001
			US	2003018035 A1		23-01-2003
-----	-----	-----	-----	-----	-----	-----
JP 0601776	A			NONE		
-----	-----	-----	-----	-----	-----	-----